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Abstract
The adenosine receptor (A^R) is an important G protein-coupled receptor (GPCR) distributed 
widely throughout the human body and influences many bodily functions. The work presented 
here investigates in detail the complex heterogeneous nature of agonist binding to the human A^R 
in order to  explore receptor-receptor interactions that might be present in oligomeric receptor 
complexes.
The equilibrium and kinetic binding properties of two cell lines expressing the A^R at different 
densities were characterised in detail. This characterisation was compared with that of a series of 
47 cell lines expressing different levels of either the A jR-GFP or A^R-GFP-Goj fusion proteins.
Equilibrium radioligand saturation and competition experiments provided evidence for a re­
lationship between the fraction of high affinity agonist binding sites and the level of receptor 
expression. Cell lines expressing lower levels of the A^R showed a greater relative ability to bind 
agonists with high affinity, and to promote formation of the activated agonist-receptor-G protein 
ternary complex.
The association of [^H]agonist to the A jR  was biphasic and determined by two different molec­
ular processes. The association rate constant of the fast component was entirely dependent on 
the concentration of [^H]agonist, whereas dependence of the slow component on concentration was 
inconclusive.
The dissociation of a [^H]inverse agonist from the A^R was rapid, mono-exponential, complete, 
and insensitive to GTP. In contrast, the kinetics of [^H]agonist dissociation were complex. Disso­
ciation of [^H]agonist from the A^R-G protein complex was biphasic and dependent on the nature 
of ligand used to prevent [^H] agonist rebinding. Greater [^H] agonist dissociation was observed in 
the presence of competing agonist than competing inverse agonist, a novel finding called “agonist- 
induced agonist dissociation,” and was dependent on agonist efficacy. The mechanism behind this 
is unknown, but appears to involve interactions between high affinity receptor-G protein complexes, 
possibly in the form of receptor oligomerisation. These interactions are absent at low expression 
levels and progressively increase with level of expression. Agonist-induced agonist dissociation was
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observed even in the presence of a high concentration of GTP.
Separation of cell membrane fractions by their buoyant density clearly showed the A^R-GFP 
and A^R-GFP-Gaj fusion proteins were not found in lower density caveolin-enriched “raft” frac­
tions. These observations have implications for the nature of the immediate receptor environment 
and whether the A^R and other components of the receptor signalling complex are actively con­
centrated in regions of the cell membrane.
The work presented here describes novel properties of agonist and antagonist binding at the 
human adenosine A j receptor and to AjR-GFP and A^R-GFP-Go^ fusion proteins. The ligand 
dependence of the kinetics of agonist dissociation provides direct evidence for receptor-receptor 
interactions, such as receptor oligomerisation.
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Chapter 1
Introduction.
1.1 The seven-transmembrane G protein-coupled receptor su­
perfamily.
The seven-transmembrane G protein-coupled receptor (GPCR) superfamily is an enormous collec­
tion of diverse but related cell surface receptors (for review see Pierce et al. 2002). In humans 
367 GPCRs have been estimated to be receptors for endogenous signals such as peptides, lipids, 
neurotransmitters and nucleotides (Vassilatis et al. 2003). GPCRs respond to a vast variety 
of stimuli, including hormones, odorants, neurotransmitters and light. Despite such diversity in 
receptor stimuli, all GPCRs have a hydrophobic core of seven membrane-spanning domains, an 
extracellular amino terminus, intracellular carboxy terminus, and typically signal through the ac­
tivation of heterotrimeric G proteins (Heuss and Gerber 2000; Pierce et al. 2002). To date, a 
high resolution crystal structure has been elucidated for only one GPCR, the vertebrate retinal 
photoreceptor rhodopsin (Palczewski et al. 2000; Teller et al. 2001).
Three distinct families of GPCRs can be identified on the basis of sequence similarity, and 
Figure 1.1 on page 20 illustrates some of the significant structural characteristics of each family. 
Family 1 which includes receptors for light (rhodopsin) and odorants (the large olfactory receptor 
subgroup) is by far the largest of the three groups. Fredriksson and Schioth (2005) estimated 87% of 
human GPCRs are members of the same family as rhodopsin. The adenosine receptor belongs 
to GPCR family 1. Family 2 is much smaller than family 1 and its members couple mainly through 
Gs G proteins which stimulate the activity of adenylate cyclase. Family 2 includes receptors for 
the gastrointestinal peptide hormone family and corticotropin-releasing hormone. Family 3 is also 
much smaller than family 1 and all members have a large extracellular N-terminal domain involved
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in ligand binding and receptor activation. Family 3 includes the metabotropic glutamate receptor 
family, the GABAg receptor and the calcium-sensing receptor.
GPCRs have very important roles in physiological and pathophysiological processes and are of 
intense interest within the pharmaceutical industry (Schoneberg et al. 2 0 0 2 ). Not only do GPCRs 
represent the largest class of drug targets, but it has been estimated that up to half of all modern 
drugs may act by either enhancing (agonists) or inhibiting (antagonists) the activation of GPCRs 
(Chalmers and Behan 2002).
GPCRs emerged from the general study of receptors as their molecular basis of action became 
apparent in the 1960s and 1970s (see Limbird 1986 and Lefkowitz 2004 for historical perspectives). 
The development of new technologies, especially radioligand binding, in the 1970s established 
fundamental principles of GPCR behaviour such as heterogeneous agonist binding (Birdsall et al. 
1978) and the ternary complex model which remain in use today (De Lean et al. 1980). The 
purification of GPCRs from tissues where they are found at high levels, followed by the cloning 
and sequencing of individual GPCRs showed that receptors with very different physiological roles 
and stimuli could be part of the same GPCR superfamily and share key structural characteristics 
such as the seven membrane-spanning helical core. Biochemical, cellular, pharmacological and 
molecular interrogation of the rapidly expanding repertoire of GPCRs has firmly established them 
as the largest and most diverse family of cell surface receptors transducing extracellular stimuli 
into intracellular effects. Today GPCRs remain the largest receptor superfamily and researchers 
in academia and industry have a wide array of tools with which to investigate GPCR activation, 
expression, localisation and function. The sequencing of the human genome (Lander et al. 2001) 
has opened yet more avenues in GPCR research and provides more candidates for characterisation 
by the experimental tools developed beforehand. The interest in G protein-coupled receptors has 
increased immensely over the last several decades and their significance appears set to grow further.
1.1.1 H eterotrim eric G proteins.
G protein-coupled receptors, as their name suggests, transduce extracellular signals into intra­
cellular actions through their ability to couple to and activate heterotrimeric G proteins. Het­
erotrimeric G proteins, typically referred to as just “G proteins,” are guanine-nucleotide regulatory 
protein complexes composed of a  and subunits. They are responsible for the majority of signal 
transduction from activated GPCRs to downstream effectors such as adenylate cyclase and phos- 
pholipases. GPCR activation is associated with formation of the high affinity agonist-receptor-G 
protein ternary complex and exchange of GDP for GTP on the G protein a  subunit. Heterotrimeric 
G proteins dissociate from the activated GPCR through separation into cn-GTP and $ 7  subunits
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Figure 1.1 Structural characteristics of the three G protein-coupled
receptor families.
COOH
a  Family 1
b  Family 2
COOH
C Family 3
<=-    COOH
Figure 1.1: Three major families of G protein-coupled receptor can be distinguished by sequence 
and structural similarity. Rhodopsin, from family 1, is the only high resolution GPCR structure 
determined to date and the orientation of the seven transmembrane helices is illustrated for fam­
ily 1, but not 2 or 3, above. Family 1 is by far the largest GPCR family and most family 1 GPCRs 
have a short N-terminus and a palmitoylated cysteine anchoring the C-terminus to the membrane- 
In general family 2 GPCRs have a longer N-terminus containing several disulphide bonds. Fam­
ily 3 GPCRs have long C- and N-termini. The red circles indicate highly conserved amino acids 
within each family. Monomeric receptors are illustrated although some GPCRs have been shown 
to function as dimers or higher order oligomeric complexes. Figure is from Ellis 2004.
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which can both have effects on cellular targets. Activation of G proteins is regulated by hydrolysis 
of GTP on the a-G TP subunit to GDP and subsequent re-association of a  and /3y subunits into 
the inactive Ga-GDP . /? 7  heterotrimeric complex. The GTPase action of the G a subunit is regu­
lated by a family of proteins called regulators of G protein signalling (RGS) or GTPase activating 
proteins (GAP). The activation of G protein is illustrated in Figure 1.2 on the next page).
The binding of guanine nucleotides to G protein G a subunits and their intrinsic GTPase activity 
have been exploited experimentally. The addition of high concentrations of GDP or GTP uncouples 
high affinity agonist-receptor-G protein complexes and all subsequent agonist binding is of low 
affinity. The mechanism by which guanine nucleotides uncouple receptor-G protein complexes is 
unknown, and not predicted by simple models such as the ternary complex model. A number of 
studies have investigated the effect of graded guanine nucleotide concentration on agonist binding 
at GPCRs. Some have reported reduced agonist affinity (Hoffman et al. 1982) while others have 
reported reduced availability of high affinity agonist binding sites (Lorenzen et al. 1993, Mahle et 
al. 1992). Previous work in the receptor group at NIMR provided evidence of both reduced affinity 
and high affinity agonist binding site availability at the adenosine A]^  receptor in the presence of 
GDP (Browning 2003).
At least twenty different G protein a  subunits have been identified (for review see Albert 
and Robillard 2002). Common examples of G protein a  subunits are Gas (which stimulates the 
activation of adenylate cyclase, raising intracellular cAMP levels), Gaq (activates phospholipase 
C which generates the second messengers inositol trisphosphate and diacylglycerol), Ga^ (inhibits 
the activation of adenylate cyclase, reducing the level of intracellular cAMP), and Ga^(activated 
by rhodopsin in response to stimulation by light). The N-terminus of Ga subunits are attached to 
the cell membrane by means of N-myristoylation or palmitoylation (Wedegaertner et al. 1995).
Pertussis toxin (or islet activating protein) from species of bacteria of the Bordetella genus (of 
which B. pertussis is responsible for the majority of cases of the respiratory infection whooping 
cough) catalyses the ADP-ribosylation of G ap Gao and Ga^ G protein subunits. This covalent 
modification prevents coupling of these G proteins to GPCRs. Pertussis toxin is of use when 
investigating the coupling of GPCRs to G proteins other than G aj?0  ^ (Cordeaux et al. 2000) 
or the coupling of receptors to G proteins covalently attached their GPCR and mutated to be 
insensitive to pertussis toxin (Bevan et al. 1999).
Although fewer in number than G protein a  subunits, there is still appreciable diversity in G 
protein (3 and 7  subunits. Currently at least five (3 subunits and twelve 7  subunits have been 
identified, most of which are distributed widely throughout the body. (3^ f heterodimers can stimu­
late or inhibit the activity of a large number of downstream cellular effectors including Ca^+ and
21
Chapter 1
Figure 1.2 The activation o f G protein by agonist and G PCR .
EXTRACELLULAR 
SIGNAL
1
XaQQQQQL xxoocc 1 1 1  1 . 1  1 i ■ - . - . . 1 . 1 .
1
INTRACELLULAR 
EFFECT
Figure 1.2: G protein coupled receptors transduce extracellular signals, such as an agonist, into 
intracellular effects largely through the control of G protein activation. The binding of extracellular 
agonist (A) to the GPCR (R) is associated with formation of the active agonist-receptor-G protein 
(ARG) ternary complex. Activation of the G protein by within the ternary complex drives the 
exchange of GDP for GTP on the G a G protein subunit and dissociation of the G protein from 
the receptor and into separate a-G TP and £ 7  subunits. Both the a-GTP and £ 7  subunits can 
act on downstream intracellular targets. The GTPase activity of the Ga subunit hydrolyses the 
bound GTP to GDP and the inactive heterotrimeric Ga-GDP ./? 7  complex reassembles.
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K~ channels, kinases and subtypes of adenylate cyclase. They also appear to fulfil further roles 
by encouraging the binding of other proteins to the receptor, such as G a subunits (Phillips et al. 
1992) and receptor kinases (Inglese et al. 1995).
Heterotrimeric G proteins are not the only signal transduction systems that can be directly 
activated by GPCRs. Identification of an increasing number of proteins which interact directly 
with GPCRs has provided evidence for G protein-independent modulation of cellular effectors, such 
as ion channels (Heuss and Gerber 2000). The influence of other proteins on GPCR behaviour is 
discussed more in Section 1.3.
1.1.2 T he m olecular structure of G protein-coupled receptors.
To date, a high resolution crystal structure has been elucidated for only one GPCR, the vertebrate 
retinal photoreceptor rhodopsin (Palczewski et al. 2000; Teller et al. 2001). Rhodopsin is a Fam­
ily 1 GPCR and a representation of its molecular structure, along with its G protein transducin, is 
illustrated in Figure 1.3 on the following page. Low resolution structural studies and sequence anal­
ysis strongly suggested the seven membrane-spanning helix conformation which was confirmed by 
the high resolution crystal structures. The inactive “resting-state” crystal structure also identified 
an eighth helix aligned parallel to the internal surface of the cell membrane. Despite consider­
able academic and industrial efforts to obtain high resolution crystal structures of other GPCRs, 
rhodopsin remains the only successful example. Rhodopsin is unique within GPCRs in that it 
can be purified in large quantities from retinae and can be locked in an inactive conformation by 
its covalently bound inverse agonist 11-cis-retinal. Exposure of the crystal to light destroyed the 
crystal (Palczewski et al. 2000) preventing the determination of the structure of the “active state” 
of the receptor. The main obstacle to the creation of suitable crystals appears to be difficulties in 
the purification of a homogeneous preparation of receptor in a uniform conformation.
The crystal structure of rhodopsin has been useful as a template from which to design structural 
models of other GPCRs. While the helical core of the rhodopsin crystal structure has been useful, 
to an extent, when modelling GPCRs who bind small molecules within that region, the crystal 
structure of rhodopsin is of limited use when modelling intra- and extra-cellular loops. Also, 
rhodopsin purified for the crystal structure was locked in its inactive conformation so there remains 
no high resolution structure of an activated GPCR. The high resolution structure of a GPCR in an 
activated conformation would provide information on the structural reorientation of the receptor 
and how this is influenced by ligands. GPCR homology models have been developed in order to 
investigate how ligands bind within the helical core of selected GPCRs. For example, a homology 
model of the muscarinic receptor based on the crystal structure of bovine rhodopsin has been
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Figure 1.3 The molecular structure of rhodopsin and transducin.
Rhodopsin
G a GTPase 
domain 4
G a V*.
helical
domain
subunit
Gy
subunit
Figure 1.3: High resolution crystal structures have been determined for both rhodopsin and its G 
protein transducin and are shown to scale (taken from Hamm 2001). The structures were deter­
mined separately and the molecular position of the interaction between receptor and G protein is 
not known. The characteristic seven transmembrane domains of rhodopsin are clearly illustrated 
and coloured red to blue from the N-terminus to the C-terminus. The last 32 residues of the 
C-terminus are not shown. Retinal, rhodopsin’s covalently-attached light-activated ligand, is indi­
cated in purple buried within the transmembrane helices. The three G protein subunits (a, ft and 
7 ) are illustrated in different colours with a space-filled guanine nucleotide (in red) within the Ga 
GTPase domain.
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used to interpret the results of mutagenesis studies on the receptor’s transmembrane core, providing 
insights into the binding of different ligands and their control of receptor activation (Hulme et al. 
2003). GPCR homology models are also of use in the pharmaceutical industry and have been 
applied to virtual screening of large chemical databases in order to identify promising compounds 
for experimental screening (Bissantz et al. 2003).
Many studies have created chimeric receptors from domains of different GPCRs in order to 
investigate the importance of structural motifs or features of receptor behaviour. The creation of 
functional chimeric GPCRs has shown that structural motifs from receptors with little sequence 
similarity can be fused to form a functional receptor (for review see Yin et al. 2004). Chimeric 
GPCRs have been used to investigate mechanisms of receptor oligomerisation (in the case of the 
GABAg receptor) and the consequences of receptor activation at GPCRs where the nature of 
endogenous ligands was uncertain (in the case of the Frizzled-2 //?2 -adrenoceptor fusion construct; 
Liu et al. 1999).
1.1.3 The oligom erisation o f G protein-coupled receptors.
Traditionally the activation of GPCRs has been considered as the functional response to formation 
of the high affinity agonist-receptor-G protein ternary complex. Models of receptor activation 
describing the binding of ligands and G protein to a GPCR have been reasonably successful in de­
scribing many aspects of GPCR behaviour. Reconstitution experiments creating functional GPCR 
systems in synthetic phospholipid vesicles using purified receptor and G protein have supported 
such simple models. However it is now apparent the formation of oligomeric receptor complexes 
is crucial to the function of a number of GPCRs. While there has been phenomenal interest in 
the study of GPCR oligomerisation over the last several years, driven in part by the emergence 
of new technologies, no consistent mechanism of receptor oligomerisation has appeared which is 
applicable to all GPCRs. As with many aspects of GPCR behaviour, the nature and mechanisms 
of receptor oligomerisation are entirely dependent on the receptor itself.
For many studies of GPCR oligomerisation it is difficult to determine whether the receptor is 
present as a dimeric complex or a higher-order oligomer. Therefore in this document the description 
“oligomer” is used to describe in general the association of GPCRs into complexes of two or more 
receptors.
An interesting account of GPCR oligomerisation reported functional rescue by co-expression 
of two different non-functional angiotensin receptors, demonstrating for the first time in peptide 
hormone receptors intermolecular complementation mediated by receptor oligomerisation (Mon- 
not et al. 1996). However, arguably the “classic” example of GPCR oligomerisation is that of
25
Chapter 1
the metabotropic 7 -aminobutyric acid (GABAg) receptor which functions as an obligate hetero­
dimer. When the GABAg receptor was first cloned, which was subsequently determined to be 
the GABAgj receptor, the cloned receptor did not behave in the same manner as endogenous 
GABA receptors characterised in brain preparations (Kaupmann et al. 1997, White et al. 1998). 
Several groups later cloned a second GABAg receptor (GABAg2) which when co-expressed with 
the originally-cloned receptor, GABAg j, restored the pharmacology observed in brain membrane 
preparations (Jones et al. 1998, Kaupmann et al. 1998, Kuner et al. 1999, White et al. 1998, 
Ng et al. 1999, Martin et al. 1999). The GABAg^ receptor when expressed alone is retained 
within the cell and does not reach the cell surface. The GABAg2  receptor however is expressed at 
the cell surface, but does not bind GABA. GABAg2  acts as a chaperone to mask the C-terminal 
ER retention signal of GABAg j and the hetero-dimer is expressed on the cell surface and can 
bind GABA and activate G protein. GABAg2  may fulfil more than just a chaperone role, and 
it appears to be important in the activation of G protein following agonist binding at GABAg^. 
While oligomerisation of the GABAg receptor has been studied in great detail, there remain few 
examples of GPCRs which function similarly as obligate hetero-dimers.
A considerable number of reports have employed co-immunoprecipitation techniques to pro­
pose the existence of GPCR oligomerisation. Co-expression of differentially epitope tagged /32- 
adrenergic receptors has provided evidence of /32  receptor dimerisation (Hebert et al. 1996). Sim­
ilar studies have proposed dimerisation of other GPCRs in both recombinant and native systems, 
including the 5 opioid (Cvejic and Devi 1997), muscarinic M3 receptor (Zeng and Wess 1999), 
dopamine D2  receptor (Guo et al. 2003) and histamine H2  receptor (Fukushima et al. 1997). Sev­
eral reports have extended co-immunoprecipitation to investigate hetero-oligomerisation of GPCRs. 
Different opioid receptor subtypes have been proposed to form hetero-dimers (for example Jordan 
and Devi 1999, George et al. 2000) and hetero-dimerisation has been reported between the adeno­
sine A i  and dopamine D^ receptors (Gines et al. 2000) and angiotensin and bradykinin receptors 
(AbdAlla et al. 2000). However, co-immunoprecipitation techniques leave concerns regarding the 
specificity and relevance of reported associations, and while they provide an interesting starting- 
point to the characterisation of GPCR oligomerisation other techniques have provided greater 
insights into the details and consequences of oligomerisation.
Other popular approaches used to investigate the oligomerisation of GPCRs involve the use of 
techniques employing resonance energy transfer. These techniques have the advantage that they 
can be performed in living cells, although typically cells recombinantly expressing the receptors 
of interest. Of considerable interest would be reports using resonance energy transfer techniques 
to show the presence or absence of oligomeric endogenously expressed receptors. In some cases
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the energy donor and acceptor are covalently fused to the C-ter mini of the receptors of interest 
and this has provided further evidence of @2 receptor oligomerisation (Angers et al. 2000), for 
example. Other reports have used energy donor and acceptors coupled to antibodies targeted at 
specific epitopes on the N-termini of GPCRs. This has the advantage of directly labelling receptor 
expressed only at the cell surface and has, for example, been employed to show oligomerisation of 
the 5 opioid receptor (McVey et al. 2001).
Reconstitution experiments using recombinantly expressed and purified human leukotriene B4  
receptor (BLT1) showed low and high affinity agonist binding (Baneres et al. 2003, Baneres and 
Parello 2003). BLT1 is a member of the rhodopsin-like GPCR family 1 . Detergent-solubilised 
BLT1 was observed to associate with heterotrimeric G protein, and activate Ge^, following agonist 
binding at the receptor. The stoichiometry of this complex was identified as only one G protein 
for every two receptors and two agonist molecules ([agonist-receptor]2  : [G protein]^), providing 
strong evidence of a role for receptor dimerisation in receptor activation.
GPCRs can form oligomeric complexes through interaction of their C- or N-termini or trans­
membrane domains depending on the receptor subtype. The C-terminus has been identified as an 
important determinant for hetero-oligomerisation of GABAg^ and GABAg2  receptors (Kuner et 
al. 1999) and homo-oligomerisation of the S opioid receptor (Cvejic and Devi 1997). A synthetic 
peptide of transmembrane helix 6  from the 02 adrenergic receptor decreased dimerisation, suggest­
ing the transmembrane helix forms an important interface between receptors (Hebert et al. 1996). 
Transmembrane helices 6  and 7 have been proposed to be important in dopamine D2  receptor 
dimerisation (Ng et al. 1996). Family 3 GPCRs have been shown to use their large N-terminal 
domains to form receptor-receptor interactions important in oligomerisation. X-ray crystallogra­
phy of the N-terminal domain of the metabotropic glutamate receptor observed a disulphide-linked 
homodimer (Kunishima et al. 2000). Also, the conformation of this dimeric extracellular domain 
was observed to change with the binding of glutamate.
1.2 The regulation of G protein-coupled receptor activation.
The most simple models developed to describe the activation of G protein by a GPCR incorporate 
three components; ligand, receptor and G protein. The physiological relevance of such models 
are supported by experiments reconstituting functional GPCR systems into phospholipid vesicles 
using purified receptor and purified G protein (for example using the /^-adrenergic receptor see 
Cerione et al. 1984). The binding of ligands which increase the overall level of receptor activation 
(agonists) increases formation of the high affinity agonist-receptor-G protein “ternary complex.”
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Other ligands which bind at the agonist binding site regardless of the presence of G protein are 
generally termed antagonists and inhibit the binding of agonist in a concentration-dependent man­
ner. Many GPCRs exhibit a level of receptor activation in the absence of agonist stimulation, 
termed “constitutive activity.” Antagonists can be divided into two further classes of ligand. Neu­
tral antagonists competitively inhibit the binding of agonist but do not directly alter the activation 
state of the receptor. Inverse agonists reduce the overall level of receptor activation by favourably 
binding to GPCRs not coupled to G protein, and as a result reduce constitutive activity. Figure 1.4 
on page 29 illustrates the change in level of receptor activation following the binding of agonist, 
neutral antagonist or inverse agonist.
1.2.1 Efficacy.
The affinity of a ligand for its molecular target, such as a GPCR, is the product of thermodynamic 
mechanisms and can be described simply and quantitatively. The extent to which a ligand can 
alter the level of receptor activation is a molecular property known as “efficacy.” There are many 
ways in which to measure the efficacy of a ligand, from immediate effects on ternary complex 
formation to downstream effects such as regulation of gene expression. Aspects of agonist binding 
at equilibrium, such as the ratio of high and low affinity constants of agonist binding (7^-), are 
thought to reflect agonist efficacy. Figure 1.4 represents the efficacy of a ligand as a shift along 
the y-axis, the level of receptor activation. Efficacy is very much more difficult than affinity to 
model quantitatively, although models have been proposed which link efficacy and affinity (Kenakin 
2002).
1.2.2 M odels o f G protein-coupled  receptor binding and function.
The ternary complex model (Figure 1.5A on page 30) has been used widely to describe and analyse 
the binding of ligands to G protein-coupled receptors (De Lean et al. 1980). It can be used, to 
an extent, to describe many aspects of GPCR behaviour including heterogeneous agonist binding 
(agonist binding of more than one affinity), receptor-G protein interactions, the actions of inverse 
agonists, allosterism and guanine nucleotide sensitivity. Figure 1.6 on page 32 shows other com­
monly used models of GPCR systems including those based on the ternary complex model. Below 
are simple descriptions for each of the models shown.
Sim ple binding and activation (Figure 1.6a) The most simple model of GPCR activation con­
sists of two steps and two receptor conformations or activation states. Agonist (A) binds to 
the inactive receptor (Rj) to form the non-signalling complex ARj which undergoes a change
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Figure 1.4 The regulation of G protein-coupled receptor activation.
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Figure 1.4: The measurement of efficacy at the level of receptor activation divides ligands into 
three classes. Many GPCRs show a level of activation in the absence of ligand, a behaviour termed 
“constitutive activity.” Ligands which bind to the receptor can increase (agonists) or reduce 
(inverse agonists) the level of receptor activation, or indeed do neither (neutral antagonists). 
Ligands can show intermediate levels of efficacy, such as partial agonists which at similar levels 
of receptor occupancy show a reduced capacity to increase receptor activation. Neutral antago­
nists and inverse agonists are often generally termed “antagonists” due to their similar ability to 
competitively inhibit the binding and action of agonists however there are important therapeutic 
differences in the action of neutral antagonists and inverse agonists. The above figure illustrates 
three hypothetical ligands of different efficacy but equal affinity for the receptor.
29
Chapter 1
Figure 1.5 T he ternary com p lex  m odel o f G p rotein -cou p led  receptor  
activation.
Figure 1.5: (A) The ternary complex model of G protein-coupled receptor activation, first proposed 
in 1980 (De Lean et al. 1980). Agonist A binds to GPCR R  w ith affinity constant K q_ g  protein
G binds independently to R  with affinity constant Kg. Binding of 4  and G to  R  is reciprocal, 
and expressed as cooperativity factor 7 . Agonists (7 >1) promote formation of the  active ARC  
ternary complex and receptor activation. Inverse agonists (7 <1) inhibit formation of the ternary 
complex, and neutral antagonists (7 =1) do not directly effect receptor activation but compete 
against agonist and inverse agonist binding. (B) The extended ternary complex model combines a 
two-state receptor model with the ternary complex model where only the activated receptor (R*) 
can couple to the G protein. Isomerisation constant L represents the transition of receptor between 
inactive (R) and active (R*) states. Three cooperativity factors a , 0  and 7  are required in this 
more complex model. Figure is from Christopoulos and Kenakin 2002
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in conformation, driven by the efficacy of the agonist, to the active receptor complex ARa 
which signals the cellular effect.
Sim ple ternary com plex m odel (Figure 1 .6 b) The inclusion of G protein (G) in models adds at 
least one further step (or two according to Figure 1.5). Formation of the high affinity agonist- 
receptor-G protein (ARa G) ternary complex is the active complex from which the response 
is effected. This model imposes a linear sequence of steps for the activation of G protein and 
does not permit the formation of receptor-G protein complexes in the absence of agonist. 
Formation of RG is however described by the ternary complex model in Figure 1.5A but no 
activity to the complex is formally implicit.
Extended ternary com plex m odel (Figures 1.5B & 1.6c) The extended ternary complex model 
includes receptor activation in the absence of agonist by formation of the Ra G complex. 
Potentially this is a means of incorporating constitutive activity into the scheme where the 
receptor can activate G protein in the absence of agonist by formation of RaG.
Cubic ternary com plex m odel (Figure 1.6d) Thermodynamics require the potential existence 
of complexes consisting of G protein and inactive receptor (RjG). Observations of ligand- 
specific coupling of G protein and GPCRs (such as for the /^-adrenoceptor (Wenzel-Seifert 
and Seifert 2000) provide evidence of a sophisticated system for which more complete, but 
complex, models may be more appropriate.
Models derived from the ternary complex model have been adapted and developed in order to 
describe other aspects of GPCR function such as allosterism and multiple receptor conformations 
(Birdsall and Lazareno 2005, Christopoulos and Kenakin 2002, Kenakin 2003). Work within the 
receptor group here at NIMR has developed a quaternary complex model which is compatible with 
the actions of the allosteric enhancer PD 81,723 which enhances agonist binding at the human 
adenosine A^ receptor (Browning 2003, Browning et al. 2000c).
1.2.3 D rug discovery for G protein-coupled receptors.
The importance of GPCRs as targets for therapeutic intervention was reinforced when the total 
number of GPCR genes in the human body was estimated by sequencing of the human genome 
(Lander et al. 2001). Of the several hundred GPCR genes identified, approximately half have 
been proposed as receptors for endogenous signals such as peptides, lipids, neurotransmitters and 
nucleotides (Vassilatis et al. 2003) providing potential targets for therapeutic intervention. Not 
only do GPCRs represent a huge family of drug targets, but it has been estimated that up to
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Figure 1.6 O ther m odels of G protein-coupled receptor activation.
a  Simple binding and activation 
A  + Rj = = = 2 s  ARj = = AFL
b  Simple ternary complex model 
A + Ri ^  AR, : ARa + G ; ARaG
C Extended ternary complex model d  Cubic ternary complex model
^AR.G
Ligand-mediated receptor activation 
Receptor activation by allosteric modulation 
Activation of G protein in absence of ligand 
Activation of G protein in presence of ligand 
Inactive receptor coupled with G protein
Figure 1.6: Many models have been developed in attempts to quantitatively model the activation 
of G protein-coupled receptors. Above are shown four of the more simple, but more commonly 
employed, models which are described in more detail starting on page 28. The Figure was taken 
from Ellis 2004, which was adapted from that in Kenakin 2002. Figure 1.5 on page 30 describes the 
ternary complex model where formation of receptor-G protein complexes is allowed in the absence 
of agonist.
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half of all modern drugs may act by either enhancing (agonists) or inhibiting (antagonists) the 
activation of GPCRs (Chalmers and Behan 2002). Currently GPCRs exhibit a general suitability 
for therapeutic intervention, so-called “drugability,” but there remains great untapped potential 
not only in the search for interesting compounds but also in the identification of novel mechanisms 
in the control of receptor activation.
A problem in the search for molecules specific for individual GPCRs is the existence of related 
receptor subtypes. For example there are five subtypes of muscarinic acetylcholine receptor in which 
the structure of the acetylcholine binding site (the orthosteric binding site) is highly conserved 
between subtypes (Hulme et al. 1990). Other sites on muscarinic receptors have been characterised 
at which the binding of other ligands can influence binding at the orthosteric binding site. Such 
aliosteric ligands offer the potential to develop agents with “absolute subtype specificity” where the 
allosteric ligand can bind to one receptor subtype with positive or negative cooperativity and to 
the other receptor subtypes with neutral cooperativity. One example of this is the enhancement 
of acetylcholine binding (by means of positive cooperativity) at the muscarinic M4  receptor by 
thiochrome which shows neutral cooperatively at the other receptor subtypes (Lazareno et al. 
2004), and selectively low affinity at the muscarinic M5  receptor (see Birdsall and Lazareno 2005 
for review on allosterism at muscarinic receptors). Cinacalcet, which acts at the calcium-sensing G 
protein-coupled receptor, is the first allosteric ligand to successfully make it to market and is used 
to lower parathyroid hormone levels in patients with uncontrolled secondary hyperparathyroidism 
(Block et al. 2004).
Proteins which modulate GPCR activity, including other GPCRs, are also targets for therapeu­
tic intervention. The regulator of G protein signalling (RGS)-family of proteins can have a direct 
influence on the behaviour of GPCRs and provide novel opportunities for drug discovery (Neubig 
and Siderovski 2002). The consideration of the composition of the receptor signalling complex 
in the development of models and assays presents tremendous complexities. Receptor homo- and 
hetero-oligomerisation along with other protein-protein interactions may in the future provide even 
more opportunities for drug discovery.
1.3 G PC R -m ediated signal transduction across the cell mem­
brane.
G protein-coupled receptors transduce physiological signals across the cell membrane. That is they 
convert an extracellular signal (such as the presence of a neurotransmitter) into an intracellular 
signal (such as a change in the activity of an enzyme like adenylate cyclase). While more simple (but
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experimentally testable) models of receptor activation may incorporate only the ligand, receptor 
and G protein, it is clear there are many other factors which influence the behaviour of GPCRs. 
A vast number of proteins have been proposed to influence GPCR function, of which only a small 
proportion are described below. GPCRs may be selectively localised into or out of a heterogeneous 
network of domains on the cell surface where differences in protein composition may alter GPCR 
function.
The cell membrane is not a homogeneous bilayer assembly of lipids, but is composed of het­
erogeneous regions of varying lipid and protein composition. Traditionally different membrane 
domains have been defined by their method of isolation or visualisation rather than by func­
tional characterisation. The most well described cell membrane domains are those that can be 
easily isolated by their low buoyant density. Typically isolation is achieved by disruption of cell 
membranes by treatm ent with detergents, such as Triton X-100, followed by ultracentrifugation 
and subsequent flotation in a sucrose gradient to separate membrane fractions by their buoy­
ant density. These detergent-resistant membranes are generally characterised by enriched levels 
of more saturated lipids such as cholesterol, glycolipids and sphingolipids and are often termed 
“lipid rafts.” Lipid rafts do not appear to have a consistent protein or lipid composition and the 
lipid profile isolated can depend on the detergent used and the method of isolation (for review 
see Pike 2004). The heterogeneity of isolation methodology and raft composition has led to a de­
gree of confusion regarding the classification and terminology of rafts, caveolae, cholesterol-enriched 
membranes, glycosphingolipid-enriched membranes, detergent-insoluble glycosphingolipid-enriched 
membranes, low-density membranes, Triton X-100 insoluble floating fraction, liquid-ordered do­
mains and detergent-resistant membranes. In this document the terms “raft” and “lipid raft” are 
used in a broad general manner to describe all membrane regions characterised by lighter buoyant 
density and enrichment for caveolin and more saturated lipids.
The functional roles of lipid rafts are manifest by their ability to include and exclude proteins 
from regions of the cell membrane. They appear to function as more structured membrane do­
mains floating within more fluid, but less structured, regions of the cell membrane. Experiments 
investigating the diffusional behaviour of the /i opioid receptor observed two distinct modes of 
diffusion. A short-term rapid diffusion, postulated to be diffusion confined within lipid raft do­
mains, and a long-term slow diffusion of the raft itself through the cell membrane (Daumas et al. 
2003). GPCRs, including the adenosine Aj receptor (Escriche et al. 2003, Gines et al. 2001), 
and G a subunits, such as G aj (Elenko et al. 2003), have been shown to accumulate in lipid rafts 
following agonist treatm ent and receptor activation. The selective localisation in rafts of other 
proteins which influence the activity of the A^ receptor and Ga^ may mediate mechanisms con­
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trolling receptor signalling such as desensitisation and internalisation. In contrast, the thyrotropin 
receptor (a GPCR) when expressed in CHO cells is predominantly present in lipid rafts regardless 
of the presence of thyrotropin (Latif et al. 2003). In Drosophila the affinity of glutamate at the 
metabotropic glutamate receptor has been observed to depend on whether the receptor is associ­
ated within lipid raft domains (Eroglu et al. 2003). As appears to be the case for many aspects 
of GPCR behaviour, the nature of association in or out of lipid rafts and the interaction with 
additional proteins are dependent on the nature of the receptor and not consistent for all GPCRs.
An important element of the control of GPCR activation is the ability to reduce the level of 
signalling from activated receptors. The reduction in the level of receptor signalling, even in the 
continued presence of agonist stimulation, is generally termed “densensitisation.” Desensitisation 
can operate directly at the level of the receptor and is usually accomplished by phosphorylation 
of the C terminus or third intracellular loop of the GPCR (Ferguson 2001). GPCRs can be 
phosphorylated by second-messenger kinases such as protein kinase A (PKA) and protein kinase 
C (PKC), or by G protein-coupled receptor kinases (GRKs; for review see Pitcher et al. 1998). 
Desensitisation may also occur at the level of G proteins where the large RGS family of GTPase 
activating proteins accelerate the rate of GTP hydrolysis (De Vries et al. 2000). Slower processes 
which result in receptor desensitisation include degradation of the receptor itself in lysosomes, and 
down-regulation of receptor transcription and translation.
Desensitisation by PKA- and PKC-mediated GPCR phosphorylation can be more “heterolo­
gous” than desensitisation mediated by GRKs which can be more agonist-specific. Phosphorylation 
of the (32  adrenergic receptor by PKA has been shown to encourage coupling of the receptor to Ga^ 
rather than Gas, changing the downstream response to adrenergic receptor activation (Zamah 
et al. 2002). Seven members of the GRK family have been identified, of which GRKs 1, 4 and 7 
have more specific actions while the other GRKs regulate a larger number of receptors (Ferguson 
2001). GRK2, also known as /^-adrenergic receptor kinase, is believed to be distributed widely and 
phosphorylate a large number of GPCRs (Krupnick & Benovic 1998).
Signalling by activated GPCRs is further reduced by the internalisation of receptors following 
continued agonist stimulation. The /3-arrest in family of proteins are involved in many GPCR 
signalling functions and have important effects on GPCR behaviour (for review see Pierce and 
Lefkowitz 2001). As well as serving other physiological roles, /3-arrestins are important in the 
internalisation of the /? 2  adrenergic receptor (Ferguson et al. 1995) and the muscarinic M2  receptor 
(Krupnick & Benovic 1998). Arrestins bind to phosphorylated receptors and can form high affinity 
agonist-receptor-arrestin complexes (Gurevich et al. 1997) which may be responsible for a small 
proportion of high affinity agonist binding which can be insensitive to guanine nucleotides.
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While some GPCRs exist as constitutive oligomers, such as the GABAg receptor, other 
GPCRs may not form constitutive oligomers but may at times form transient or ligand-dependent 
oligomeric complexes. Formation of temporary oligomeric complexes requires individual GPCRs 
to locate other available receptors before they can form an oligomer. Increasing the local concen­
tration of the receptor, by clustering into or out of membrane domains such as rafts, may favour 
this. Selective localisation of membrane proteins may not only control the concentration and type 
of GPCR available, in the case of hetero-oligomerisation, but also the availability of other proteins 
important in GPCR function and signalling such as G proteins or RGS proteins.
1.4 Adenosine and adenosine receptors.
Extracellular nucleotides and nucleosides such as adenosine and ATP are involved in many different 
physiological functions. The actions of extracellular ATP and other nucleotides (such as ADP, UTP 
and UDP) are mediated through the the P2 class of purinoceptors which include the P2X family 
of ligand-gated ion channels, and the P2Y family of G protein-coupled receptors (for reviews see 
Vial et al. 2004 and von Kugelgen and Wetter 2000, for P2X and P2Y receptors respectively). 
The PI class of purinoceptors consists of four G protein-coupled receptors for adenosine (A]_,
A2 g , and A3 ) each encoded by distinct genes (Fredholm et al. 2000). Conservation of the four 
adenosine receptors in several different species is visualised in Figure 1.7 on page 44. In general, 
functional classification separates adenosine receptors into their ability to inhibit (in the case of 
Aj and A 3 )  and stimulate ( A 2 A and A2 g ) adenylate cyclase activity following receptor activation. 
Activation of A^ and A3 adenosine receptors can also increase levels of intracellular Ca^ r  and alter 
the electrical potential across the cell membrane. Figure 1.8 on page 45 illustrates these immediate 
downstream consequences of adenosine receptor activation.
Adenosine receptors are expressed throughout the human body, and adenosine A^ receptors 
are found in abundance in the cardiovascular system and the brain (for reviews see Fredholm et al. 
1999, Fredholm et al. 2000). Levels of adenosine can increase as a result of oxidative stress and 
ischemia where inhibition of synaptic excitability is believed to be the consequence of adenosine Aj 
receptor activation. Depression of rat hippocampal slice excitability induced by in vitro ischaemia 
can be reduced by the selective adenosine Aj receptor antagonist DPCPX at concentrations of 50- 
500 nM (Latini et al. 1999). Adenosine is generally perceived as a molecule with inhibitory actions 
within the brain and heart, with roles including overall reduction in wakefulness and protective 
inhibition of metabolism following ischaemic injury.
Adenosine is produced within the cell and in extracellular regions and can be transported across
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the cell membrane passively and actively. In both environments adenosine can be synthesised 
by dephosphorylation of AMP and metabolised by adenosine deaminase into inosine. Adenosine 
deaminase has been described in extracellular plasma, membrane-bound and in the cytosol (for 
review see Deussen 2000). The molecular structure of adenosine is illustrated in Figure 2.1 along 
with other adenosine A j receptor agonists and antagonists.
Reported values of the concentration of endogenous adenosine in rat brain range from 30 nM 
to 30 /xM (Cohen et al. 1996a, Porkka-Heiskanen et al. 1997 and Latini et al. 1999). It is difficult 
to measure the concentration of endogenous adenosine in the immediate receptor environment, 
although electrophysiological studies observed a maximum local adenosine concentration of 30 /xM 
during an ischaemic episode (Latini et al. 1999). Estimation of the affinity of adenosine for adeno­
sine receptors is difficult due to the presence of endogenous adenosine in purified cell membranes. 
Typically adenosine deaminase is applied to remove endogenous adenosine, but adenosine deami­
nase itself has to be removed if adenosine is then used as a ligand. Reported affinities of adenosine 
are 7 xlO^ and 1.3 xlO^ for the high and low affinity states of the adenosine Aj receptor 
(Cohen et al. 1996a). Local /xM adenosine concentrations would therefore largely occupy and 
activate the high affinity adenosine A^ receptor state.
Few adenosine receptor ligands have made it into clinical use, other than adenosine itself which 
can be used in the treatm ent of excessively rapid beating of the heart. However adenosine receptors 
axe molecular targets of the most widely consumed recreational drug in the world, namely caffeine 
(for review see Fredholm et al. 1999). Adenosine receptors remain attractive targets for drug 
development due to their widespread distribution throughout the human body and roles in many 
important physiological and pathophysiological processes. Interest is only increased by the current 
lack of clinically effective ligands targeting adenosine receptors and the general interest in G protein- 
coupled receptors as therapeutic targets.
1.4.1 T he adenosine receptor.
The adenosine A^ receptor is expressed throughout the brain and is found both pre- and post- 
synaptically. Activation of the adenosine A^ receptor inhibits neurons pre-synaptically by reducing 
the release of neurotransmitter and post-synaptically by modulating ionic currents. The inhibitory 
actions of adenosine A j receptor activation are transduced largely through activation of Gj and Go 
G proteins mediating activation of phospholipases, inhibition of Ca^+  conductance and activation 
of K+  conductance as illustrated in Figure 1.8 (for review see Haas and Selbach 2000). Immunopre- 
cipitation of G a subunits from stable CHO cell lines expressing the human adenosine A^ receptor
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showed the receptor to activate Gaj, and Gets G protein a  subunits (Cordeaux et al.
2000). Also, differential activation of Ga^, Gaq and Gas may be dependent on the nature of the 
agonist bound at the receptor (Cordeaux et al. 2004).
The adenosine receptor is of use experimentally for a number of reasons. Agonists of varying 
efficacy and radiolabelled agonists and antagonists are readily available for the A^ receptor. The A^ 
receptor shows a large separation between high and low agonist affinity binding constants (“GTP 
shift”) which provides a large window with which to investigate the effect of agonist efficacy or 
guanine nucleotides on the nature of agonist binding. The A^ receptor also possesses an allosteric 
binding site, permitting its use as a model of allosterism at GPCRs. Finally, the A^ receptor is 
a member of the large rhodopsin family of GPCRs and shares similarities with a large number of 
other GPCRs. All these features, along with physiological interest in the Aj receptor itself, make 
the adenosine Aj receptor an interesting and useful model GPCR.
The adenosine A j receptor was originally cloned using a canine thyroid library (Libert et al. 
1992) and soon afterwards the receptor was cloned from other mammals including humans. Both 
the human and mouse adenosine Aj receptors are translated from two exons separated by a single 
intron while transcription is controlled by two upstream promoters. The human adenosine A^ 
receptor amino acid sequence is 326 residues long and shows a characteristic seven transmembrane 
domain composition with a very short N-terminus (10 residues) and an eighth helix in the plane 
of the membrane at the C-terminus (Figure 1.9 on page 46). The sequence contains a potentially 
palmitoylated cysteine residue in the C-terminus (residue 309), a potential N-linked glycosylation 
site in the second extracellular loop (residue 159) and a putative disulphide bond between cysteine 
residues in the first (residue 80) and second (residue 169) extracellular loops. The estimated 
molecular weight of the human adenosine A^ receptor from its sequence is 36.5 kDa.
Targeted disruption of the adenosine A^ receptor in mice removed the effect of adenosine on 
excitatory neurotransmission and altered the neuronal response to hypoxia (Johansson et al. 2001). 
In normal conditions mice with targeted disruption of the adenosine Aj receptor showed normal 
viability (up to an age of 50 days) supporting a largely protective role for the receptor.
Adenosine Aj receptor activation is modulated by both desensitisation and internalisation. 
Wetherington and Lambert (2002) showed desensitisation of the adenosine A^ receptor following 
chronic agonist application in rat hippocampal neurons. Also, pre-synaptic A^ receptors desen­
sitised much more slowly than post-synaptic A^ receptors, suggesting the mechanism of desensi­
tisation differ in different membrane domains of the same cell. Although adenosine Aj and A3  
receptors share generally inhibitory actions, the A3  receptor is desensitised much more quickly 
(Palmer et al. 1996, TYincavelli et al. 2002). Different sensitivity of the A^ and A3  receptors
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to phosphorylation may contribute to the differences observed in desensitisation (Ferguson et al. 
2000). Other studies have shown ligand-induced internalisation of the receptor involving ac­
cumulation of the receptor into low-density gradient fractions characterised by increased levels of 
caveolin (Escriche et al. 2003, Gines et al. 2001). Recently, Briddon et al. (2004) observed the 
intracellular accumulation of the fluorescently labelled Aj receptor antagonist XAC-BY630 fol­
lowing longer periods of incubation, which was blocked to an extent by the unlabelled antagonist 
DPCPX. This suggests tha t XAC-BY630 can accumulate within the cell by a receptor-dependent 
mechanism such as receptor internalisation. It is unclear whether relocation of the adenosine A^ 
receptor into less-dense caveolin-enriched membrane domains is important in receptor function or 
whether it is primarily a mechanism of ligand-induced receptor internalisation.
There is little evidence of adenosine A^ receptor homo-oligomerisation. A provisional im- 
munoblotting and immunoprecipitation report described the isolation of adenosine Aj receptor 
dimers from pig brain cortex, however these complexes were not stable in the presence of agonist 
or antagonist (Ciruela et al. 1995). The adenosine Aj receptor has been reported to form hetero- 
oligomeric complexes with other GPCRs including the dopamine Dj receptor (Gines et al. 2000), 
metabotropic glutamate type l a  receptor (Ciruela et al. 2001), and the P2Y | receptor (Yoshioka 
et al. 2001). Of the three reports listed, the report by Ciruela et al. is of the most interest because 
they characterised the interaction of m G lula and A^ receptors in detail in transiently transfected 
cells and also provided evidence for co-localisation of the two receptors in vivo, in rat cerebellar 
neurons.
Adenosine receptor agonists.
Adenosine, the endogenous agonist for adenosine receptors is of limited use as an experimental tool 
because adenosine deaminase is routinely added in order to remove adenosine found in membrane 
preparations. Consequently estimation of the affinity of adenosine is difficult, as discussed above. 
Adenosine provides the structural core for other adenosine receptor agonists and partial agonists. 
Figure 1 .1 0  on page 47 shows the three positions on adenosine which are modified in the creation 
of the agonists and partial agonists illustrated in Figure 2.1 on page 50. CHA and PI A are two 
adenosine receptor agonists which have been modified at the iV6-position of the adenosine purine. 
Both CHA and PIA are resistant to adenosine deaminase and exhibit affinities for the human 
adenosine A^ receptor up to 1 0 -fold greater than adenosine (Cohen et al. 1996a). Affinities of 
CHA and PIA for the human adenosine Aj receptor are determined in Chapter 4. All adenosine 
receptors, but especially the adenosine Aj receptor, show strong stereoselectivity for R-PIA rather 
than the S-isomer (Klotz et al. 1998). The human adenosine A^ receptor shows almost 40-fold
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higher affinity for J7-PIA than 5-PIA (the structure of P-PIA is shown in Figure 2.1 with the 
chiral centre illustrated at the top of the molecule). The lower efficacy adenosine Aj receptor 
agonists GR162900 and GR161144 (Figure 2 .1  and Sheehan et al. 2 0 0 0 ) axe modified at both the 
A pposition of the purine ring and the 5‘-position of the ribose. GR190178 is modified at all three 
positions described in Figure 1.10 and shows the highest efficacy out of the three GR compounds, 
although still considerably less than CHA or PIA. The affinity and measure of efficacy of the three 
GR compounds for the human adenosine A^ receptor are characterised in Chapter 4 .
Adenosine receptor antagonists and inverse agonists.
The adenosine receptor antagonist caffeine is arguably “the most widely consumed behaviourally 
active substance in the world” (Fredholm et al. 1999). Caffeine is a member of the methylxanthine 
class of compounds which includes other adenosine receptor antagonists such as theophylline and 
DPCPX (illustrated in Figure 2.1). In humans DPCPX is selective for the adenosine A^ receptor 
over the other adenosine receptor subtypes by at least 30-fold, and in the rat by over 1000-fold 
(Klotz et al. 1998). Consequently [^H]DPCPX has established itself as the ligand of choice for 
measuring the adenosine A^ receptor Bmax- DPCPX is actually an inverse agonist at the adenosine 
A | receptor, although it is generally referred to as an antagonist.
Allosterism  at the adenosine A^ receptor.
Increasing interest in GPCR pharmacology and drug discovery is being driven by the potential of 
allosteric compounds. The compound PD 81,723 is an allosteric enhancer of agonist binding at 
the adenosine A^ receptor (Bhattacharya and Linden 1995, Bruns and Fergus 1990, Cohen 1995). 
Work in the group prior to this study investigated the mechanism of action of PD 81,723 on the 
binding of a series of ligands with a range of intrinsic activities to the coupled and uncoupled states 
of the human adenosine A^ receptor. The results were explained by the ability of PD 81,723 to 
activate the adenosine A^ receptor from the allosteric site on the receptor and by its ability to act 
as a co-agonist with agonist binding to the orthosteric site to increase affinity of the A^ receptor 
for its G protein (Browning 2003, Browning et al. 2000c).
1.4.2 A denosine A j  recep tor-G  protein  fusion proteins.
Proteins where a G protein a-subunit is covalently attached to the C-terminus of a GPCR have 
been developed for several different receptors including the /? 2  adrenoceptor (Bertin et al. 1994), 
a 2A adrenoceptor (Wise et al. 1997), IP prostanoid receptor (Fong and Milligan 1999), 5-HT1A 
receptor (Kellet et al. 1999) and adenosine Aj receptor (Bevan et al. 1999, Wise et al. 1999).
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Typically the attached G proteins are modified by mutation of the cysteine residue near the C- 
terminus of the G protein. This has the effect of rendering the mutated G protein insensitive to 
ADP-ribosylation by pertussis toxin, which functionally inactivates members of the Gj family of 
G proteins. However, mutation of the cysteine residue can interfere with the normal interactions 
between receptor and G protein and effects can vary depending on the amino acid to which the 
residue to mutated (Jackson et al. 1999). Often GPCR-G protein fusion proteins are constructed 
in order to constrain the system to a 1:1 stoichiometry. The fusion of pertussis toxin insensitive 
G proteins to the receptors enables the use of pertussis toxin to inactivate endogenous G protein 
with which the receptor might otherwise interact. Even when there is an available G protein in 
close proximity for each receptor both high and low affinity agonist binding is observed. Despite 
the 1:1 stoichiometry of receptor to G protein, the GPCR-G protein fusion constructs appear to 
behave in much the same manner as when not covalently attached to G protein.
Adenosine A^ receptor-G protein fusion constructs have been used to investigate features of 
receptor-G protein interaction. Wise et al. 1999 reported little difference in the ability of the 
adenosine A} receptor to couple to the G proteins G a ^ , G c ^ , Gcxjg and G a0 i .  They also 
showed for a range of agonists no selective activation of any adenosine receptor-G^/Q protein 
combination studied. Waldhoer et al. 1999 used adenosine Aj receptor-G protein constructs (G a^ 
and Gao) to investigate the kinetics of the formation and dissociation of the ternary complex 
(agonist-receptor-G protein). Adenosine A^ receptor-G a^ fusion proteins were created where the 
pertussis toxin sensitive cysteine was replaced with glycine or isoleucine. The two fusion proteins 
show different affinities of the receptor for the G protein. Using both constructs they found receptor 
activation was the rate limiting step in ternary complex formation rather than the availability and 
recruitment of G protein.
Klaasse et al. 2004 observed similar allosteric modulation by PD 81,723 for the adenosine A^ 
receptor alone and A} receptor-G protein fusion constructs, using G a ^  subunits where the cysteine 
residue conferring pertussis toxin sensitivity was replaced with one of eight different amino acids 
(Gly, lie, Phe, His, Pro, Arg, Ser, Val). The affinity of agonist CPA increased by more than 8 -fold 
for the fusion proteins than the receptor alone, whereas DPCPX showed no significant difference 
in affinity between the receptor alone and the fusion proteins. This provides further evidence of 
relatively “wild-type” behaviour for adenosine A2 receptor-G protein fusion constructs. Functional 
analysis of receptor activation by means of [^S ]G T P 7 S binding showed increased basal levels of 
receptor activation (constitutive activity) for the fusion proteins relative to the adenosine A^ 
receptor alone.
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1.4.3 A denosine recep tor-G F P  fusion proteins.
The labelling of proteins by covalent attachment of green fluorescent protein (GFP) is a phenom­
enally popular technology in the investigation of protein localisation, trafficking and expression 
(Tsien 1998). There have been only limited reports of the effects of labelling the adenosine 
receptor with GFP. The functional analysis of membranes prepared from stable CHO cell lines 
expressing either the human adenosine receptor—Gcq (A^R-Gcq) or adenosine A^ receptor-
G FP-G aj (A jR-G FP-G aj) fusion constructs found little difference in the response to agonist 
activation in the absence of pertussis toxin (Bevan et al. 1999). This provided evidence tha t GFP 
may be attached to the human adenosine Aj receptor without disrupting receptor behaviour. The 
Gcq subunit used in both fusion constructs was resistant to inactivation by pertussis toxin. How­
ever, in the presence of pertussis toxin, only the A^R-GFP-Gcq construct showed stimulation of
QC
[ SJGTP7 S accumulation by the adenosine Aj receptor agonist NECA. Confocal microscopy of 
the A^R-GFP-Gaj construct in live CHO cells observed GFP fluorescence in cytoplasmic mem­
branes and the cell membrane.
1.4.4 S tudies in vestigatin g  th e  effect o f adenosine A^ receptor expres­
sion level.
Previous studies within the receptor group at NIMR have used two stable CHO cell lines expressing 
the human adenosine Aj receptor at high (A^HE) and low (A^LE) levels (Cohen 1995, Browning 
2003). Features of agonist binding to the adenosine A^ receptor at equilibrium were dependent on 
the level of receptor expression, but not quantitatively compatible with all the predictions of the 
ternary complex model of agonism (Browning et al. 2000b). Differences in the functional response 
to agonist activation of the adenosine A^ receptor, characterised by [^S ]G T P 7 S accumulation, 
were observed using the two cell lines (Browning et al. 2000a,c). Also, the effect of the allosteric 
enhancer PD 81,723 was investigated at both levels of receptor expression (Browning et al. 2000c).
The dissociation of radiolabelled agonist from A^HE membranes was incomplete, and in prelim­
inary experiments was enhanced by the presence of an excess concentration of unlabelled agonist 
(so-called “agonist-induced agonist dissociation;” Browning 2003). This behaviour was not ob­
served at low levels of adenosine A j receptor expression using the A^LE membranes. The kinetics 
of agonist dissociation and dependence on the level of receptor expression and the nature of com­
peting unlabelled ligand were not characterised. These observations provided the basis from which 
a large proportion of the work presented in this study developed.
Using membranes prepared from stable CHO cell lines expressing different levels of the human
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adenosine Aj receptor differences have been identified in some agonist potencies and “agonist 
trafficking” at two levels of receptor expression (Cordeaux et al. 2000). The concept of “agonist 
trafficking,” where the nature of the functional response to receptor activation can be influenced 
by a particular agonist, may be of help in improved understanding of the functional response to 
receptor activation (Kenakin 1995).
1.5 Project Aims.
The aim of this project was to investigate in detail the effect of the level of receptor expression on 
the binding of agonists and antagonists at the human adenosine receptor. Membranes prepared 
from a large number of stable CHO cell lines expressing the adenosine A^ receptor or AjR-GFP 
fusion proteins were used in order to investigate in detail the effect of receptor expression level on 
agonist binding at equilibrium and the kinetics of agonist binding directly at the adenosine A^ 
receptor. The work presented in this thesis is described in five chapters of experimental results;
Chapter 3 describes the creation by flow cytometry of the series of stable CHO cell lines express­
ing the A jR -G FP fusion proteins at a wide range of expression levels.
Chapter 4 examined in detail the effect of the level of A \  receptor expression on the binding of 
agonists and antagonists at equilibrium.
Chapter 5 characterised in detail the kinetics of agonist and antagonist binding at the adeno­
sine A^ receptor and describes novel details of the promotion of [^H]agonist dissociation by 
unlabelled agonist, so-called “agonist-induced agonist dissociation.”
Chapter 6 describes the dependence of agonist-induced agonist dissociation on the level of adeno­
sine A i  receptor expression.
Chapter 7 investigated the distribution of the adenosine A^ receptor and A^ R-GFP fusion pro­
teins in cell membrane fractions separated by their buoyant density.
43
Chapter 1
Figure 1.7 A denosine receptor phylogenetic tree.
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Figure 1.7: Phylogenetic tree of A^, A2 ^ ,  A2 g , and A3  adenosine receptor sub-
types. Taken from Fredholm et al. 2001, which was redrawn from that available at 
http://www.gpcr.org/7tm /seq/001_007_001/001_007_001.TREE20.html (as of April 2005).
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Figure 1.8 Adenosine receptor coupling.
a  Adenosine A, and A3 receptor coupling to G/G0 G proteins
K+
AC
Cter
icAMP
b  Adenosine A2A and A2B receptor coupling to Gs G proteins
Cter
tcAMP
Figure 1.8: (a) The inhibitory actions of adenosine A | and A3 receptor activation axe associated 
with activation of Gcq and G a0 G proteins and the subsequent inhibition o f adenylate cyclase (AC) 
activity, activation of K + channels and inhibition of Ca2+ channels. It appears the A^ receptor 
can also activate G a s and G aq subunits to a lesser extent than Geq and in an agonist-specific 
manner (Cordeaux et al. 2004) ( b )  Activation of adenosine A2a  and A2B receptors stimulate the 
activity of adenylate cyclase. Figure adapted from Ellis 2004.
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Figure 1.9 The human adenosine A j receptor am ino acid sequence.
General information
Entry name AA1R_HUMAN
Accession number P 305 4 2 . Q8TAM8 
Created Rel. 25, 1 -APR-1993
Sequence update Rel. 25, 1-APR-1993 
Annotation update Rel. 47, 1-MAY-2005
Description and origin of th e  Protein
Description Adenosine Al receptor.
Gene name(s) ADORA1
Organism source Homo sapiens (Human).
Features
■ DOMAIN
■ TRANSAtN
• 0ISULFI0
■ CMDOH-iO 
LWID
■ CONFLICT
3 «= = =
■ •
f t
-  -----
>«• 15 * 2*1 250 300
Key Begin End Length Description
DOMAIN 1 10 10 Extracellular (Potential).
|TBA.NSMEM 11 33 23 1 (Potential).
DOMAIN 34 46 13 Cytoplasmic (Potential).
|  TRANSMEM 47 69 23 2 (Potential).
DOMAIN 70 80 11 Extracellular (Potential).
|  TlVWSMEM 81 102 22 3 (Potential).
DOMAIN 103 123 21 Cytoplasmic (Potential).
|  TRANSMEM 124 146 23 4 (Potential).
DOMAIN 147 176 30 Extracellular (Potential).
|  TRANSMEM 177 201 25 5 (Potential).
DOMAIN 202 235 34 Cytoplasmic (Potential).
|  TRANSMEM 236 259 24 6 (Potential).
DOMAIN 260 267 8 Extracellular (Potential).
|  TFA.NSMEM 268 292 25 7 (Potential).
DOMAIN 293 326 34 Cytoplasmic (Potential).
| DISULPID 80 169 90 By similarity.
I  CARBOHYD 159 159 1 N-linked (GlcNAc..) (Potential).
LIPID 309 309 1 S-palmitoyl cysteine (Potential).
Sequence information
Length: 326 aa, molecular weight: 36 512  Da, CRC64 checksum: 1B555893BCDEC9A6
SO S e q u e n c e  3 2 6  B P ;
M PPSISAFQA A Y IG IE V L IA  LVSVPGNVLV IWAVKVNQAL RDATFCFIVS LAVADVAVGA 60
L V IP L A IL IN  IGPQTYFHTC LMVACPVLIL TQ 5SILA LLA  IAVDRYLRVK IPLRYKMW T 1 2 0
PRRAAVAIAG C W ILSFW G L TPMFGWNNLS AVERAWAANG 3MGEPVIKCE FEKVISMEYM 180
VYFNFFVWVL PPLLLMVLIY LEVFYLIRKQ LNKKVSASSG DPQKYYGKEL KIA KSLA LIL 2 4 0
FLFALSWLPL K IL N C IT L FC  PSC H K PSILT YIA IFLTHGN SAMNPIVYAF RXQKFRVTFL 3 0 0
KIMNDHFRCQ PA PPID ED LP EERPDD 3 2 6
Figure 1.9: The amino acid sequence of the human adenosine A i  receptor. Also shown are de­
tails including the entry name and accession number, and the proposed composition of features 
such as transmembrane domains and post-translational modifications. The image was taken from 
http://srs.ebi.ac.uk/.
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Figure 1.10 T he m odification  o f adenosine to  create other adenosine  
receptor agonists.
A/6-position of the purine
2-position of the purine
HO
HO 'OH
5-position of the ribose
Figure 1.10: Adenosine is typically modified in three positions (indicated above) in order to alter 
affinity and specificity for adenosine receptors and sensitivity to degradation by adenosine deam­
inase. Figure 2.1 on page 50 illustrates the structures of adenosine receptor agonists CHA, PIA, 
GR190178, GR162900 and GR161144 which show modifications at one or more of the three posi­
tions and are all insensitive to adenosine deaminase. The above illustration was redrawn from that 
in Klotz 2000.
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Materials and methods.
2.1 M aterials.
Cell C ulture
Chinese hamster ovary (CHO) cells stably expressing the human adenosine receptor at two 
different densities were a kind gift from Prof. Stephen Hill, The University of Nottingham. Stable 
CHO cell lines expressing either HA-A^R, A^R-GFP or A^R-GFP-Ga^ fusion proteins were a kind 
gift from Dr. Chris Browning, GlaxoSmithKline, Stevenage. The A^R-GFP-Gaj construct had 
Cys351 of the Gjt* sequence m utated to glycine, thereby rendering the G protein insensitive to ADP 
ribosylation by pertussis toxin (Bevan et al. 1999). DMEM-F12 media, G418 and HBSS were from 
Sigma. Penicillin, streptomycin, glutamine and trypsin versene were from in-house media supplies. 
All plastic culture vessels were BD Falcon. BCA Protein Assay Reagent Kit (including 2 mg/ml 
BSA ampules) was from Pierce Biotechnology. Foetal calf serum was from Labtech International 
(batch no. F-2395).
C om pounds
ADA (A-9876), CHA (C-9901), DMSO (D-8779), DPCPX (C-101), GTP (G-8877), Hepes (H- 
3375), N0840 (N-154), PIA (P-4532), polyethyleneimine (P-3143), Saponin (S-1252), Theophylline 
(T-1633) and Tris (T-1503) were from Sigma. EDTA was from Fisons. GR1690178, GR161144 and 
GR162900 (see Figure 2.1 on page 50) were a kind gift from Dr. Chris Browning, GlaxoSmithKline, 
Stevenage.
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R adioligand b inding
pHJCHA (29.5 and 32.3 Ci/mmol) and [3 H]DPCPX (108.3, 111.6 and 120.0 Ci /mmol) were from 
Perkin Elmer Life Sciences, Inc. [^H]CHA (24 Ci/mmol) was from Moravek Biochemicals, Califor­
nia. Ready Safe scintillation fluid and 6  ml Pony vials were from Packard Bioscience. GF/B glass 
fibre filter paper was from W hatman. Printed Filtermat A, Meltilex A and Sample Bags were from 
Wallac, Finland.
D en sity  gradient separation  o f m em brane fractions
OptiPrep (60% w /v iodixanol in water) was from Axis-Shield PoC AS, Oslo. Triton X-100 (T 9284) 
and Protease Inhibitor Cocktail in DMSO (P 8340) was from Sigma. Open-top 5 ml polyallomer 
centrifuge tubes were from Beckman. OptiPrep is the trademark name for sterile 60% (w/v) 
solution of iodixanol in water.
SD S-PA G E and W estern  b lottin g
10% and 4-12% Bis-Tris NuPAGE Novex gels, NuPAGE MOPS SDS running buffer (20x), Nu- 
PAGE transfer buffer (20x), NuPAGE Sample Buffer (4x), PVDF Membrane Filter Paper Sand­
wich and SeeBlue Plus2 Pre-Stained Standard were from Invitrogen Ltd, Paisley. Dithiothreitol was 
from Sigma. Rabbit polyclonal primary antibodies for A^R (ab3460 and abl3295), D^R (abl2969), 
G 'Qi l + 2  (ab3522) Caveolinl (ab2910) and Fyn (abl3955) were from Abeam Ltd, Cambridge. Rab­
bit polyclonal primary antibodies for G a ^ 2  (S-20), G a ^  (A-20) and Gaj^(I-20) were from Santa 
Cruz Biotechnology Inc, California. Goat polyclonal primary antibody for G a ^ 0// ^ Z(D-15) was 
from Santa Cruz Biotechnology Inc, California. Rabbit polyclonal IgG antibody for GFP (A-1 1 1 2 2 ) 
was from Molecular Probes Europe BV, The Netherlands. Rabbit polyclonal HRP-linked secondary 
antibody to goat IgG (ab6741) was from Abeam Ltd, Cambridge. Donkey polyclonal HRP-linked 
secondary antibody to rabbit IgG (NA934) was from Amersham Biosciences UK Ltd. Tween-20 
(polyoxyethylene sorbitan monolaurate) was from Bio-Rad Laboratories, California. Marvel Dried 
Skimmed Milk powder was from Premier International Foods (UK) Ltd. Enhanced chemilumines- 
cence (ECL) detection system was from Amersham Biosciences UK Ltd. PBS was from in-house 
media supplies. Blue-light sensitive Kodak X-OMAT AR autoradiography film (8  x 10 inch) was 
from Kodak. Table 2.1 on page 57 lists all the primary antibodies used for Western blots presented 
in Chapters 2, 3 and 7.
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Figure 2.1 T he structures o f adenosine A j  receptor ligands used in th is  
study.
NH;
HO
HO OH
NH
HO
HO OH
Adenosine CHA
OH;
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HO' OH
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N
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Theophylline DPCPX
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CH;
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N N
OHHOHO OH
GR190178
NH
OHHO
GR161144
Figure 2.1: CHA and PI A are high efficacy agonists at the human adenosine A^ receptor. 
GR190178, GR162900 and GR161144 are agonists of lower efficacy. DPCPX, N0840 and theo­
phylline are antagonists /  inverse agonists. Adenosine is shown for comparison.
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2.2 M ethods.
2.2.1 C ell cu lture
Stable CHO cell lines were maintained in a routine fashion in DMEM-F1 2  medium supplemented 
with penicillin, streptomycin, glutamine and 1 0 % foetal calf serum (all foetal calf serum in this 
study was from the same batch) at 37°C in 5% CO2 . Typically cells were detached using trypsin 
versene and passaged 1:10 to 1:20 approximately every 3 days. For preparation of membranes, cells 
from a confluent 175 cm2  flask were seeded into a 1750 cm2  cell culture roller bottle with 300 ml 
media and incubated at 37°C in normal air (although roller bottle is airtight when closed) while 
rotating at approximately 0.5 rpm. Membranes were harvested after 4-7 days incubation. Media 
was exchanged for fresh media if the roller bottles were incubated for longer than 4 days.
2.2.2 M em brane preparation
All radioligand binding presented in this thesis was performed using membranes prepared from 
CHO cell lines stably expressing the human adenosine Aj receptor or A jR  fusion constructs.
The preparation of cell membranes was based on previous protocols (Cohen et al. 1996a&b,
c\
Browning 2003). Briefly, membranes from cells grown in 1750 cm roller bottles were harvested 
when the cells were between 80% and fully confluent. Cells were washed with HBSS a t room 
temperature and incubated and lysed with a hypotonic homogenisation buffer (20 mM Hepes, 
10 mM EDTA, pH 7.4, 4°C), detached by gentle agitation, and separated by slow centrifugation for 
5 min at 3000 rpm at 4°C. The lysed cells were resuspended in homogenisation buffer, disrupted in a 
Polytron homogeniser (12,000 rpm for 15 sec or 3 intervals of 5 sec) and the membranes separated by 
centrifugation at 40,000 g for 20 min at 4°C. The membrane pellet was resuspended in membrane 
buffer (20 mM Hepes, 0.1 mM EDTA, pH 7.4, 4°C), disrupted in a Polytron homogeniser and 
centrifuged at 40,000 g as above. The membrane pellet was resuspended in membrane buffer, 
passed through a 27G needle and stored in 0.5 ml aliquots at -70°C. The protein concentration of 
thawed membranes was determined in triplicate using the Pierce BCA Protein Assay reagent kit 
in 96 well microplates (Smith et al. 1985). Absorbance at 550 nm was referenced against serial 
dilutions of BSA.
2.2.3 Equilibrium  radioligand binding
All equilibrium binding assays were performed at RT in a final volume of 1 ml in binding assay 
buffer as described previously, 20 mM Hepes, 100 mM NaCl, 10 mM MgCl2 , pH 7.4, (Cohen et
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al. 1996b). Saturation assays were performed in quadruplicate, competition assays in triplicate 
or quadruplicate. In order to remove endogenous adenosine which would interfere with the as­
says, membranes were pre-incubated with approximately 3 U/ml adenosine deaminase (ADA) for 
30 min at RT, and stored on ice afterwards. No apparent difference was observed in association 
time courses of [^H]CHA to A^HE membranes following incubation with 1 or 10 U/ml adenosine 
deaminase (data not shown), suggesting the typical concentration of 3 U/ml ADA to be adequate 
at removing adenosine. All equilibrium binding assays contained 30 ng/ ml of the membrane per- 
meabilising agent saponin unless indicated. For radioligand equilibrium saturation binding studies, 
radioligand was incubated with 10 to 37 /ig/ml of membrane protein in the presence of 30 pg/ml 
saponin for 60 min before rapid filtration onto glass fibre filters soaked in 0 .1 % polyethyleneimine 
using either a 48 well Branded cell harvester or a 96 well Tomtec Mach III M Harvester 96. Fol­
lowing filtration, the glass fibre filters were rapidly washed three times with ice cold water. The 
48 well filters were transferred to liquid scintillation vials and 4 ml of scintillation fluid added. 
Typically vials were left for 24 hours, but at least overnight, at RT to allow the filters to become 
universally translucent. Vials were shaken thoroughly before counting in a Beckman LS 5000CE 
liquid scintillation counter for 5 or 20 min. 96 well filters were dried overnight at RT or 1 hour 
at 50°C, then Meltilex scintillation sheets were melted onto the filters using a Wallac 1495-021 
Microsealer, and bound radioligand counted in a Wallac 1450 Microbeta Liquid Scintillation and 
Luminescence Counter. In all experiments non-specific radioligand binding was determined in the 
presence of 3 mM theophylline.
A simplified [^H]DPCPX saturation and [^H]DPCPX /  CHA competition assay was developed 
to estimate [^HjDPCPX Bmax and affinity from three concentrations of radioligand, and frjj, pKjj 
and pK^ from the inhibition of [^HJDPCPX binding by three concentrations of CHA (see Figure 4.7 
on page 93). The [^H]DPCPX saturation curve was measured in triplicate; the [^HJDPCPX 
(1 nM) /  CHA competition was in duplicate. Reactions were incubated for one hour at RT before 
harvesting on a 48 well Branded harvester and counting as described above.
2.2.4 T he K in etics o f radioligand binding
A reverse time course strategy to enable simultaneous filtration of samples was used to measure the 
kinetics of radioligand association and dissociation (Hulme Sz Birdsall 1992). Briefly, membranes 
were incubated with 3 U /m l ADA for 30 min at RT and the reaction quenched on ice. For 
association assays, membranes were incubated with radioligand in a final volume of 1 0 0  /d, and the 
reaction terminated by rapid filtration as described above (Chapter 2.2.3, page 51). For dissociation 
assays, membranes were incubated with radioligand in a final volume of 1 0 0  /d as above for the
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period of association, and dissociation initiated by 2 0 -fold dilution (2  ml) into binding assay buffer. 
Following the period of dissociation, the reaction was terminated by rapid filtration as described 
above (Chapter 2.2.3, page 51).
A simplified assay of the dissociation of [3 H]CHA was developed in order to allow fitting the 
equation for two-phase exponential dissociation to four time points (0 , 1 0 , 60 and 180 min) and a 
plateau of NSB (see Figure 4.7 on page 93).
2.2.5 FACS analysis and single cell selection
Polyclonal CHO cell lines expressing either the A^R-GFP or A^R-GFP-Ga^ fusion constructs were 
analysed and sorted by Chris Atkins (Laboratory of Immunoregulation, NIMR) on a DakoCytoma- 
tion MoFlo High-Performance Cell Sorter using an excitation wavelength of 488 nm. Individual 
cells were directed into separate wells on 96 well plates containing media as detailed above (Chap­
ter 2.2.1, page 51). Media was changed after 3 days. After 6  days, 12 colonies from each 96 well plate 
that were growing well were chosen and transferred to 1 2  well plates with 2  ml media in each well. 
Media was changed after 3 days, and after one week 24 A^R-GFP and 23 A^R-GFP-Gojcolonies
O
were selected and transferred into 25 ever" flasks with 4 ml media. A variety of fast and slower
growing colonies were chosen for transfer to 25 cm^ flasks. When confluent, cell lines in 25 cm^
9 9flasks were transferred to 175 cmz flasks. From confluent 175 cm flasks, stocks were stored in liq­
uid nitrogen and 1750 cm^ roller bottles seeded and harvested as described above (Chapter 2.2.2,
cy
page 51). The entire process from individual cells through to confluency in 1750 cm roller bottles 
took between 24 and 39 days, depending on the rate of growth. Cell lines expressing higher levels 
of either fusion construct grew more slowly than those of lower expression levels. It is possible that 
stimulation of the A^R by endogenously produced adenosine has a negative influence on the rate 
of cell growth. Presence of the A^R inverse agonist DPCPX (10"^ M) did not affect growth rate, 
receptor yield or equilibrium binding properties. This suggested that stimulation of the A^R by 
endogenous adenosine was not contributing to slower growth.
2.2.6 F luorescence m icroscopy
Stable CHO cell lines expressing either the A^R-GFP or A^R-GFP-Gaj fusion constructs were 
visualised on a Deltavision cooled CCD imaging system incorporating an Olympus 1X70 inverted 
microscope and a Photometries CH350L liquid cooled CCD camera with a Kodak KAF1400 sensor. 
The objective lens used was 40x Olympus UPL APO. Images were captured on an SGI O2  work­
station running Softworx image acquisition and deconvolution software under SGI IRIX. Further
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analysis and manipulation of images was performed using ImageJ 1.28 for Mac and Linux, Wayne 
Rasband, National Institutes of Health, USA, http:/ /rsb.info.nih.gov/ij.
2.2 .7  D en sity  gradient m em brane fractionation
All density gradient materials, procedures and incubations were performed on ice or at 4°C. Using 
the same membrane preparations as used for radioligand binding (Chapter 2.2.2, page 51), 1 mg of 
membrane protein was isolated by centrifugation at 5,000 g for 5 min, and resuspended in 500 /d 
TNET buffer (50 mM TYis, 150 mM NaCl, 5mM EDTA, 0.5% Triton X-100, pH 7.4), and incubated 
on ice for 20 min. The sample was vortexed, and adjusted to 35% iodixanol (500 jA sample + 
700 fA 60% iodixanol) in a 5 ml Beckman polyallomer centrifuge tube. 3 ml of 30% iodixanol (in 
TNET buffer) was placed carefully and slowly above the sample, and 5% iodixanol added until the 
centrifuge tube was full (approximately 900 /d). Samples were spun at 170,000 g (37,402 rpm in 
a Beckman SW55Ti rotor) for 4 hours. Fractions of 730 /d were removed carefully from the top of 
the centrifuge tube, and any pellet resuspended in 730 /d of TNET buffer. Fractions were stored 
at -70°C. The density of individual fractions was determined by measurement in duplicate of the 
absorbance at 340 nm after repeated 1 :1  dilution in 0.85% NaCl, referenced against 0.85% NaCl 
alone.
2.2.8 SD S-PA G E  and W estern  b lottin g
Samples were prepared, electrophoresed and transferred to PVDF according to Invitrogen’s instruc­
tions. Briefly, NuPAGE Sample Buffer containing membrane protein or density gradient fractions 
was heated to 90°C for 1 - 2  min, followed by the addition of reducing agent dithiothreitol (final 
50 mM) and a thorough vortex. Samples were added to NuPAGE Bis-Tris PAGE gels submerged in 
NuPAGE SDS Running Buffer containing NuPAGE Antioxidant to maintain reducing conditions. 
Gels were run at 200 V for typically 50 min. Gels were removed and protein transferred onto 
PVDF at 25 V for 1.5 hours in NuPAGE Transfer Buffer (with 10% methanol). Different heating 
temperatures (65, 80 and 90°C) and times (1  and 2  min) did not make any visible difference to 
the appearance of A^HE or A^R-GFP-Gaj samples when electrophoresed, transferred and blotted 
for A jR  (ab3460), (Figure 2.2 on the next page). The band of greatest molecular weight in the 
A^R-GFP-Gaj samples of Figure 2.2 may show an increase in intensity with temperature, however 
this band is extremely faint in comparison to the main A^R-GFP-Gai band.
All PVDF membrane incubations and washes were performed with gentle agitation. PVDF 
membranes were rinsed in water, and NSB blocked by incubation for 2 hours at RT or overnight at
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Figure 2.2 O ptim isation of sample heating before gel electrophoresis.
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Figure 2.2: The effect of the period and temperature of heating prior to SDS-PAGE and West­
ern blot analysis was investigated using membranes from A^HE and A^R-GFP-Goj cell lines (see 
Table 4.3 on page 95 for equilibrium binding properties of A^R-GFP-Gaj cell line 1B9) and adeno­
sine A} receptor antibody ab3460. No obvious difference can be observed between the different 
A^HE or A^R-GFP-Goj heating conditions, therefore conditions of 90°C and 1 min were used 
for subsequent sample preparation. The human adenosine A^ receptor should be approximately 
37 kDa in size which generally agrees with the See Blue Plus2 Pre-stained markers shown above. 
The A^R-GFP-Gaj construct should be approximately 104 kDa (37, 27 and 40 kDa for A^R, GFP 
and Gcq respectively), although the exact size coded by the construct is unknown. The See Blue 
Plus2 markers appear to underestimate the size of the A^R-GFP-Gaj construct, which is typically 
identified as two bands in close proximity in other Westerns, for example Figure 3.5 on page 71.
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4°C in blocking buffer (PBS, 0.1% Tween-20, 5% milk powder). PVDF membranes were incubated 
for 1 hour at RT with primary antibody diluted in blocking buffer. Table 2.1 on the following page 
lists the primary antibodies used for Western blotting throughout this study. PVDF membranes 
were washed in PBS-T (PBS, 0.1% Tween-20) for 15 and 5 min, followed by incubation for 1 hour 
at RT with secondary antibody diluted in blocking buffer. PVDF membranes were washed in 
PBS-T for 15 min followed by 4 washes of 5 min each.
Enhanced chemiluminescence (ECL) detection of bound secondary antibody was performed 
entirely according to supplied instructions (Amersham), followed by short exposure to blue-light 
sensitive autoradiography film and developed in a Fujifilm FPM-3800A film processor.
All blots shown in this document are from separate gels and subsequent Western blots, apart 
from Caveolin. No membranes were stripped and re-probed. Western blots for caveolin were 
performed on PVDF membranes which had been used for one of the other primary antibodies, 
washed thoroughly in PBS-T, and re-probed for caveolin.
2.3 D ata analysis.
All radioligand binding experiments were performed in either duplicate, triplicate, quadruplicate 
or sextuplicate. Results are expressed as mean ±  standard error of mean, of n independent 
experiments.
All linear regression and non-linear least-squares analysis was performed using GraphPad 
Prism versions 3 and 4 for Macintosh, GraphPad Software, San Diego California USA, h ttp ://  
www.graphpad.com. The equations used by Prism are described below.
2.3.1 A nalysis o f  b ind ing at equilibrium
Saturation binding; Specific binding (SB) was estimated by subtraction of non-specific binding 
(NSB) from total binding (TB) and was analysed by non-linear regression using the equation,
C D  _  B m a x  ■ [ L ]
-  K d +  [L]
where B max is the maximum binding capacity of the membrane preparation for ligand L of 
dissociation constant K d -
O ne-site com p etition  binding; Competition of radioligand binding to a single binding site was
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Table 2.1 Prim ary antibod ies used for W estern blot analysis presented
in th is study.
Antibody Description Figures
AXR
(ab3460)
Immunogen peptide CQPKPPIDEDLPEEKAED 
corresponding to the extreme C-terminus of the rat adenosine 
A i  receptor
2.1 3.5 3.6 
7.3 7.6
A jR
(abl3295)
Immunogen peptide attached to keyhole limpet haemocyanin 
(KLH) corresponding to the third cytoplasmic loop of the 
A^R (peptide sequence not supplied by the manufacturer)
3.5
GFP
(A-11122)
M anufacturer’s information; “Raised against GFP isolated 
directly from Aequorea victoria”
3.6 7.6
Gcq
(ab3522)
Immunising peptide KNNLKDCGLF corresponding to the 
C-terminus of human Gcq
7.3 7.6 7.7
G an  I1' 20)
M anufacturer’s information; “Raised against a peptide 
mapping within a highly divergent domain of rat G a ^ ”
3.5
G q1 3  (A-20)
“Raised against a peptide mapping at the amino terminus of 
mouse G aqg”
7.3
Caveolin
(ab2910)
“Immunising peptide (MSGGKYVDSEGHLYTVP) 
corresponds to amino acid residues 1-17 from human 
caveolin-1”
7.3 7.6
Fyn
(abl3955)
“Immunogen; Recombinant protein expressed in E. coli 
(Human)”
7.4
Table 2.1: Above are listed the primary antibodies used in the Western blots presented in Chapters 
2, 3 and 7 of this document.
57
Chapter 2
analysed using the equation,
T B  -  N S BBound radioligand = N S B  -f
1  _j_ 1 0 O - l o S / C 5 o )
where x  is log (concentration of competing unlabelled ligand), and JC 50 is the mid-point of 
inhibition dose response curve. Log/Cso values were converted to p K t values using the Cheng 
Prusoff correction (Cheng & Prusoff 1973), where [L*] is concentration of radioligand with
dissociation constant K
pKi =  —loglCso 4- log( 1 +  % ^)
D
Two-site com p etition  binding; Competition of radioligand binding to two binding sites of dif­
ferent affinity for the unlabelled competing ligand was analysed using the equation,
Bound radioligand =  N S B  +  O N E  -f T W O
O N E  = S P A N f r "I 10( x - l o g I C 50H)
T W O  =  S P A N U  W r q )
1 _j_ \ Q { x - \ o g I C 50L)
S P A N  = T B  -  N S B
where f r n  is fraction of binding of high affinity, logIC$0H and logIC$oL are mid-points of high 
and low affinity components of inhibition of radioligand binding. loglC^oH and logICsol 
were converted to pK jj and pK ^, the negative log dissociation constants, respectively using 
the Cheng Prusoff correction.
2.3.2 A nalysis o f  th e  k inetics o f binding
One phase exponential association; Simple mono-exponential association of a radioligand was 
analysed using the equation,
Y  = Ymax-i 1 -  exp(-Jcx))
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which starts at zero and ascends to Ymax with a rate constant x.
Two phase exponential association; The association of radioligand with two components was 
analysed using the equation,
Y  =  Ymaxi ( l  -  ex p (-k ix ) )  +  Ymax2 (1  -  exp(—k2x))
which starts at zero and ascends to Ymaxi +  Ymax2 with rate constants k\ and k2.
One phase exponentia l decay; Mono-exponential dissociation of radioligand was analysed us­
ing the equation,
Y  = S P A N ,  exp( - k x )  +  P L A T E A U  
which starts at S P A N  +  P L A T E A U  and decays to P L A T E A U  with a rate constant k.
Two phase exponential decay; The dissociation of radioligand with two components was anal­
ysed using the equation,
Y  — S P A N i .e x p ( - k ix )  + S P A N 2.exp(—k2x) + P L A T E A U
which starts at S P A N i + S P A N 2+ P L A T E A U  and decays to P L A T E A U  with rate constant 
k\ and k2.
2.3.3 S tatistica l analysis
Unpaired t tests were used to estimate whether there was a statistically significant difference 
between mean log affinities. It was assumed that the data followed a generally Gaussian distribution 
and that both data sets had the same variances (same standard deviations). F tests to compare 
variances were performed at the same time as t tests, and most variances were not significantly 
different. The threshold P value for statistical analysis was 0.05. P values greater than 0.05 were 
regarded as not significant. Such analysis was used as an indication of statistical significance, but 
as Harvey Motulsky writes (Motulsky 2003);
“Statistically significant” is not the same as “scientifically important.”
Statistical significance should be interpreted in the context of the experimental procedure, the data 
gathered, other related observations and whether in general it makes sense. All statistical analysis 
was performed using GraphPad Prism 4 for Macintosh, GraphPad Software, San Diego California 
USA, http://www.graphpad.com .
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The creation and molecular 
characterisation of multiple stable 
cell lines expressing different levels of 
adenosine receptor-GFP fusion 
proteins.
3.1 Introduction.
Receptor function and radioligand binding studies have identified differences in the behaviour of the 
human adenosine receptor in membranes prepared from two stable CHO cell lines expressing 
the receptor at high (AjHE) and low (A^LE) levels (Cohen 1995, Browning 2003). These studies 
have provided evidence tha t features of adenosine A^ receptor behaviour are dependent on the 
level of receptor expression. The aim of the work presented in this chapter was to create a series 
of stable CHO cell lines expressing either A^R-GFP or A^R-GFP-Gaj fusion proteins at many 
different levels. Membranes prepared from these cell lines were then used to characterise the 
dependence of aspects of A^R behaviour on the level of receptor expression. These observations 
were compared to those using the two cell lines expressing the adenosine A^ receptor alone (AjHE 
and A^LE). These further investigations are described in Chapters 4, 5, 6  and 7. The use of GFP 
brightness as an indication of the level of receptor expression allowed rapid and specific isolation,
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by means of flow cytometry, of individual cells expressing either the A^R-GFP or A^R-GFP-Gaj 
fusion proteins from polyclonal stable CHO cell lines.
3.2 Flow cytom etric analysis of stable CHO cell lines express­
ing human adenosine receptor-GFP fusion proteins.
A stable polyclonal CHO cell line expressing the adenosine A | receptor with Green Fluorescent 
Protein (GFP (Tsien, 1998)) and the G protein subunit Gcq covalently fused in series to the A^R C 
terminal (AjR-GFP-Gcq) was a kind gift from Dr Chris Browning, GlaxoSmithKline, Stevenage. 
Membranes prepared from this unsorted polyclonal cell line exhibited a [3 H]DPCPX Bmax of 
2.79 ±  0.33 pmol/mg protein and log affinity of 8.78 ±  0.12 (mean ±  s.e.m., n =  3, see Table 4.3 
on page 95 for more details).
In order to create a series of clonal cell lines expressing the adenosine A^ receptor over a range of 
densities, individual A jR -G FP-G aj cells of different GFP brightness were isolated by fluorescence 
activated cell sorting (FACS) into separate wells of four 96 well plates. 96 individual cells were 
isolated from four different gates of increasing GFP fluorescence (see Figure 3.1 on page 63). Six 
cell lines from each of the four gates were grown successfully to confluency and stocks stored in 
liquid nitrogen, except for sort 4 where only five selected cell lines grew sufficiently well. A total 
of 23 cell lines expressing the A jR -G FP-G aj construct were created. Figure 3.2 on page 64 shows 
examples of flow cytometric analysis for cell lines from each of the four gates. Three of the lines 
appeared monodisperse but the cell line in analysis 3 has split into two populations of different 
GFP brightness. The [^HJDPCPX Bmax of membranes prepared from cell lines 1C1, 2A3, 3A3 
and 4F2 shown in Figure 3 .2  are 2.80 ±  0.23, 3.45 ±  0.13, 3.30 ±  0.37 and 2.85 ±  0.57 pmol/mg 
piotein respectively (n =  2, see Table 4.3 on page 95 for more details). Despite selection by gate 
4, cell line 4F2 does not show a high level of AiR-GFP-Gcq expression by either flow cytometry 
(this figure) or radioligand binding analysis (Table 4.3). However, other cells selected by gate 4 did 
mature into cell lines expressing a high level of the A^R-GFP-Gcq construct. It should be noted 
that selection of individual cells of high GFP brightness does not discriminate between normal 
sized cells expressing a high density of AiR-GFP-Gcq and larger cells expressing a lower density 
of AxR-GFP-Gap
A stable polyclonal CHO cell line expressing the adenosine A i  receptor with GFP covalently 
fused in series (A^R-GFP) to the A^R C terminal was also a kind gift from Dr. Chris Browning, 
GlaxoSmithKline, Stevenage. Figure 3.3 on page 65 shows a FACS plot of GFP brightness (rr-axis) 
against a measurement of cell size {y-axis) for the polyclonal A^R-GFP cell line before selection of
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individual cells. It is referenced against a polyclonal cell line expressing the adenosine receptor 
covalently labelled with the influenza A virus haemagglutinin (HA) epitope tag (HA-A^R). The 
cells naturally exhibit a level of fluorescence during the analysis (“auto-fluorescence”) for which 
the strength of signal is dependent on the size of the cell. The FACS plot of the HA-AjR cell 
line in Figure 3.3 shows this characteristic linear dependence of cell auto-fluorescence with cell 
size. Specific GFP fluorescence is distinguished by its independence from cell size where increased 
GFP brightness is observed without an increase in cell size. This has been described in some 
instances as a “GFP-shift.” Both FACS plots in Figure 3.3 contain a region marked “RT” where 
cells expressing a significant level of GFP would be expected. The cell line expressing HA-AjR 
did not contain any cells with GFP fluorescence, however the A^R-GFP cell line did show a small 
number (0.34% of 17429 cells were within region R7) with the characteristic FACS GFP-shift. Two 
96 well plates of individual A jR-G FP cells were selected from region R7 by flow cytometry. From 
these two 96 well plates, 24 cells were grown into mature stable cell lines. Membranes prepared 
from the unsorted A^R-GFP cell line did not show any specific [^H]DPCPX binding in contrast 
to membranes prepared from the A^R-GFP-Ga^ cell line described above. Table 4.3 on page 95 
describes the equilibrium binding properties of all 23 A^R-GFP-Gaj and 24 AjR-GFP cell lines 
created by this process.
3.3 Localisation by fluorescence microscopy of the A^R-GFP- 
Goti construct in live cells.
The cellular distribution of GFP, and therefore the adenosine Aj receptor, was visualised in live 
A;[R-GFP-Gcq cells on a Deltavision cooled CCD imaging system (Figure 3.4 on page 67), as 
described in Materials and Methods (Chapter 2.2.6 on page 53). Three cell lines were studied 
thoroughly, one of lower A^R-GFP-Ga^ expression from gate 1 of the single cell sort and two 
of higher expression from gate 4. The cells were transferred to chambered microscope coverslips 
containing media 24 hours before visualisation. Typically the cells of higher expression grew more 
slowly, were larger and showed greater variation in cell morphology and AjR-GFP-G aj localisation. 
In general the cells appeared to show accumulation of the AiR-GFP-Gcq construct in perinuclear 
regions of the cell and in the cell membrane. A small number of cells from high expression cell 
lines were too large to fit in the camera’s field of vision shown in Figure 3.4 on page 67. Growth in 
the presence of 10" 7  M of the A jR  antagonist DPCPX did not obviously alter the distribution of 
AiR-GFP-Gcq fluorescence or the general appearance of the cells, suggesting increased stimulation 
of expressed A^R by endogenously produced adenosine at greater levels of receptor expression was
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Figure 3.1 Flow cytom etry  profile of the polyclonal A ^R -G FP-G aj cell 
line.
276
207 1 i
Log GFP Fluorescence Intensity
Figure 3.1: Flow cytometry profile of the stable polyclonal AjR-GFP-Gcq cell line prior to sorting 
96 individual cells within each of the four gates shown (1 to 4). Six isolated cells from each gate 
were grown successfully to confluency (only five from gate 4) and stocks stored in liquid nitrogen. 
GFP fluorescence (x-axis) is in arbitrary units of fluorescence.
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Figure 3.2 Flow  cytom etric analysis of cell lines expressing the 
A ^R -G F P-G qj fusion construct.
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Figure 3.2: Flow cytometric analysis of cell lines originating from single cells selected within 
each of the four gates (1  to 4) described in Figure 3.1 on the previous page. Cell line 3 shows 
two populations of different GFP brightness. See Table 4.3 on page 95 for equilibrium binding 
properties of membranes prepared from the cell lines shown here (1=1C1, 2=2A3, 3=3A3, 4=4F2). 
GFP fluorescence (x-axis) is in arbitrary units of fluorescence.
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Figure 3.3 T he selection  of individual cells expressing the A^R-G FP  
fusion construct.
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Figure 3.3: FACS plots of GFP brightness (rr-axis; fluorescence intensity using 530±20 nm “green” 
emission filter) against a measurement of cell autofluorescence and therefore cell size (y-axis; flu­
orescence intensity using 570±20 nm “red” emission filter). Fluorescence intensity is expressed in 
log arbitrary units of fluorescence as in Figures 3.1 and 3.2.
A stable polyclonal CHO cell line expressing the A^R-GFP construct was referenced against a 
stable CHO cell line expressing HA-tagged A^R (HA-AjR). In general, the A^R-GFP cell line 
showed a low level of A jR-G FP expression. Two 96-well plates of individual cells were selected 
from region R7 of the A^R-GFP plot. A variety of slow and fast growing colonies were grown from 
individual cells into mature cell lines, and 24 chosen for use in this study. 17429 cells are shown 
on the A jR-GFP plot, of which 60 (0.34%) fall within region R7. 75006 cells are shown on the 
HA-AjR plot, of which none are found in region R7.
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not responsible for slower growth and variations in cellular morphology.
Cell lines expressing the A ^ -G F P  construct showed a cellular morphology and GFP localisa­
tion that could not be distinguished from that shown for A^R-GFP-Gcq in Figure 3 .4  (data not 
shown).
3.4 W estern blot analysis of cell membranes expressing the 
human adenosine receptor and GFP fusion constructs.
Antibodies against the adenosine A^ receptor, GFP and Gcq were used to identify the presence 
and molecular constitution of the A^R-GFP and A^R-GFP-Gq^ fusion constructs in membrane 
preparations used for radioligand binding analysis. Details of the antibodies used in the Western 
blots shown in this Chapter, and throughout the rest of this study are described in Table 2.1 on 
page 57. Figures 3.5 and 3.6 (pages 71 and 72 respectively) show representative Western blots 
of solubilised membrane preparations expressing the adenosine A]_ receptor and the A^R fusion 
constructs. Along with membranes prepared from the the A^HE and A^LE cell lines, a selection 
of A^R-GFP and A^R-GFP-Gaj membranes were chosen expressing the fusion constructs over a 
range of densities. Membranes from A^R-GFP cell lines 5Ft6, 5C6, 6E10 and 5E10 covered a 6 -fold 
range of receptor expression from 1.3 to 8.2 pmol/mg protein (see Table 4.3 on page 95 for further 
equilibrium binding details). A^R-GFP-Gcrj membranes 2H7, 3D4, 4E8 and 4H1 showed a 7-fold 
range of receptor expression from 1.8 to 13.4 pmol/mg protein (Table 4.3). Membranes prepared 
from A^HE and A^LE cell lines showed a 13-fold range in adenosine A^ receptor density with 
mean levels of receptor expression ([^H]DPCPX Bmax) of 8.19 ±  0.35 and 0.60 ±  0.12 pmol/mg 
protein respectively (n =  5).
Membranes prepared from a stable CHO cell line expressing the human M j muscarinic receptor 
(MjR) were a kind gift from Dr Sebastian Lazareno (MRC Technology) and were chosen as a 
negative control for the Western blots. However, A^R antibody ab3460 identified a band of the 
same size as the human adenosine A^ receptor (approximately 37 kDa) within the M jR  membranes 
(lane 3 on Figure 3.5a). 3 nM [^H]DPCPX showed no significant specific binding at these M^R 
membranes (data not shown). In view of this nonspecific band at 37 kDa in the M^R membranes, 
another adenosine A^ receptor antibody (abl3295) was utilised (Figure 3.5b). This antibody is 
directed at the third intracellular loop of the receptor compared to the extreme C terminus for 
ab3460 (Table 2.1). A jR  antibody abl3295 also identified a band running at similar speed to the 
39 kDa pre-stained marker in all samples, although there was greater contrast in intensity between 
the A ^ E  and A^LE bands (lanes 1 and 2, Figure 3.5b). W ith longer periods of exposure to
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Figure 3.4 F luorescence m icroscopy of live cells expressing the  
A ^R -G F P -G qj fusion construct.
Figure 3.4: Typical cellular localisation of the A^R-GFP-Goj fusion protein expressed in cells 
selected in gate 1 (a) and 4 (b and c) of single cell sort described in Figure 3.1 on page 63.
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autoradiography film, abl3295 identifies weak bands in lanes 1 and 3 corresponding to the size of 
the A^R which are not visible on the blot shown in Figure 3.5b. Therefore the specificity of the 
abl3295 primary antibody for the adenosine receptor alone is not absolute and it only detects 
high levels of adenosine A]_ receptor expression. Primary antibody abl3295 also identified several 
other "non-specific’ bands of which only one is visible in Figure 3.5b, of greater mobility than the 
39 kDa band. It wras not investigated whether this band indicates proteolysis or "nicking" of the 
adenosine Aj receptor or whether it is one of the several non-specific bands identified by antibody 
abl3295. The intensity of these other non-specific bands was entirely independent of [^H]DPCPX 
Bmax and they appear unlikely to be the adenosine A^ receptor.
Western blot analysis o f A^H E and A^LE membranes.
The human adenosine Aj receptor has an estimated molecular size of 37 kDa in the absence of 
any glvcosylation (Figure 1.9 on page 46). As described above, a sharp band close to the 39 kDa 
pre-stained marker was observed in all samples using the adenosine Aj receptor antibody ab3460 
(Figure 3.5a). This band is within the expected range of molecular weight for the adenosine 
A} receptor but as it was observed in all samples, even in membranes expressing the human 
muscarinic receptor (M |R ) it is assumed to reflect a non A^ receptor protein. The slight increase in 
intensity and “fuzziness” of the A^HE sample (lane 2) in Figure 3.5a is in agreement with the A^R 
antibody ab3460 labelling a broad 39 kDa band with low sensitivity. Western blot analysis using 
A^R antibody abl3295, such as that shown in Figure 3.5b, showed a greater degree of contrast 
between A^LE and A^HE membrane samples (lanes 1 and 2 respectively). Both A jR  antibodies 
identified a stronger broad band at 39 kDa in A^HE samples than A |LE, which is consistent with 
this band being, or at least containing, the adenosine A^ receptor.
Western blot analysis o f  A ^ R -G F P  and A ^R -G FP-G qj membranes.
The AjR-GFP construct has a theoretical molecular size of 64 kDa (37 and 27 kDa for A^R and 
GFP respectively). Lanes 4 to 7 of both Figures 3.5a and 3.5b show a band likely to be A^R-GFP 
but which runs faster than the 64 kDa pre-stained marker. A lower intensity band at the same 
mobility in the blots was more clearly observed in lane 4 following longer exposure (not shown). The 
A^R-GFP band is routinely characterised as a "fuzzy” band rather than a crisp distinct band even 
following short exposures (not shown). As described above, both A^R antibodies identified a band 
of approximately 39 kDa in all samples including the A ^ -G F P  and AiR-GFP-Gq^ membranes. 
These bands may represent non-specific labelling by the antibodies rather than the presence of 
non-fusion adenosine A^ receptor in the membrane preparations. The small band in lane 8  in
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Figure 3.5a was an artifact of th a t particular gel rather than the sample, and was not observed in 
other Western blots of the sam e sample (such as Figure 3.5b).
In all samples the A ^R -G FP-G oj construct was identified as two closely spaced bands, or 
“doublet,” illustrated in lanes 8  to  11 in Figures 3.5a and 3.5b. The A 1 R-GFP-Goi band in 
lane 8  in Figure 3.5a was visualised more clearly following longer exposures (not shown). The 
molecular explanation of the  doublet is not clear although the slower moving band could represent 
glycosylated receptor. The A ^R -G FP-G oj doublet w^ as observed when using antibodies for A^R 
(Figures 3.5a and 3.5b), G F P  (Figure 3.6) and Gc^ (Figure 3.5c).
In A^R-GFP-Ga^ m em branes the A^R antibodies routinely identified two weak bands of greater 
molecular size than the strong  A ^R-G FP-Goj doublet. These two higher molecular size bands can 
be seen in Figure 3.5 using A ^R antibody abl3295 (A^R-GFP-GQj lanes 9-11) and Figure 3.6 
using A^R antibody ab3460. These bands of greater molecular size were very faint relative to the 
main A jR-G FP-G oj bands.
The A^R-GFP-Gaj doublet ran  slightly faster than  the 97 kDa pre-stained marker, however the 
A^R-GFP-Goi construct is expected to show a molecular size of 104 kDa. The Invitrogen See Blue 
Plus2 pre-stained m arkers utilised in Figures 3.5 and 3.6 may not accurately identify the expected 
molecular size of the A ^R -G FP and A^R-GFP-Gq  ^ fusion constructs. Figure 3.7 on page 73 
compares estimates of different pre-stained protein markers with un-stained protein standards, 
generally considered to  be more accurate. The un-stained markers (lane c of Figure 3.7) are in 
better agreement with the  expected molecular sizes of the fusion constructs. The Invitrogen See 
Blue Plus2 Pre-stained m arkers may be underestimating the molecular size of the bands of greater 
size.
Two of the A ^R -G FP-G oj membranes in Figures 3.5a and 3.5b (lanes 10 & 11) contain a 
truncated construct identified by antibodies for A^R and GFP, but not G ax (Figure 3.5c). This 
is suggestive of proteolysis of the full-length construct and may be due to cleavage or degradation 
of part of the fused G a j possibly during cell growth as membrane preparations were performed 
on ice at all times in order to  reduce protein degradation. The presence of EDTA in membrane 
preparation buffers will also have helped to further inhibit the action of proteases dependent on 
divalent cations.
The expected molecular weight of endogenous human Gcn^i is approximately 40 kDa (Bray et 
al. 1987) and the G a x antibody used in Figure 3.5 identifies, as expected, a band of this size in all 
of the membranes used, including the larger A^R-GFP-Gaj construct when present. The G ax_i 
band however appears more intense in the membranes expressing higher levels of the AjR-GFP- 
Ga j construct, suggesting either limited proteolysis of the construct or up-regulation of native
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Ga i-1  expression.
3.5 D iscussion.
The work presented in this chapter describes the creation of 23 stable CHO cell lines expressing the 
AjR-GFP-Gcq fusion construct, and 24 stable CHO cell lines expressing the A2 R-GFP construct at 
different levels. Membranes prepared from these cell lines were used in the investigations described 
in the following chapters along with membranes prepared from CHO cell lines expressing the human 
adenosine A 2 receptor at two different levels (AjLE and AjHE). Figure 3.8 on page 77 shows the 
four gate approach versus one gate used for FACS isolation of individual cells resulted in similar 
ranges of expression of both GFP fusion constructs. Little difference was observed in the mean 
level of A jR -G FP-G aj expression from cell lines selected in gates 1 and 2 . Cell lines grown from 
cells selected within gates 3 and 4 showed higher levels of A^R-GFP-Ga^ expression. All but two 
of the AjR-GFP-Gckj cell lines fell within the range of receptor expression of the A^R-GFP cell 
lines selected using just one gate. Both approaches appear to successfully create a series of cell 
lines expressing their GFP fusion protein at a similar range of densities. Membranes prepared 
from the polyclonal A jR -G FP cell line before FACS showed no specific [^HJDPCPX binding. The 
growth of mature cell lines from individual cells showing GFP fluorescence provides a means of 
rescuing the expression of the A^R-GFP construct.
Typically cell lines expressing greater levels of either fusion construct grew more slowly. This 
relationship is visualised in Figure 3.9 on page 78 where cell lines with a higher [^H]DPCPX Bmax 
took significantly longer (P =  0.005) to progress from single cells to harvested membrane prepa­
rations. A similar significant relationship (P =  0.02) was observed when the period of incubation 
in 1750 cm^ roller bottles before membrane preparation was plotted against pH]DPCPX Bmax 
(data not shown). To investigate whether stimulation of the adenosine A 2 receptor by endoge­
nously produced adenosine or by the constitutive activity of the receptor slowed the growth of cell 
lines expressing greater levels of the fusion constructs, membranes were prepared from both high 
and low expressing cell lines grown in the presence of the inverse agonist DPCPX (10' 7  M). No dif­
ferences in cellular morphology or equilibrium radioligand binding properties were observed (data 
not shown), suggesting tha t stimulation of the A^R by endogenous adenosine was not contributing 
to the slower growth of highly expressing cell lines.
There was a degree of heterogeneity between different cell lines expressing the same construct. 
As well as differences in the level of expression of the construct ([3 H]DPCPX Bmax), differences 
were observed in the molecular composition of the expressed construct and the FACS GFP profiles.
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Figure 3.5 W estern blots o f membranes containing A^R and GFP
fusion constructs.
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Figure 3.5: Membranes from cell lines expressing different levels of A^R and both fusion constructs 
were probed by Western blot using two A^R antibodies (a and b) and an antibody for Gaj (c). 
20 fig of total membrane protein was loaded in each well. Invitrogen See Blue Plus2 Pre-stained 
markers are shown with molecular weights indicated in kDa.
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Figure 3.6 W estern blot o f A ^R -G FP-G qj fusion constructs for A^R  
and GFP.
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Figure 3.6: Using membranes prepared from AiR-GFP-Gcq cell lines 3F2 and 4F12, A^R antibody 
ab3460 identifies the same bands as shown in Figure 3.5 on the previous page. Western blot of 
the membranes using an antibody for GFP identifies the same A^R-GFP-Ga^ doublet band as the 
A |R  antibody. See Table 4.3 on page 95 for the radioligand binding properties. The very faint 
band observed between the 51 and 64 kDa markers on the GFP blot is also observed in A^HE 
and AjLE membranes. See Figure 7.6 on page 193 for a Western blot using the GFP antibody on 
fractionated A jR-G FP membranes.
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Figure 3.7 C om parison o f the pre-stained markers used for W estern  
blot analysis w ith  unstained protein standards.
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Figure 3.7: The Invitrogen SeeBlue Plus2 Pre-Stained Standard used throughout the Western 
blots presented in this study (lane b) were compared to Invitrogen MultiMark Multi-Colored 
Standard (lane a) and Bio-Rad un-stained Broad Range SDS-PAGE Standards (lane c: visu­
alised by Coomassie Blue stain). All molecular sizes indicated are in kilodaltons. Electrophoresis 
conditions and buffers used were the same as for all gels prior to Western blot.
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Figures 3.5a and 3.5b show two of the A^R-GFP-Goj membrane preparations contain a truncated 
construct missing a large fraction of the Gcq component (lanes 10 and 1 1 ) while two other A^R- 
GFP-Gqj membrane preparations showed no evidence of truncation even after prolonged exposure 
of the X-ray film (not shown). Proteolysis, or incomplete translation, of the A^R-GFP-Gaj con­
struct may still result in functional receptor without large effects on binding or function being 
observed.
Figure 3.2 shows that despite originating from a single selected cell, some of the fusion cell lines 
may not be monoclonal and may have at some point in their growth split into two populations 
expressing different levels of the receptor. Also of interest is the FACS profile of cell line 4F2 
in Figure 3.2. 4F2 was grown from a single cell which showed a large GFP signal (gate 4  in 
Figure 3.1). Despite this selection, the mature cell line showed a relatively low level of A^R-GFP- 
Gcq expression with a pH]DPCPX Bmax of less than 3 pmol mg protein (Table 4.3 and is also 
clearly distinguished in Figure 3.8). However, Chapter 4 shows that features of agonist binding 
to membranes prepared from cell line 4F2, including the fraction of total agonist binding which 
is of high affinity (frpj), show more similarity with cell lines expressing the construct at a much 
higher density. Again, there appears to be heterogeneity between the cell lines characterised even 
at similar levels of receptor expression.
Striking visual differences were observed between cell lines expressing different levels of the 
fusion constructs. Although hard to present quantitatively, cell lines expressing lower levels of the 
fusion constructs were more homogeneous in appearance. The cell lines characterised by greater 
[^HJDPCPX Bmax were more varied in their morphology and showed great differences in their 
size with some cells many times larger than the normal size observed at low levels of expression. 
Although analysis was very qualitative, there appear to be cell morphological consequences to 
increased expression of either the A^R-GFP or A^R-GFP-Gcq fusion construct.
Other studies have characterised the cellular localisation and molecular composition of mem­
branes prepared from CHO cell lines expressing adenosine A]_ receptor fusion constructs. By means 
of Western blot analysis, Bevan et al. 1999 reported successful identification of the human adeno­
sine A i  receptor alone, and A jR -G aj and AjR-GFP-Ga} fusion constructs. Similar to the results 
presented in Figures 3.5a and 3.5b, a faint band of the same size as the A^R alone was observed 
in the membranes expressing the fusion constructs. The A^R alone can be discerned, but was not 
described by the paper, as a '‘doublet” within a generally fuzzy band. However it is not possible to 
detect in their published Western blot whether the A ^ -G c ^  and A ^ -G F P -G a i fusion constructs 
are present as doublets or not. The paper did not include information on whether they observed 
high molecular sized AjR-GFP-G cq bands as described here Figures 2.2, 3.5b, and 3.6.
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GPCRs show different extents of glycosylation and different sensitivities to disruption of glyco- 
sylation, for example by treatm ent with tunicamycin (an inhibitor of glycosylation) or site-directed 
mutagenesis. Different GPCRs expressed in the same type of cell line can show different responses 
to the inhibition of glycosylation. For example, the treatment with tunicamycin of S49 cells (a 
mouse lymphoma cell line) which express the prostaglandin E j receptor (a GPCR) decreases E j 
receptor function whereas tunicamycin has no effect on the expression, binding and function of 
/3-adrenergic receptors expressed by S49 cells (George et al. 1986). Glycosylation may also con­
tribute to heterogeneous Western blot observations and can show effects including “fuzzy” bands, 
two bands in close proximity (“doublets”), or bands of greatly different molecular size (as for mus­
carinic receptors; see van Koppen and Nathanson, 1990). The human prostacyclin receptor (also a 
G protein-coupled receptor) shares a number of similar characteristics with the adenosine re­
ceptor. The human prostacyclin receptor activates adenylate cyclase by means of Gs proteins, and 
has a molecular weight of approximately 41 kDa with an N-linked glycosylation site on its short 
N-terminus (16 residues compared to 10 residues for the A^R N-terminus). Glycosylation of the 
human prostacyclin receptor has been observed by Western blot as two bands in close proximity 
with the band of greater mass removed after the treatment of cells with tunicamycin (Zhang et al. 
2001). The “fuzziness” of lane 2 in Figures 3.5a and 3.5b and the fusion protein “doublets” may be 
indications of glycosylation of the adenosine A^ receptor. Both the A^ and adenosine recep­
tors contain a potential N-linked glycosylation site in the second extracellular loop. Figure 1.9 on 
page 46 shows this asparagine residue at position 159 for the human adenosine A^ receptor. The 
adenosine A^ receptor has been reported to exist in a glycosylated form in rat cerebral cortex and 
adipose tissue, migrating to approximately 38 kDa (Stiles 1986). Following treatment with endo- 
glycosidase F in order to remove any N-linked or complex carbohydrate chains, the Aj receptor 
was estimated at 32 kDa in both cerebral and adipose tissue. The Aj receptor was relatively insen­
sitive to a-mannosidase providing evidence for glycosylation of largely complex-type carbohydrate 
chains. The implications and functional significance of A^ receptor glycosylation are unknown. 
The adenosine A2 A receptor from bovine brain contains one glycosylation site containing either 
complex or high mannose-type carbohydrate chains (Barrington et al. 1990). It would have been 
possible to investigate the importance of glycosylation for adenosine A^ receptor activation by 
treating the cells with tunicamycin prior to membrane preparation, or the membranes with a- 
mannosidase and endoglycosidase F to investigate the type of any glycosylation present. This was 
not investigated.
In summary, the results presented in this Chapter describe the isolation of individual cells, 
expressing either the A^R-GFP or A^R-GFP-Gaj fusion constructs, from which mature cell lines
75
Chapter 3
were grown. The characterisation of selected mature cell lines by microscopy, FACS and West­
ern blot analysis showed a level of heterogeneity of both the cellular morphology and molecular 
composition between cell lines expressing the same A^R fusion construct.
Membranes prepared from the cell lines created and characterised in this chapter were then 
studied in detail, the results of which are presented in the Chapters that follow. Chapter 4 investi­
gates the effect of receptor expression level on equilibrium binding properties of the A jR  using the 
A^R-GFP and A^R-GFP-Gcq membranes. Chapter 6  uses the fusion membranes to investigate 
the dependence of the kinetics of binding on the level of A^R expression. Chapter 7 investigates the 
localisation of the A^R-GFP and A}R-GFP-Gcq fusion proteins in domains of the cell membrane 
isolated by means of density gradient fractionation.
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Figure 3.8 T h e level o f  receptor expression related to  flow cytom etry
selection .
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Figure 3.8: The [^H]DPCPX Bmax of A jR -G FP-G aj membranes prepared from cell lines grown 
from individual cells selected by gates 1 to 4, as described in Figure 3.1 on page 63. The mean 
[^HjDPCPX Bmax (±  s.e.m.) for membranes from cell lines selected by each flow cytometry gate 
is indicated by the black bar. For comparison, the [^HJDPCPX Bmax of A^R-GFP membranes 
are shown. Individual A^R-GFP cells were selected using only one gate, as described in Figure 3.3 
on page 65. The [^HjDPCPX Bmax data illustrated above is listed in Table 4.3 on page 95.
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Figure 3.9 Cell lines expressing greater levels of A 1R -G FP-G qj and 
A ^R -G F P fusion proteins typically grow more slowly.
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Figure 3.9: The graph describes the dependence of the level of receptor expression (y-axis) on the 
period of growth (ic-axis) from a single cell to the harvesting of membrane preparations. Non-linear 
regression of combined A^R-GFP-Gaj and A^R-GFP data generated a line with a significantly 
non-zero slope, indicated by broken line (slope =  0.3, P = 0.005). A similar significant relationship 
(P = 0.02) was observed using the period of growth in 1750 cm^ roller bottles prior to membrane 
preparation rather than total days growth shown above (data not shown).
78
Chapter 4
The effect of receptor expression level 
on equilibrium binding properties of 
the human adenosine receptor.
4.1 Introduction.
Previous studies within the receptor group at NIMR have investigated aspects of the binding and 
functional properties of the human adenosine receptor (Cohen, 1995; Cohen et al., 1996a,b). 
Two stable CHO cell lines recombinantly expressing the adenosine A]_ receptor at low (A^LE) and 
high (AjHE) densities have also been useful for comparing predictions of mathematical models 
of drug receptor interactions with binding properties of the A^R (Browning, 2003; Browning et 
al., 2000a,b,c). Subtle differences observed in the equilibrium radioligand binding properties and 
the kinetics of radioligand association of the two cell lines were associated with more profound 
differences in the dissociation of radioligands at the two levels of A^R expression.
Chapter 3 describes the creation and molecular characterisation of a series of cell lines expressing 
the GFP fusion proteins A^R-GFP and A^R-GFP-Goj at different densities. The aim of the work 
presented in this Chapter was to examine whether the equilibrium binding properties of the A^R- 
GFP and A^R-G FP-G aj fusion proteins;
• differ from each other and the A^R alone, and
• whether these properties are sensitive to the level of receptor expression.
79
Chapter 4
4.2 R adiolabelled agonist and antagonist saturation equilib­
rium binding to  the hum an adenosine receptor ex­
pressed at two different densities.
The equilibrium agonist and antagonist binding properties of membranes prepared from A^LE 
and A^HE cell lines were characterised in order to provide core A^R binding data against which 
the GFP fusion proteins could be compared. If the A^R-GFP and A^R-GFP-Gaj fusion proteins 
showed similar agonist and antagonist binding affinities as the A jR  alone, then the series of cell lines 
described in the previous Chapter would be useful as a model of the effect of receptor expression 
level on adenosine A], receptor behaviour.
Specific binding of the A^R antagonist [3 H]DPCPX and agonist [3 H]CHA to both A^LE and 
AjHE membranes was saturable (Figure 4.1 on the next page). [3 H]DPCPX bound to A}LE mem­
branes with Bmax 0.60 ±  0 .1 2  pmol/mg protein and log affinity constant (log K ^) 8.62 ±  0.06 
(n =  5), and to A^HE membranes with Bmax 8.19 ±  0.35 pmol/mg protein and log 8.72 ±  0.03 
(n =  5) (see Table 4.1 on page 8 8 ). [3 H]CHA bound to A^LE membranes with Bmax 0.38 ±  0.05 
pmol/mg protein and log 8.48 ±  0.08 (n =  7), and to A^HE membranes with Bmax 3.20 ±  0.27 
pmol/mg protein and log 8.60 ±  0.05 (n =  7). In general, A^HE membranes exhibited a 14 fold 
greater total number of A^R binding sites ([3 H]DPCPX Bmax) than A^LE membranes. [3 H]CHA 
bound with high affinity to a smaller population of binding sites than [3 H]DPCPX in both AjLE 
and A^HE (Table 4.1), consistent with well established observations of agonist binding heterogene­
ity at the adenosine A j receptor (Cohen et al, 1996b) and GPCRs in general (for example Birdsall 
et al, 1978). The fraction of high affinity agonist binding sites was greater for A jLE relative to 
A^HE (0.63 versus 0.39). Unpaired t tests showed no significant difference between the A^HE 
and A^LE mean log affinity constants, for both [3 H]DPCPX and [3 H]CHA. Also, the affinities 
of [3 H]DPCPX and [3 H]CHA for the adenosine Aj receptor were indistinguishable, showing no 
significant difference in unpaired t tests. Therefore both [3 H]DPCPX and [3 H]CHA showed no 
difference in affinity between A^HE and A ^ E  membranes, and the affinities of [°H]DPCPX and 
[3 H]CHA themselves were indistinguishable although independent. Unpaired t tests showed a sig­
nificant difference between A^HE and A^LE Bmax h* the case of both [3 H]DPCPX and [3 H]CHA 
(P < 0.0001). Difference in means was considered significant only if P < 0.05 (as described in
Chapter 2.3.3 on page 59).
All radioligand binding experiments described in this Chapter were incubated for one hour, 
unless otherwise stated, before filtration onto glass fibre filters. Experiments investigating the
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Figure 4.1 [^H ]Antagonist and [^Hjagonist saturation curves at the
expressed at two densities.
Specific Binding 
(pmol / mg protein)
A ^ E
6
4
2
H]DPCPX
H]CHA
0
12
A ^ E
Specific Binding 
(pmol / mg protein)
0.4-I
0.3-
0 . 2 -
0 . 1 -
0.0
0 4 8
[3H]Ligand (nM)
Figure 4.1: Representative saturation curves for the binding of [^HJDPCPX (antagonist) and 
pH]CHA (agonist) to A^HE and A^LE membranes. The best fit parameters estimated by non­
linear regression of the above curves were; [^H]DPCPX log affinity 8.63 &; 8.73 and Bmax 7.23 
& 0.42 pmol/mg protein (A^HE and A^LE respectively), [3 H]CHA log affinity 8.48 & 8.47 and 
Bmax 1-76 & 0.29 pmol/mg protein (AjHE and AjLE respectively). The means of estimated 
parameters are described in Table 4.1 on page 8 8 . Data plotted above are mean ±  s.e.m. of a 
single experiment performed in quadruplicate.
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effect of incubation time on the saturation of A^HE membranes by [3 H]CHA observed an increase 
in Bmax between association times of 5 min and 4 hours when incubated at RT. Figure 4.2 on 
the following page shows [3 H]CHA saturation experiments performed using A^HE membranes 
after six association times ranging from 5 min to 4 hours (240 min). The saturation data were 
transformed to a Scatchard plot which is also illustrated in Figure 4.2. The Scatchard plot provides 
an alternative means to visualise the Bmax and Kpj (x-axis intercept and respectively) of
q
[ H]CHA for A^HE membranes at the six association times. However for quantitative analysis of 
saturation data the Scatchard plot is less reliable than direct non-linear regression.
Figure 4.3 on page 84 examines the dependence of [3 H]CHA Bmax and on the incubation 
time using non-linear regression data from two experiments, one of which is illustrated in Figure 4.2.
q
The Bmax of [ H]CHA for A jH E membranes increased exponentially with time extrapolating to 
a maximum of 4.1 pmol mg protein and to 2.2 pmol/mg protein at zero time. While [3 H]CHA 
Bmax increases from 5 min to 4 hours, the estimate of [3 H]CHA Kj^ appeared constant from 
30 min to 4 hours (Figure 4.3). Periods of incubation of less than 30 min may unreliably estimate 
the affinity of [3 H]CHA. Unfortunately the errors are large, performing the experiment more than 
twice would likely reduce the errors however the interpretation would not be expected to change 
significantly.
Figure 4.3a may provide an insight into the availability of G protein to the adenosine A  ^
receptor. The increase in [3 H]CHA binding after 30 minutes appears to be due to an increase in 
high affinity agonist binding capacity rather than a change in Kpj. The rate of this increase in 
[3 H]CHA binding from the data shown in Figure 4.3a was 0.016 m in '1. Using the estimates of 
Bmax which showed a constant K q  (30, 60, 1 2 0  and 240 min) the same estimates of the rate of 
increase and maximum Bmax were obtained (0.0016 min ' 1 and 4.1 pmol mg protein respectively). 
This rate of increase in available high affinity agonist binding sites may be a representation of the 
rate at which the adenosine A i  receptor can recruit extra G protein from other regions of the cell 
membrane.
4.3 The effect o f unlabelled ligands on binding of the radio­
labelled antagonist [3H ]D PC PX  to the human adenosine 
A i receptor expressed at two different densities.
The ability of unlabelled ligands to inhibit the binding of [3 H]DPCPX at the adenosine Ax receptor 
was investigated. Three unlabelled antagonists (DPCPX, X0840 and theophylline) inhibited spe-
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Figure 4.2 [^H]CHA saturation curves o f A^HE m em branes at different
association  tim es.
[3H]CHA s p e c i f i c  b in d in g  
(pmol / m g  p ro te in )
3
2
1
o
Association time (min)
• 240
•  120 
• 60
• 30
• 15
• 5
(transformed as Scatchard)
B o u n d  / F ree
2 .0 -|
Association time (min)
1.5- 240
120
60
1. 0 -
0.5-
0.0
1 20 3
B o u n d  PHICHA 
(pm ol / m g prote in)
Figure 4.2: Representative [3 H]CHA saturation curves from a single experiment investigating the 
effect of the length of incubation (association time) on the saturation of A^HE membranes by 
[3 H]CHA. [3 H]CHA Bmax and affinity were estimated from non-linear regression of the saturation 
curves, and the curves were transformed to a Scatchard plot for visual inspection. The final assay 
volume was 100 ^1 and was performed at RT. Data were corrected for depletion of the concentration 
of [3 H]CHA.
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Figure 4.3 T he dependence of |3 H ]C H A  B m a x  and K D w ith incubation
t i m e .
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Figure 4.3: (a) [3 H]CHA Bmax at A^HE membranes increases exponentially with association 
time asymptoting to a maximum of 4.1 pmol / mg protein, (b) The estimate of [^H]CHA Kj) 
appears to be reliable from 30 min onwards. All data shown in the above Figures are the mean 
of two independent experiments (±  s.e.m.) performed in a final volume of 100 /d at RT, one of 
which is illustrated in Figure 4.2 on the previous page. The estimates of [3 H]CHA Bmax and 
Kj} were obtained from nonlinear regression of saturation curves, and not from linear regression 
of Scatchard transformations (although the estimates obtained from the Scatchard plots were in 
general agreement with those from nonlinear regression).
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O
cific [ H]DPCPX binding over a 1000-fold range in affinity. As well as enabling the characterisation 
of ligands which are not radiolabelled, competition assays allow investigation of low affinity agonist 
binding which may occur at high concentrations that would make direct saturation prohibitive. 
The effect of two unlabelled agonists of high efficacy (CHA and PIA) on the binding of [3 H]DPCPX 
to AiHE and A ^ E  membranes was investigated. In addition, [3 H]DPCPX competition assays 
were used to examine the binding of three agonists of lower efficacy.
[3H ]D PC PX  /  antagonist co m p etitio n  experim en ts.
DPCPX, N0840 and theophylline inhibited 100% of the specific [3 H]DPCPX binding to AXHE 
membranes (Figure 4.4 on the following page). N0840 bound with log affinity 6.23 ±  0.07 (n = 3) 
and theophylline with log affinity 5.40 ±  0.15 (n =  3). The log affinity of N0840 reported here is 
similar to a Kj of 0.54 pM reported in [3 H]PIA N0840 competition experiments at rat cerebral 
cortex membranes (Ukena et al. 1987). The binding of DPCPX w^ as of approximately 100-fold 
higher affinity than N0840. The Cheng Prusoff correction is not appropriate wffien the labelled 
and unlabelled ligands are the same. In this situation it is more appropriate to analyse the results 
as a saturation curve resulting from increasing degrees of isotopic dilution of [3 H]DPCPX by cold 
DPCPX. Possibly as a consequence of adsorption issues during the serial dilution of cold DPCPX 
the data in Figure 4.4 underestim ates the affinity of DPCPX relative to th a t shown in direct 
[3 H]DPCPX saturation experiments (Table 4.1). The most accurate estimate of DPCPX affinity 
was obtained from the direct saturation curves (Table 4.1).
[3H ]D PC PX  /  agonist co m p etitio n  experim en ts.
The highly efficacious A^R agonist CHA inhibited 100% of the specific [3 H]DPCPX binding to 
both A^LE and A^HE membranes in a biphasic manner (Figure 4.5 on page 89). The inhibition 
curves were analysed by a two-site model for which mean param eters are described in Table 4.2 
on page 8 8 . The observed high affinity CHA binding constant (log K jj A jLE  8.75 ±  0.16 (n = 4), 
A^HE 8.57 ±  0.06 (n =  7)) was similar to th a t observed in the saturation experiments (Table 4.1). 
Additionally, a low affinity CHA binding component w^ as observed (log K l  A jL E  5.68 ±  0.17 
(n =  4 ), A^HE 5.79 ±  0.05 (n =  7)), approximately 1000-fold lower in affinity. Unpaired t tests 
found no significant difference between the membranes from the two cell lines for both high and low 
CHA affinities. The observation of low affinity specific CHA binding agrees with the inability of 
[3 H]CHA to identify as many high affinity binding sites as [3 H]DPCPX when [3 H]CHA is used at 
nM concentrations (Table 4.1). The fraction of total CHA binding of high affinity (frH ) observed in 
competition equilibrium binding assays was higher in A jLE membranes (0.71 ±  0.02, n =  4) than
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Figure 4.4 T h e d isp lacem en t o f  [^H ]D P C P X  binding by unlabelled
an tagon ists.
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M ean param eters from  th e  analysis o f com p etition  curves.
unlabelled ligand log affinity (n =  3)
N0840 6.23 ±  0.07
Theophylline 5.40 ±  0.15
DPCPX* 8 .1 2  ±  0 .1 1 *
Figure 4.4: Representative individual [3 H]DPCPX competition curves on AjHE membranes using
O
the antagonists N0840 and theophylline, and DPCPX for comparison. The mean [°H]DPCPX 
concentration was 0.66 =t 0.08 nM (n =  3). Mean log affinity estimates of three independent 
experiments are shown in the table. * DPCPX competition curve and the estimate of mean
O
log affinity is shown only for comparison, as Cheng Prusoff correction of [ H]DPCPX DPCPX 
competition curves is not appropriate. The estimate of DPCPX affinity here is an underestimate 
compared to direct [3 H]DPCPX saturation  (Table 4.1 on page 8 8 ).
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in A jHE (0.52 ±  0.02, n — 7) as found in the direct saturation experiments. The mean estimates 
of frH for each cell line were significantly different (P =  0.0005). Similar to CHA, the AXR agonist 
PIA inhibited all specific [^H]DPCPX binding in a biphasic manner with log affinities 8.72 ±  0.03 
and 6.17 ±  0.04 (n =  2). 54% of PIA binding was of high affinity (Table 4.2). The two estimates 
°f &H usin§ CHA and PIA for A^HE membranes were in reasonable agreement with each other, 
although with only two observations using PIA this was not tested statistically. Therefore the 
difference in agonist binding between A^LE and Aj HE membranes is due to a difference in frjj 
and not a difference in either affinity.
[^HJDPCPX /  CHA competition assays on A^HE membranes in the presence of 100 /zM GTP 
exhibited only low affinity CHA binding (frH =  0). The mean log affinity of CHA for AjHE 
membranes in the presence of 100 /zM G TP was 5.68 ±  0.03 (n =  3), similar to the low affinity 
CHA binding component observed in the absence of GTP (Table 4.2).
For a number of reasons the [^H]DPCPX /  CHA competition assays were performed using 
concentrations of [^H]DPCPX below its Kjy . Although lower concentrations of [^HJDPCPX 
showed lower levels of total binding than for higher concentrations, non-specific binding was reduced 
to a greater extent, and increased the signal to noise ratio. Higher concentrations of [^HJDPCPX 
would increase the difference between the observed ICgQ-  ^ values and the affinities calculated 
by application of the Cheng Prusoff correction, potentially leading to increased uncertainty from 
increased reliance on the precision of the correction factor. For [^HJDPCPX /  CHA competition 
assays at A^HE and A^LE membranes the mean correction factors were 0.313 ±  0.001 (n =  7) 
and 0.312 ±  0.001 (n =  4) log units respectively.
Compounds GR190178, GR161144 and GR162900 (shown in Figure 2.1 on page 50) are A^R 
agonists of lower efficacy than CHA or PIA. A limited number of studies (n =  2) investigating 
the ability of these lower efficacy agonists to inhibit [3 H]DPCPX binding were performed and are 
described in Figure 4.6 on page 91. Direct two-site analysis of [^H]DPCPX competition assays 
using CHA and GR190178 are relatively straightforward as they show a clear separation of affinities 
(A^-). The two-site nature of the inhibition curves is apparent from visual inspection of the curves. 
However, competition curves using ligands of low efficacy such as GR161144 and GR 162900 are 
more difficult to analyse directly by non-linear regression due to decreased separation of their high 
and low binding affinity constants. To compensate for this, the competition assay was performed 
in the presence and absence of 100 /zM GTP. Both curves (±  GTP) are performed in the same rack 
of tubes at the same time in order to reduce variability and to increase the reliability of analysis 
using shared parameters from both curves. The curve in the presence of GTP was best fit to a 
one-site model and the low affinity binding constant was obtained. Two-site analysis of the curve
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Table 4.1 P aram eters describing antagonist ([3 H ]D P C P X ) and agonist 
([ H ]C H A ) satu ration  b inding curves o f th e  hum an adenosine
receptor.
[3 H ]D P C P X  saturation Bmax (pmol mg protein) log affinity
AXHE (n =  5) 8.19 ±  0.35 8.72 ±  0.03
A jLE (n =  5) 0.60 ±  0 .1 2 8.62 ±  0.06
[3H ]C H A  saturation Bmax (pmol / mg protein) log affinity
AXHE (n =  7) 3.20 ±  0.38 (39% of [3 H]DPCPX Bmax) 8.60 ±  0.05
AXLE (n =  7) 0.38 ±  0.05 (63% of [3 H]DPCPX Bmax) 8.48 ±  0.08
Table 4.1: Summary of [3 H]DPCPX (antagonist) and [3 H]CHA (agonist) saturation experiments 
using AjHE and A^LE membranes. Representative curves are shown in Figure 4.1 on page 81. 
Unpaired t tests showed no significant difference between the affinities of [3 H]DPCPX or [3 H]CHA 
for membranes prepared from either cell line. In addition, although independent, the affinities of 
[3 H]DPCPX and [3 H]CHA for the adenosine A^ receptor were indistinguishable. These saturation 
assays were performed in quadruplicate, and values shown represent the mean ±  s.e.m. of n 
independent experiments.
Table 4.2 T w o-site analysis o f  [^H ]D P C P X  /  agonist com petition
curves.
C H A frH log Kh log KL
A XBE  (n =  7) 0.52 ±  0.02 8.57 ±  0.06 5.79 ±  0.05
A1LE (n =  4) 0.71 ±  0.02 8.75 ±  0.16 5.68 ±  0.17
P IA frH log Kh log Kl
AXHE (n =  2) 0.54 ±  0.01 8.72 ±  0.03 6.17 ±  0.04
Table 4.2: Data shown represents the mean ±  s.e.m. of n independent experiments performed in 
triplicate on each membrane type. The effect of PIA, another high efficacy A^R agonist, on the 
binding of [3 H]DPCPX at A^HE membranes was investigated. Mean [3 H]DPCPX concentrations 
were 0.76 ±  0.06 and 0.84 ±  0.06 nM for A jH E and A^LE membranes respectively in the CHA 
competition assays, and 0.58 dt 0.07 nM in the PIA assays. Unpaired t tests found no significant 
difference between the two membranes for both high and low CHA affinities. The difference between 
CHA frjj means was significant (P =  0.0005).
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Figure 4.5 T h e b ip h asic  d isp lacem ent o f [3 H ]D P C P X  binding by CH A.
1 0 0 H A,HE 
AXE
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Figure 4.5: Representative [3 H]DPCPX /  CHA competition curves of the effect of CHA on the 
binding of 0.7 nM [3 H]DPCPX to A jH E  (grey) and AXLE (black) membranes. The A ^ E  curve 
shows a higher fraction of CHA binding which is of high affinity (frjj) than AjHE. Data shown are 
mean ±  s.e.m. of a single experiment performed in triplicate. Competition assays were analysed by 
an equation describing two-site competition binding, with mean estimates described in Table 4  2  
on the preceding page.
89
Chapter 4
in the absence of G T P  was constrained to 0% and 100% (bottom and top respectively) and the low 
affinity binding constant obtained in the presence of GTP. This left only frjj and the high affinity 
binding constant to  be estimated from the two-site curve. Figure 4.6 illustrates this approach using 
GR190178, GR161144, GR162900 and, for comparison, CHA. The estimates of CHA affinities in 
Figure 4.6 are similar to those observed in Table 4.2. GR161144 and GR162900 exhibit a small, 5 
to 10-fold difference in affinities, GR190178 shows almost a 100-fold difference and CHA a 700-fold 
GTP shift. No difference was observed between the fraction of binding which is of high affinity 
(frn) f°r CHA, GR190178 and GR161144. GR162900 does appear to exhibit a lower frj_j which is 
consistent with o ther reports (Browning 2003).
4.4 R adioligand equilibrium  binding to  A^R-G FP and A^R- 
G FP-G cq fusion constructs expressed at different densi­
ties.
Stable polyclonal CHO cell lines stably expressing either the A^R-GFP or A^R-GFP-Gcq fusion 
constructs were a  kind gift from Dr Chris Browning, GlaxoSmithKline, Stevenage. In order to 
create monoclonal cell lines expressing different levels of these constructs, individual cells were 
isolated and grown into m ature cell lines as described in Chapter 3 above. In order to facilitate 
characterisation of the equilibrium binding properties of membranes from such a large number 
of cell lines (24 for A^R-GFP and 23 for A^R-GFP-Goj), simplified [3 H]DPCPX saturation and 
[3 H]DPCPX /  CHA competition assays were required. These are described in Figures 4.7 and 4.8 
(on pages 93 and 94 respectively). The simplified assays were designed in order to estimate the 
following equilibrium binding parameters;
•  total number of [3 H]DPCPX binding sites ( B m a x ) ,
• [3 H]DPCPX affinity,
• CHA binding affinities K jj and K^, and
• fraction of CHA binding which is of high affinity (frjj)-
[3 H]DPCPX saturation curves using three radioligand concentrations (0.1, 1 and 10 nM) were 
measured in triplicate with both total and non-specific binding being determined at each concen­
tration. Two concentrations (0.1 and 1 nM) lower than the affinity of [3 H]DPCPX for the A^R were 
chosen to accurately estim ate Kj}, and a further concentration 10-fold greater (10 nM) in order
90
Chapter 4
Figure 4.6 In h ib ition  o f  [3 H ]D P C P X  binding at A XH E m em branes by 
A ^ R  agon ists  o f  differing efficacy.
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M ean param eters from  th e  analysis o f com p etition  curves.
Unlabelled ligand 100 (iM GTP frH log KH log KL k hKu_.
CHA T [0 ] - 5.70 ±  0.02
(n =  2 ) - 0.60 ±  0.003 8.56 ±  0.05 - 728 ±  49
GR190178 + [0 ] - 6.21 ±  0.003
(n =  2 ) - 0.58 ±  0.01 8.13 ±  0.11 - 85 ±  20
GR161144 + [0 ] - 7.14 ±  0.03
(n =  2 ) - 0.60 ±  0.05 8.03 ±  0.08 - 8 .2  ±  2 .0
GR162900 + [0 ] - 7.47 ±  0.03
(n =  2 ) - 0.43 ±  0.05 8.30 ±  0.002 - 6.7 ±  0.4
Figure 4.6: Representative curves and mean non-linear regression estimates of equilibrium agonist 
binding parameters for CHA and agonists of lower efficacy using A^HE membranes. Log Kj  ^ was 
estimated in the presence of 100 fiM GTP (broken curves) and used to constrain the two-site curve 
(solid curves) so tha t frjj and log K jj were the only variables estimated by two-site non-linear 
regression. Top and bottom  of the two-site curves were fixed to 100% and 0% respectively. Non­
linear regression analysis of the data  in the presence of GTP was not constrained. The ratio of 
agonist affinities ( £ f , alternatively termed “GTP shift”) is generally considered an indication of
agonist efficacy.____________ _________________________________ ____________________________
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to estimate Bmax by sufficiently saturating the receptor whilst still maintaining a good ration of 
total to non-specific binding. 10 nM [3 H]DPCPX would be expected saturate approximately 80% 
of available [3 H]DPCPX binding sites, according to the Langmuir isotherm (bound L =  ,
where [L] is concentration of ligand L with dissociation constant K d at a receptor preparation 
with maximum binding capacity B max).
O
The 1 nM [ HJDPCPX / CHA competition assay using three concentrations of CHA was 
measured in duplicate, and used the 1 nM [3 H]DPCPX values from the saturation curve for total 
and non-specific binding. The concentrations of CHA were chosen to be approximately at the 
midpoints of the high and low affinity components of the two-phase inhibition curve, along with 
a concentration of CHA at the expected point of inflection between the two components in order 
to estimate ffjj. Figure 4.8 on page 94 illustrates in greater detail the analysis of the simplified 
competition assay. The combined saturation and competition assay occupied 24 binding assay 
tubes, allowing two membranes to be characterised in one 48-tube rack. In retrospect the assay 
could have been simplified further as the results obtained were precise and reproducible as shown 
by the size of the error bars in Figures 4.7 and 4.8.
Table 4.3 on page 95 lists the mean equilibrium binding properties of membranes prepared 
from all the A jR-G FP and AjR-GFP-Gcq cell lines using the simplified assay. Also shown are the 
equilibrium binding properties of membranes made from the polyclonal A jR-GFP-G aj cell line 
before cytometric selection of the cell line series. Membranes prepared from the AjR-GFP-Gcq 
series of cell lines ranged in [3 H]DPCPX Bmax from approximately 1.8 to 13 pmol/mg protein. 
Membranes from the A^R-GFP series of cell lines showed a comparable range of [3 H]DPCPX 
Bmax (1 .3  to 9.3 pmol/mg protein).
The mean [3 H]DPCPX log affinities of the A^R-GFP and AiR-GFP-Gcq membranes were 
similar (8 .8 8  ±  0.01 (n =  46) and 8.72 ±  0.02 (n =  65) respectively; see Table 4.4 on page 99), 
as illustrated in Figure 4.9 on page 96. The [3 H]DPCPX affinity of membranes from most A^R- 
GFP and AiR-GFP-Gcq cell lines fell within a two-fold range (0.3 log units). Comparison by 
unpaired t test observed a significant (P < 0.0001) but small (0.16 log unit) difference between 
the mean affinity of [3 H]DPCPX for A iR -G FP and AxR-GFP-Gcq membranes. When the A^R- 
GFP and A;[R-GFP-Gcq [3 H]DPCPX log affinities were analysed together, [3 H]DPCPX affinity 
was not dependent on the level of receptor expression (no significant non-zero slope). When 
analysed separately by linear regression no significant non-zero slope was observed for AiR-GFP- 
Ga{ membranes but A ^ - G F P  did show a significant slope (P =  0.006). The affinity of [3 H]DPCPX 
for the A^R-GFP and AjR-GFP-Gcq membranes was similar to that observed for AjHE and AjLE
(Table 4.4).
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Figure 4 .7  Sim plified  [3 H ]D P C P X  saturation  and [3 H ]D P C P X  /  CHA
co m p etitio n  binding assays.
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Figure 4.7: The equilibrium binding properties of membranes prepared from all the A^R-GFP 
and A^R-GFP-Gaj cell lines were estimated by a combined three-point saturation and five-point 
competition assay. Figure 4.8 on the following page describes in greater detail the analysis of the 
simplified competition assay. The graphs shown on this figure are from a single experiment using 
membranes prepared from A^R-GFP cell line 6D2 (the error bars on the competition curve are 
present but too small to be visible).
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Figure 4.8 T he estim a tio n  o f C H A  affinities and frjj using a simplified  
[^H JD PC PX  /  C H A  com p etition  assay.
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Figure 4.8: The affinities of agonist binding to the adenosine receptor (IC^q HIGH an<i 
IC^Q LOW) anc  ^ fraction of binding which is of high affinity (frjj) can be reliably estimated 
using three concentrations of unlabelled CHA along with total (T) and non-specific (NS) levels of 
[^HJDPCPX binding in the absence of CHA. All competition curves were normalised as a percent 
of maximum specific binding and best fit by an equation describing two-site competition binding. 
The top and bottom  of the curves were fixed to 100% and 0% respectively leaving only three 
variables to be estimated (ffjj, IC5 Q HIGH an(  ^ ^ 5 0  LOW )- ^he use of mean IC^q HIGH anc  ^
IC5 0  LOW values to constrain the fit even more so that frjj was the only variable, did not no­
ticeably improve the reliability of frjj estimation and was not pursued further. Shown above is 
a single experiment using membranes prepared from A^R-GFP cell line 5F4 (see Table 4.3 for 
details). Log IC5 0  values were corrected to log affinity values using the Cheng Prusoff correction. 
In order to increase the reliability between different estimates of CHA affinity the mean log affinity 
of [3 H]DPCPX for all the cell lines from each fusion construct was used for the Cheng Prusoff 
correction, rather than  the individual estimates for that particular cell line.
NS
-12 -10
CHA (logM)
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Table 4.3 T he equilibrium  b inding properties o f m em branes prepared  
from  all th e  A jR -G F P  and A 1R -G F P -G a i cell lines.
[*H]DPCPX saturation [“H]DPCPX / CHA competiUon
8
O
I
Qai
l l
O
i
c c
<L
O
i
CC
(pmol /  
mg protein) log affinity log Kh log iq
2H7 1.77 ± 0.08 8.70 ± 0.13 0.64 ± 0.04 8.69 ± 0.10 6.42 ± 0.051B9 2.18 ± 0.36 8.90 ±0.18 0.66 ± 0.07 8.51 ± 0.39 6.26 ± 0.07
1C1 2.80 ± 0.23 8.50 ±0.08 0.66 ± 0.06 8.63 ±0.06 6.02 ±0.19
4F2 2.85 ± 0.57 8.78 ± 0.12 0.39 ± 0.08 8.61 ±0.35 5.75 ± 0.04
2H6 3.00 ± 0.29 8.52 ±0.12 0.62 ± 0.04 8.61 ± 0.15 6.13 ± 0.13
3A3 3.30 ± 0.37 8.76 ±0.14 0.58 ± 0.04 8.55 ± 0.27 6.07 ± 0.10
2A3 3.45 ± 0.13 8.79 ± 0.11 0.64 ± 0.06 8.53 ± 0.15 634 ±0.11
1C9 3.48 ± 0.13 8.48 ±0.09 0.58 ± 0.06 8.53 ± 0.06 5.81 ± 0.01
103 3.57 ± 0.24 8.71 ±0.03 0.57 ± 0.02 8.54 ± 0.21 6.39 ± 0.14
2C3 3.59 ± 0.03 8.66 ±0.09 0.67 ± 0.03 8.51 ±0.10 5.88 ±0.02
2G3 3.77 ± 0.41 8.73 ± 0.02 0.57 ± 0.03 8.63 ± 0.21 636  ±0.15
1H9 4.06 ± 0.44 8.72 ±0.03 0.60 ± 0.04 8.58 ±0.16 6.21 ± 0.12
3F5 4.19 ± 0.49 8.69 ±0.05 0.62 ± 0.02 8.52 ± 0.08 6.05 ± 0.15
1A5* (5.15) (8•54) (0.68) ©•61) ©■95)
3C4 5.18 ± 0.00 8.63 ±0.11 0.57 ± 0.02 8.51 ± 0.13 6.02 ±0.04
2H8 5.96 ± 0.44 8.72 ± 0.05 0.56 ± 0.02 8.42 ± 0.14 5.75 ± 0.00
304 6.52 ± 0.55 8.73 ±0.06 0.55 ± 0.02 8.59 ± 0.01 5.94 ± 0.02
4F12 7.69 ± 0.64 8.75 ± 0.07 0.50 ± 0.02 8.34 ± 0.06 5.85 ± 0.10
3F2 7.88 ± 0.05 8.72 ±0.09 0.57 ± 0.04 8.40 ± 0.02 5.92 ± 0.07
3C2 8.23 ± 0.39 8.74 ± 0.07 0.60 ± 0.00 8.37 ± 0.34 5.90 ±0.07
4E8 8.53 ± 0.02 8.78 ±0.01 0.43 ± 0.01 8.29 ± 0.18 5.78 ± 0.09
488“ 12.95 i: 1.73 8.82 ±0.05 0.52 ± 0.05 8.27 ± 0.32 5.88 ±0.10
4H1 13.41 ±: 0.73 8.73 ±0.06 0.46 ± 0.02 8.15 ± 0.43 5.64 ± 0.12
mean - 8 . 7 1 ± 0 . 0 2 - 8.49 ± 0.03 8.01 ±  0.05
5H6 1.28 ± 0.05 8.95 ±0.00 0.70 ± 0.01 8.63 ±0.22 6.45 ± 0.06
5E4 1.56 ± 0.05 8.97 ± 0.03 0.72 ± 0.03 8.56 ±0.17 6.57 ± 0.09
687 2.53 ± 0.09 9.09 ± 0.07 0.67 ± 0.02 8.45 ± 0.05 6.16 ± 0.19
6E3 2.72 ± 0.65 9.02 ±0.14 0.62 ± 0.01 8.39 ± 0.53 5.92 ± 0.24
5C4 2.91 ± 0.11 8.99 ± 0.04 0.61 ± 0.01 8.50 ± 0.18 5.93 ±031
6G6 3.15 ± 1.10 8.98 ±0.03 0.67 ± 0.03 8.48 ± 0.02 6.03 ± 0.03
6H3 3.85 ± 0.58 8.80 ±0.03 0.69 ± 0.03 8.62 ± 0.08 5.90 ± 0.14
5E3 3.94 ± 0.55 8.92 ± 0.05 0.64 ± 0.03 8.27 ± 0.47 5.93 ± 030
5H9 3.94 ± 0.27 8.79 ±0.04 0.67 ± 0.03 8.56 ± 0.16 5.59 ± 0.19
5F4 3.97 ± 0.30 8.89 ±0.02 0.60 ± 0.02 8.39 ± 0.23 535 ± 0.01
6G5 4.34 ± 0.15 8.93 ± 0.00 0.67 ± 0.04 8.63 ± 0.14 6.13 ± 0.00
588 4.47 ± 0.27 8.73 ±0.06 0.66 ± 0.05 8.46 ± 0.22 5.73 ± 0.01
6H11 4.93 ± 0.49 8.87 ± 0.03 0.64 ± 0.01 8.51 ± 0.25 5.94 ± 0.12
507 5.33 ± 0.10 8.92 ±0.01 0.69 ± 0.02 8.62 ± 0.15 531 ± 0.05
6F12 5.34 ± 0.60 8.80 ±0.06 0.63 ± 0.00 8.64 ± 0.16 5.81 ± 0.13
5F5 5.45 ± 0.09 8.89 ±0.00 0.63 ± 0.02 8.47 ± 0.16 5.97 ± 0.07
5C6 6.18 ± 0.31 8.86 ±0.03 0.62 ± 0.03 8.38 ± 0.15 5.84 ± 0.03
6E5 6.32 ± 1.06 8.82 ±0.09 0.64 ± 0.02 8.52 ± 0.06 5.86 ±0.02
5H4 6.55 ± 0.48 8.78 ±0.06 0.69 ± 0.02 8.48 ± 0.12 5.79 ± 0.03
6E10 6.58 ± 0.22 8.84 ±0.00 0.71 ± 0.04 8.60 ± 0.13 5.63 ± 0.15
6E4 7.39 ± 0.26 8.91 ±0.01 0.58 ± 0.00 8.54 ±0.11 5.99 ± 0.05
5E10 8.22 ± 0.24 8.80 ±0.00 0.59 ± 0.02 8.41 ± 0.12 5.82 ± 0.04
602 9.35 ± 1.16 8.86 ±0.03 0.51 ± 0.03 8.42 ± 0.23 5.85 ± 0.05
6C9 - - - - -
mean - 8 . 8 9 ± 0 . 0 2 - 8.50 ±  0.02 5.94 ± 0.05
overall mean - 8 . 8 0 ± 0 . 0 2 - 8.50 ± 0.02 5.98 ± 0.03
A,R-GFP-Gai** 2.79 ± 0.33 8.78 ±0.12 0.61 ± 0.02 8.52 ± 0.23 5.88 ± 0.13
Table 4.3: Equilibrium binding properties of all A^R-GFP and AiR-GFP-Gcq membranes, esti­
mated using the simplified binding assay described in Figure 4.7 on page 93. All estimates are 
n=2, except * (n = l)  and ** (n=3). Results from membranes 1A5 were not included in calculation 
of the mean values shown because they were only n = l. Membranes from cell line 6C9 did not show 
any specific [3 H]DPCPX binding. Values shown are expressed as mean ±  (where n=2) or
mean ±  s.e.m. (n=3), and where shown as ±  0.00 are ±  < 0.005.
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Figure 4.9 [^H ]D PC P X  affinity is similar for A ^R -G FP and 
A ^ R -G F P -G qj, and is essentially  independent of B max-
-8 .O-1
-8 .5 -
[3H]DPCPX
PKa -9.0
-9 .5 -
- 10 . 0 -
■ i t I2 fold range of affinity
A ^-G FP-G a,
A.R-GFP
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Figure 4.9: Graph of [3 H]DPCPX Bmax against [3 H]DPCPX affinity from Table 4.3 on the pre­
vious page. Although there is a statistically significant difference between mean [3 H]DPCPX 
affinities for A^R-GFP and A iR-G FP-G aj membranes (P < 0.0001, see Table 4.4 on page 99), 
the difference is small (0.16 log affinity units) and most values fall within a 2 -fold range of affinity 
(0 .3  log units) as indicated on the graph.
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Both affinities of CHA were not significantly different between A jR -G F P  and A jR -G F P -G a j 
membranes, and agreed writh direct [^H]CHA saturation of A ^R -G F P -G cq membranes (Table 4.5 
on page 99). Table 4.5 also shows the CHA affinities for A |H E  and AjLE membranes for com­
parison. Comparison by unpaired t test of the mean estimates of high affinity CHA binding to 
the A^ R -G F P -G cq  construct by competition and saturation experiments showed no significant 
difference (Table 4.5).
Linear regression of the dependence of CHA affinity on the level of receptor expression (Fig­
ure 4.10 on page 100) showed both log K jj and log to have significantly non-zero slopes 
(P = 0.004 & P < 0.0001 for log Kj_j and log respectively). However, these slopes were very 
shallow (-0.03 and -0.05 for log Kpj and log respectively) and statistical significance may have 
been encouraged by the large number of x  values (n =  102). Estimation of log KL is more difficult 
at low levels of expression when using the five-point competition assay due to increased frjj, as can 
be seen in Figure 4.10 where the estimate of log at the lowest levels of expression appears to be 
higher than most others. Weighting of errors was not employed in any of the analysis in this study, 
however the effect of weighting on the estimation of log using the simplified competition assay 
was investigated. Weighting by y  and yjy? did not alter the estimates of CHA affinities and fr^  at 
low, medium and high levels of expression. This may be due to the generally small size of the errors 
observed in the assay, as can be seen in the competition curves used as examples in Figures 4.7 
and 4.8 (pages 93 and 94 respectively). Accurate estimation of CHA log at the lowest levels of 
receptor expression would require detailed competition assays, such as those shown in Figure 4.6 
on page 91. A real dependence of log on the level of receptor expression is probably unlikely 
as no difference is observed in log and log K jj values for A jH E and A^LE membranes, and 
most of the data for A^R-GFP and A jR -G FP-G aj is consistent with these values.
While the affinities of both [^H JD P C PX  and CH A  are essentially independent of the level of 
receptor expression, the fraction of CH A  binding which is of high affinity (frH ) is dependent on the 
level of expression. Figure 4.11 on page 101 illustrates the dependence of frH (estimated by the 
simplified five-point competition assay) on the level of A ^R -G F P  and A ][R -G FP-G aj expression. 
Linear regression of each construct individually shows significant non-zero slopes (both slopes are - 
0.01 with P  < 0.0001 & P  =  0.004 for A jR -G F P -G c q  and A ^ - G F P  respectively). The dependence 
of frH on the level of receptor expression is similar to the behaviour reported above using A -^E  
and A ^ E  membranes. Figure 4.12 on page 102 combines the frH values as a function of expression 
level from A ^ E ,  A XH E  with all the A jR -G F P  and A iR -G F P -G cq  cell line membranes. Linear 
regression of A ^ - G F P  and AiR-GFP-Gcq frH combined again shows a significantly non-zero 
slope (P < 0.0001) which agrees with the A ^H E  and A ^ E  membranes shown for comparison.
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There is one outlier to the correlation of ffjj with A^R-GFP-Goj expression (cell line 4 F 2 ) which 
is discussed later.
The incubation of low and high expression A^R-GFP-Gcq cell lines with pertussis toxin for 24 
hours before membrane preparation inhibited all detectable high affinity agonist binding, indistin­
guishable from the effect of 100 fiM G TP (data not shown). The Gcq subunit in the AiR-GFP-Gcq 
fusion construct may have been m utated in order to be insensitive to pertussis toxin, although this 
was not confirmed. If the Gcq subunit on the A^R-GFP-Gcq fusion construct is insensitive to 
pertussis toxin, the complete sensitivity of high affinity agonist binding at the A jR-GFP-Gaj fu­
sion protein to pertussis toxin suggests th a t the fused G aj subunit does not couple well to the 
attached A^R. The equilibrium binding properties presented here are very similar at AjR-GFP, 
A^R-GFP-Gcq and A^HE membranes showing the fused Gcq has little influence on binding at 
the AiR-GFP-Gcq construct. This validates the series of A^R-GFP-Gcq cell lines differentially 
expressing A^R as a model for investigating the effect of receptor expression alone on receptor 
behaviour.
4.5 D iscussion.
The work presented in this chapter describes the binding of the inverse agonist DPCPX and a 
selection of agonists of varying efficacy at the human adenosine A^ receptor. Membranes were 
prepared from stable cell lines expressing the adenosine Aj receptor and Aj receptor-GFP fusion 
proteins at a range of densities, and were used to investigate the effect of receptor expression density 
on features of binding at equilibrium. The affinity of DPCPX for the adenosine Aj receptor was 
essentially independent of the level of receptor expression. The affinities of the high efficacy agonist 
CHA for the A^ receptor were also largely independent of the level of receptor expression. However, 
the fraction of specific CHA binding of high affinity (frjj) was clearly dependent on the level of 
receptor expression for the adenosine A^ receptor alone and the A^R-GFP and A^R-GFP-Goj 
fusion constructs.
H eterogeneous agonist b inding at th e  adenosine receptor m easured using A^LE 
and A^HE m em branes.
Previous studies here have investigated the properties of two stable CHO cell lines expressing 
the adenosine A^ receptor a t different densities, A^LE and A^HE (Browning 2003, Browning et 
al. 2001a,b,c). Here, characterisation of those cell lines has been continued in detail. A^HE 
membranes exhibited a 14-fold greater mean [^HJDPCPX Bmax than A^LE membranes and 8 -
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Table 4.4 M ean log affinities o f [3 H ]D P C P X  for A XHE, A XLE, 
A ^R -G F P  and A ^R -G F P-G aj m embranes.
[3 H]DPCPX log k a
AXHE (n =  5) 8.72 ±  0.03
A^LE (n =  5 ) 8.62 ±  0.06
AiR-GFP-Gcq (n =  65) 8.72 ±  0.02
A ^ -G F P  (n = 46) 8 .8 8  ±  0 .0 1
Table 4.4: The mean affinities shown for both fusion constructs are the mean of all individual obser­
vations rather than the mean of means shown on Table 4.3. The mean affinities of [3 H] DPCPX for 
AjR-GFP and A^R-GFP-Gaj membranes were significantly different (P < 0.0001). The estimates 
of [3 H]DPCPX affinity for the fusion constructs were generated by the the three-point [3 H]DPCPX 
saturation assay (in triplicate), whereas the A^HE and AjLE membranes were characterised by 
means of six-point [3 H]DPCPX saturation assays (in quadruplicate) and are reproduced from 
Table 4.1 on page 8 8 .
Table 4.5 M ean log affinities o f C H A  for A^H E, A^LE, A ^R -G FP and
A ^ R -G F P -G qj m em branes.
log Kl log Kh [3 H]CHA satn. log KA
AiR-GFP (n =  41) 6.02 ±  0.14 8.42 ±  0.06 (no data)
A ^ -G F P -G a i (n = 61) 6.05 ±  0.05 8.47 ±  0.04 8.55 ±  0.04 (n =  3)
AXHE (n =  7) 5.79 ±  0.05 8.57 ±  0.06 8.60 ±  0.05 (n =  7)
AjLE (n =  4) 5.68 ±  0.17 8.75 ±  0.16 8.48 ±  0.08 (n = 7)
Table 4.5: Shown are the means of all the individual estimates of CHA affinity on A ^ -G F P  
and A ^-G F P-G cq membranes using the simplified binding assay (highlighted in pink). For 
comparison, results from [3 H]CHA saturation experiments and experiments using AXHE and A ^ E  
membranes are shown (these were not generated using the simplified assay and are reported in 
Tables 4.1 and 4.2 on page 8 8 ). The mean values at the bottom of each section shown in Table 4.3 
are the means of the mean of each cell line, whereas the table here describes the mean of all 
the individual estimates. Also, the A^R-GFP-Gaj means above include data not presented in 
Table 4.3. t tests showed no significant difference in the log KL and log KH means, for both 
AjR-GFP and A1 R-GFP-G ai membranes.
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Figure 4.10 The affinities of CHA for A ^R -G FP and A 1R -G F P -G ai are 
essen tia lly  ind ep en dent o f B m ax- 
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Figure 4.10: Shown above are the affinities of CHA for A^R-GFP and A^R-GFP-Gaj fusion 
constructs, as detailed in Table 4.3, plotted against [^H]DPCPX Bmax. These estimates were 
all measured using the simple three-point saturation and five-point competition assays. Linear 
regression observed significantly non-zero slopes for both log Kpj and log (slopes -0.03 & -0.05 
and P = 0.004 & P < 0.0001 for log Kpj and log respectively). The number of data points for 
each affinity was 102. Also shown, for visual comparison, are mean estimates of CHA log affinities 
for A^LE and A} HE membranes (from Tables 4.1 and 4.2). The AjLE and AjHE data (•) were 
measured using more detailed competition and saturation assays rather than the smaller simple 
assays used for the AjR-GFP and A^R-GFP-Gaj membranes.
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Figure 4.11 C H A  frjj is dependent on [**H]DPCPX B m a x-
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Figure 4.11: The fraction of CHA binding which is of high affinity (frjj) is dependent on the level 
of A^R-GFP and A^R-GFP-Ga^ expression. Linear regression of the data in both graphs showed 
significantly non-zero slopes (both slopes -0.01; P < 0.0001 Sz P =  0.004 for A^R-GFP-Ga^ and 
A^R-GFP respectively, illustrated by the broken straight lines). Table 4.3 on page 95 lists the 
parameters illustrated in the graphs above.
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Figure 4.12 T he fraction of high affinity agonist binding (frjj) is 
dependent on the level o f A XR, A ^ - G F P  and A xR -G FP-G aj
expression.
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Figure 4.12: Shown above are the data from the two graphs in Figure 4.11 on the preceding 
page along with A^HE and A^LE for comparison, showing the dependency of frjj on the level of 
receptor expression. As observed for both constructs individually, linear regression of AjR-GFP 
and AjR-GFP-G aj data combined showed a significantly non-zero slope (slope -0.02, P < 0.0001, 
illustrated by the straight line shown).
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fold greater levels of high affinity [3 H]CHA binding (Table 4 .1 ). The mean log affinity constants 
for both [3 H]DPCPX and [3 H]CHA were independent of the type of membranes used. Previous 
characterisation of [3 H]DPCPX binding at A^LE and A^HE membranes showed no significant 
(P > 0.05) difference in pKD values (Browning 2003). Cordeaux et al. 2000 reported over 3- 
fold higher affinity of [3 H]DPCPX at membranes from stable CHO cell lines expressing a lower 
(0.2 pmol/mg protein) rather than at higher (3.4 pmol mg protein) level of the human adenosine 
Aj receptor. They also reported 2-fold higher affinity of the A^ receptor antagonist XAC at the 
higher level of receptor expression although this may not be a significant difference. However these 
experiments were performed in a different buffer system (Tris-EDTA), in a smaller volume (200 /d) 
and incubated for an increased period of time (90 min) compared to the results presented here.
Although A^LE membranes showed lower levels of both [3 H]DPCPX and [3 H]CHA high affin­
ity binding than A^HE, the fraction of total high affinity binding (frjj) which was available for 
[3 H]CHA was much greater (63% compared to 39% for A^HE; Table 4.1). CHA binding at A^HE 
and A^LE membranes measured by [3 H]DPCPX CHA competition experiments was of two com­
ponents, approximately 1000-fold different in affinity (Table 4.2). As shown by direct radioligand 
saturation the estimates of frpj by competition experiments were greater at A^LE (71%) than 
A} HE (52%) membranes. Despite being similar, the estimates of frj_j from saturation and compe­
tition experiments were not in absolute agreement although this was not determined statistically. 
A number of factors may contribute to differences in estimates of frj^ observed by competition 
and saturation experiments. Differences in the number of ligands present, the nature of binding of 
each ligand, the association kinetics of each ligand and methods of data analysis are different for 
saturation and competition experiments.
Estimates of [3 H]CHA Bmax increased with longer periods of incubation up to four hours 
(Figure 4.3a). The Kj^ of [3 H]CHA appeared constant from incubation times of approximately 
30 min onwards (Figure 4.3b). The non-linear regression shown in Figure 4.3a extrapolates to 
a level of [3 H]CHA specific binding of 2.2 pmol; mg protein at zero association time, which is 
approximately half of the maximum of 4.1 pmol mg protein. Half of the maximum number of 
high affinity [3 H]CHA binding sites are available immediately and half are the result of a slow 
increase. Such 1:1 stoichiometries of binding site populations raises the intriguing thought of 
whether this is a reflection of receptor dimerisation. This is discussed later in this document. 
Chapter 5 investigates the kinetics of the binding of [3 H]DPCPX and [3 H]CHA to A^HE and 
A^LE membranes in detail. In contrast to the binding of [3 H]CHA, [3 H]DPCPX rapidly reached 
its maximum within a m atter of minutes. There appear to be subtle differences in the binding of 
[3 H]CHA and [3 H]DPCPX which may be responsible for the different estimates of frH by means of
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competition and saturation experiments. Possible mechanisms behind the changes in [^HjDPCPX 
and [3 H]CHA binding with time are discussed later in Chapter 5.
Heterogeneous agonist binding at G protein-coupled receptors has been widely reported for a 
considerable period of time (Birdsall et al. 1978). Heterogeneous agonist binding at the adenosine 
Aj receptor has been observed for both recombinantly expressed and native receptor. The work 
presented here along with previous work within the group has characterised in detail heterogeneous 
agonist binding at the adenosine A^ receptor recombinantly expressed in stable CHO cell lines 
(Browning 2003, Cohen et al. 1996b). The adenosine A^ receptor agonist PIA has been observed 
to inhibit 38% of antagonist binding with high affinity in guinea pig forebrain (Kollias-Baker et 
al. 1994). [^H]DPCPX /  PIA competition experiments in the presence of 10 mM MgCl2  at rat 
cortical membranes have observed a fry  of 0.75 (Finlayson et al. 2003). These observations are in 
contrast to the estimate of frjj observed here at A] HE membranes which was 0.54 ±  0.01 (n =  2, 
Table 4.2). However these are quite different preparations, two from endogenously expressed rat 
A i  receptor and the other from recombinantly expressed human A^ receptor which show quite 
different levels of receptor expression.
In summary, the affinities of [^H]DPCPX, [^H]CHA and CHA were not different between 
membranes from A jH E and A jLE cell lines. However the fraction of CHA binding which was of 
high affinity (frjj) was clearly reduced at A^HE membranes compared to AjLE. The frjj observed 
in AjHE membranes was only reduced by one third, compared to A^LE membranes, despite the 
large increase in Bmax (Tables 4.1 and 4.2). Assuming [^H]CHA binds with high affinity to 
the A jR  as part of the agonist-receptor-G protein ternary complex, such an increase in receptor 
number alone would be expected to result in a fr^j of approximately 0.05 for A}HE membranes. 
The observed frjj in A^HE membranes of 0.52 implies there is a change in the system between 
A^LE and A^HE membranes, such as an increase in G protein availability. The dependence of frjj 
on the level of receptor expression was investigated in greater detail using membranes prepared 
from stable cell lines expressing either the A^R-GFP or A^R-GFP-Ga^ fusion constructs, and is 
discussed further below.
The binding o f low efficacy agonists at the adenosine receptor.
The ratio of agonist affinities for the “high affinity” G protein-coupled (KH) and “low affinity” 
G protein-uncoupled (KL) receptor states has long been linked with agonist efficacy (Birdsall et 
al. 1978 and Kent et al. 1980). Previous work here used adenosine A^ receptor low efficacy 
agonists GR190178, GR161144 and GR162900 in order to investigate the ability of the ternary 
complex model to describe the relationship of this ratio to relative agonist efficacy (Browning
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2003, Sheehan et al. 2000). The work presented in this study attempted to measure with greater 
accuracy the equilibrium binding properties of these ligands before their use in kinetic experiments 
presented in Chapter 5.
[^H]DPCPX competition curves using low efficacy agonists such as GR161144 and GR162900 
are difficult to analyse directly by non-linear regression due to the reduced separation of their high 
and low affinity constants. [^H] ant agonist /  agonist competition experiments are often analysed 
by one-site models with a variable Hill slope of the inhibition curve (for example see Finlayson et 
al. 2003). Shallow Hill slopes indicate heterogeneous agonist inhibition of [^H]antagonist binding. 
However one-site competition curves with variable Hill slopes do not provide estimates of the two 
agonist affinity constants or the fraction of agonist binding which is of high affinity. Therefore in 
order to more accurately describe biphasic binding of partial agonists the competition assay was 
modified and performed in the presence and absence of 100 /iM GTP. Both curves (± GTP) were 
performed in the same rack of tubes at the same time in order to reduce variability and to increase 
the reliability of analysis using shared parameters from both curves. The curve in the presence of 
GTP was best fit to a one-site model and the low affinity binding constant was obtained. Two-site 
analysis of the curve in the absence of GTP was constrained to 0% and 100% (bottom and top 
respectively) and the low affinity binding constant obtained in the presence of GTP. This left only 
frjj and the high affinity binding constant to be estimated from the two-site curve.
The work presented here shows the adenosine Aj receptor agonists GR190178, GR161144 and 
GR162900 all exhibit reduced “GTP shift” than the high efficacy agonist CHA when examined in 
competition binding experiments with [^H]DPCPX (Figure 4.6 on page 91). That is, they show 
a reduced difference between the high (K jj) and low (Kj^) affinity constants of agonist binding 
at equilibrium. This can be expressed as the ratio of agonist affinities (7^*-), alternatively termed 
“GTP shift.” If this is related to agonist efficacy, then the competition curves presented in Figure 4.6 
suggest a rank order of efficacy at the human adenosine A^ receptor of CHA GR190178 
GR161144 > GR162900. This is in agreement with previous work on these compounds (Browning 
2003, Sheehan et al. 2000).
The best fit curves and estimates of frH in Figure 4.6 are possibly not visually reliable. Other 
studies have observed decreased frjj with reduced ligand efficacy at the adenosine A 7 receptor 
(Lorenzen et al. 1996), and visual inspection of the data in Figure 4.6 appears to indicate this 
too, but non-linear regression does not resolve a difference in frjj between CHA, GR190178 and 
GR161144. The experiments described in Figure 4.6 using the partial agonists were performed 
using Ax HE membranes which exhibited an unusually high frH compared to other batches of 
A^HE membranes. However, of interest is the estimate of frH relative to the other agonists in
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the experiment, rather than comparison of absolute ffjj values between different experiments. 
Non-linear regression of the [3 H]DPCPX / GR162900 competition curves does identify a reduced 
ffjj compared to CHA, GR190178 and GR161144. Previous [3 H]DPCPX competition binding 
experiments here by Chris Browning using a slightly different approach indicated that GR190178 
and GR161144 both exhibited reduced frjj compared to CHA (Browning 2003). An estimate of 
ffjj for GR162900 was not resolved as the [3 H]DPCPX competition data could not be adequately 
described by a two-site competition curve.
q
The [ HJDPCPX competition assay performed in the same rack of tubes both in the presence 
and absence of GTP enabled estimation of the GTP shift for partial agonists of very low efficacy 
such as G R l62900. The results provide evidence that agonists of very low efficacy may also exhibit 
reduced frjj. This implies that ffjj may be dependent on the nature of the bound agonist as well 
as the molecular composition of the receptor signalling complex.
Equilibrium  antagonist and agonist binding at m em branes expressing the A ^R -G FP  
or A i R -G F P -G qj fusion constructs.
A simplified combined [3 H]DPCPX saturation and [3 H]DPCPX /  CHA competition assay was 
designed in order to characterise the equilibrium binding properties of membranes prepared from 
all 24 AXR-GFP and 23 AXR-GFP-Gcq cell lines. Details of this assay are described on page 90, 
and in Figures 4.7 and 4.8 on pages 93 and 94 respectively. The simplified assay enabled rapid and 
efficient characterisation of a large number of membrane preparations in a single experiment and 
the results obtained were precise and reproducible. Table 4.3 on page 95 lists mean parameters 
estimated using the simplified assay for all membranes expressing the AXR-GFP or AXR-GFP- 
Gcq fusion constructs. Tables 4.4 and 4.5 compare mean [3 H]DPCPX and [3 H]CHA affinities 
estimated using the simplified assay (AXR-GFP and AXR-GFP-Gcq membranes) and more detailed 
experiments (AXLE and AXHE membranes). In general the mean log affinities obtained were similar 
for each membrane type (AXLE, AXHE, AXR-GFP and AjR-G FP-G aj) although a thorough 
experimental and statistical comparison of the reliability of the simplified assay compared to more 
thorough experiments was not performed. Of more interest was not the absolute accuracy of the 
estimates obtained by the simplified assay, but instead whether there was a dependence of any of 
the parameters on the level of receptor expression.
When [3 H]DPCPX log affinity results for both the AXR-GFP or AXR-GFP-Gaj fusion con­
structs were combined, [3 H]DPCPX affinity was not dependent on the level of receptor expres­
sion. Also, the AXR-GFP-Gcq [3 H]DPCPX log affinity data alone was not dependent on the level 
of receptor expression. However the AXR-GFP membranes did show a significant reduction in
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[3 H]DPCPX log affinity with increased receptor expression. Estimation of [3 H]DPCPX affinity at 
very low levels of expression was at times more difficult due to the much reduced level of specific 
[ HJDPCPX binding. Visual inspection of the data presented in Figure 4 .9  on page 96 shows a 
greater spread of log affinity estimates at low levels of expression for the A^R-GFP-Gcq construct. 
This may be a reflection of the reduced accuracy of affinity estimates at low levels of expression 
with low levels of specific binding. Why the A jR-G FP membranes appear to exhibit increased
q
[ H]DPCPX affinity at low levels of receptor expression is unclear. However as the A^R-GFP-Goj 
membranes, along with A^LE and A jH E membranes, show no evidence of any dependence of
q
[° HJDPCPX affinity on receptor expression it would be difficult to propose a mechanism by which 
the level of A^R-GFP expression appreciably determines [3HJDPCPX affinity.
No significant difference was observed between the two fusion constructs for both the high 
and low CHA affinity constants estimated by means of the simplified 5-point [3 H]DPCPX / CHA 
competition assay. Table 4.5 on page 99 shows mean CHA log affinities for A^LE, AjHE, AjR- 
GFP and AiR-GFP-Gcq membranes and compares them to direct [3 H]CHA saturation data. In 
general the CHA log affinity estimates of membranes expressing the fusion constructs are similar 
to that of the A jLE and A jH E membranes, although the fusion constructs show a reduced “GTP 
shift” compared to A^LE and A^HE. From Table 4.5 GTP shifts of 251, 263, 602 and 1174 (for 
AjR-GFP, A^R-GFP-Gcq, A^HE and A^LE respectively) can be calculated. It should be noted 
that the A^LE and A^HE CHA affinity constants were estimated by means of detailed competition 
assays, whereas the A jR -G FP and A^R-GFP-Goj membranes were characterised by the 5-point 
competition assay. However, the simplified assay was not designed for absolute accuracy in order to 
compare estimates outwith the assay, but was designed in order to investigate the effect of receptor 
expression on features of equilibrium binding.
No significant difference was observed between the two fusion constructs for either the low (Kp) 
or high (Kpj) mean log affinity constants of CHA binding. The two fusion constructs have indistin­
guishable mean affinities for CHA. Therefore the data from both constructs were pooled in order 
to investigate the effect of receptor expression level on the estimate of each CHA affinity constant. 
In addition to the CHA affinity constants for both fusion constructs Figure 4.10 on page 100 also 
shows the affinities of CHA for A^LE and A} HE membranes for comparison. Although again it 
should be noted that the A1LE and A jH E data was generated from detailed competition binding 
experiments and the A^R-GFP and A ^-G F P -G cq  data was from the simplified 5-point competi- 
tion assay. Both log KL and log KH appear to be essentially independent of [^HJDPCPX Bmax- 
Both affinity constants show a significant, but shallow, dependence on receptor expression (Fig­
ure 4.10). Repeat analysis of individual observations (rather than the means shown in Table 4.3)
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showed the same shallow dependence of the CHA affinity constants on [3H]DPCPX Bmax-
In general it appears the affinities of [3H]DPCPX and CHA are essentially independent of the 
level of expression of either the A^R-GFP or AiR-GFP-G aj fusion construct. Where a significant 
dependence on [ H]DPCPX Bmax was observed the slopes were shallow. In agreement with 
observations at A^LE and A^ HE membranes, the affinities of both a high efficacy agonist and an 
inverse agonist are constant over a large range of levels of expression of the human adenosine A^ 
receptor.
D etailed characterisation o f the effect o f receptor density on frjj.
As discussed above, membranes prepared from cell lines expressing A^R, A^R-GFP or A^R-GFP- 
Gaj all showed similar affinities for [3H]DPCPX and CHA which were essentially independent 
of the level of receptor expression. However the fraction of CHA binding which was of high 
affinity (frjj) was clearly dependent on the level of receptor expression. The relationship between
Q
[ HJDPCPX Bmax and CHA frj_j observed at A^LE and A^HE membranes was confirmed in 
detail using membranes from all of the A^R-GFP and A^R-GFP-Goj cell lines. Figure 4.11 on 
page 101 illustrates the significant dependence of frjj on the level of receptor expression for both 
the A jR-GFP and A j R-GFP-Gqj series of membranes. Figure 4.12 on page 102 shows that the 
dependence of frjj on [3 HJDPCPX Bmax was similar for the adenosine A | receptor alone (AjLE 
and A^HE membranes) and the A^R-GFP and A^R-GFP-Ga^ fusion constructs. Although linear 
regression was used to determine a significant relationship or not, it is not known whether the 
nature of the relationship is indeed linear or whether f r p la te a u s  at the extreme low and/ or high 
levels of receptor expression.
Membranes from A^R-GFP-Ga^ cell line 4F2 show a [3H]DPCPX Bmax and CHA fr^  that 
do not follow the relationship observed at all the other membranes (Table 4.3). 4F2 is clearly 
distinguished in the lower left region of Figures 4.11 and 4.12. Cell line 4F2 was selected as an 
individual cell of high fluorescence by means of gate 4 (Figure 3.1 on page 63), and cells from 
the mature 4F2 cell line were analysed by flow cytometry (Figure 3.2 on page 64) and observed to 
exhibit a low mean GFP brightness similar to cell lines created from cells selected by gates 2 and 3. 
While 4F2 exhibits reduced GFP fluorescence and [3H]DPCPX Bmax, it exhibits a low frjj of 0.39 
more similar to cell lines expressing much greater levels of the A jR-GFP-Goj construct. Careful 
re-examination of the competition binding assay results clearly showed that this unusually low frjj 
was indeed a property of the membranes and not an experimental artifact. In general membranes 
from most A^R-GFP-Gaj and all A^R-GFP cell lines show a similar dependence of frjj on the 
level of receptor expression. However membranes from cell line 4F2 show that it is possible in rare
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situations to observe low frjj at low levels of receptor expression.
Previous work here investigated the ability of the ternary complex model to predict the change 
in frjj with level of receptor expression at A^LE and A^HE membranes (Browning 2003). While 
the ternary complex model was able to predict a reduction in frjj at increased levels of receptor 
expression with no change in agonist or antagonist affinity, the predictions were not quantitatively 
compatible with observations at A jLE and A] HE membranes. As for A jLE and A} HE mem­
branes discussed above, membranes prepared from cell lines expressing greater levels of the A^R 
fusion constructs show lower frpj but appear to be able to recruit greater amounts of G protein. 
The change in frpj with receptor expression implies that the stoichiometry of adenosine A^ re­
ceptor and G protein may change as the concentration of receptor increases. Also, studies have 
provided evidence that at increased level of adenosine A^ receptor expression the receptor can 
stimulate functional responses through pertussis toxin-insensitive G proteins as well as pertussis 
toxin sensitive G proteins (Cordeaux et al. 2000). It is possible the increase in available G protein 
at higher levels of receptor expression may be the consequence of increased availability of pertussis 
toxin-sensitive G protein and also an increased ability to couple to pertussis toxin sensitive G 
protein.
The equilibrium binding properties of A jR-G FP and A^R-GFP-Goj are not sensitive to the 
presence of the tethered GFP or G ap These constructs appear to interact with free G protein as 
effectively as the A jR  alone. This validates their use as models of the behaviour of the adenosine 
A^ receptor alone. As the fused Ga^ does not appear to contribute to the radioligand binding 
properties of the A jR -G FP-G aj construct, the presence of the truncated construct in some mem­
branes (Figure 3.5 on page 71) may not be of pharmacological significance. Bevan et al. 1999 
reported no coupling of tethered G aj at the A^R-Ga^ construct, and much reduced potency for 
NECA stimulation of [^SJG TPyS binding at the A^R-GFP-Gaj construct expressed in CHO cell 
membranes when endogenous Ga^ was inactivated by pertussis toxin. At best the tethered Gaj 
of the A^R-GFP-Gaj fusion appears to couple to the receptor much more weakly than does en­
dogenous G ap It is possible this reduced level of coupling is not measurable by the [^HJDPCPX 
/  CHA competition assay used in the present study.
In summary, the equilibrium binding properties of membranes prepared from 49 cell lines 
(AjLE, A^HE, 23 for A^R-GFP-Gaj and 24 for A jR-GFP) were characterised in detail. The 
affinities of DPCPX and CHA at these membranes were essentially independent of the level of 
receptor expression. While the affinities of CHA were independent of receptor density, the fraction 
of CHA binding of high affinity (frH ) was clearly observed to decrease with greater levels of receptor 
expression. These observations provide evidence that the composition of the receptor signaling
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complex is dependent on the level of receptor expression. The receptor signalling complex may be 
composed of several different proteins, and changes in its composition has the potential to alter 
many aspects of receptor behaviour and signalling. The A jR-G FP and A ^ -G F P -G a j constructs 
appear to be valid models of the adenosine A2 receptor alone.
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The kinetics of agonist and 
antagonist binding at the human 
adenosine receptor.
5.1 Introduction.
The kinetics of binding at GPCRs provides insights into both the binding of ligand and the response 
of the receptor to ligand. In common with the nature of equilibrium agonist binding, the kinetics 
of agonist binding at the adenosine Aj receptor are complex. Previous work within the receptor 
group at NIMR described novel observations of agonist and antagonist binding at the human 
adenosine receptor expressed in stable CHO cell lines. These observations included two-phase 
exponential association of the antagonist [^H]DPCPX and incomplete dissociation of the agonist 
[^H]CHA (Cohen et al. 1996b, Browning 2003). In this Chapter the nature of association and 
dissociation of [^HJDPCPX and [^H]CHA at A jH E membranes has been characterised in detail 
and compared briefly to other adenosine A^ receptor membrane preparations.
5.2 D escription of m ethodology.
To study the kinetics of radioligand dissociation a reverse time course strategy to enable simulta­
neous filtration was developed based on previous studies (Cohen et al., 1996b; Hulme and Birdsall, 
1992). A reverse time course strategy offers significant benefits in assay throughput by allowing 
many time points to be filtered simultaneously at the end of their incubation. A rack of 48 tubes,
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or a 96-well plate, containing many different incubation times and, on occasion, both association 
and dissociation time courses can be processed rapidly and uniformly at the same time.
Prior to the initiation of dissociation, radioligand and membrane were incubated in a volume 
of 100 /d for between 5 min and 3 hours. Following the period of association, dissociation was 
initiated by means of a 20 fold dilution into buffer in order to reduce the concentration of radioligand 
significantly below its Kjy. In order to reduce interference arising from the rebinding of radioligand 
even at these reduced concentrations, the 20 fold dilution contained in many experiments an excess 
concentration of unlabelled competing ligand, generally termed a “chase”. The presence of GTP 
in the chase solution was employed in some experiments to investigate the effect of disruption of 
receptor-G protein coupling on radioligand dissociation. A dissociation incubation of between 5 
min and 3 hours followed before simultaneous filtration onto glass fibre filters. Briefly outlined, 
the methodology employed to characterise the kinetics presented in this Chapter (and Chapter 6) 
was as follows;
1. Membranes were prepared from stable CHO cell lines expressing the adenosine receptor 
alone (A^HE and AjLE), or either of the A jR-G FP and A^R-GFP-Gq  ^ fusion constructs 
(Chapter 2.2.2 on page 51).
2. The membrane preparations were incubated with adenosine deaminase for 30 min at RT 
(22°C) in order to remove endogenous adenosine which, if not removed, would inhibit the 
binding of radiolabelled and unlabelled ligands. Membranes were diluted and placed on ice 
after adenosine deaminase incubation.
3. Radioligand and membranes were incubated in a small volume (100 /d) at RT for 1 hour. 
[For association assays the incubation was terminated at the appropriate time here by rapid 
filtration onto glass fibre filters.]
4. The dissociation experiments were initiated by means of a 20-fold dilution of the 100 /d 
aliquots from step 3 above (addition of 2 ml buffer in the presence or absence of chase 
ligand) reducing the concentration of radioligand to well below its Kq .
5. Dissociation of the radioligand was terminated at given times by rapid filtration onto glass 
fibre filters.
Figure 5.1 on page 115 illustrates differences between measuring the dissociation of bound radioli­
gand by dilution with buffer and dissociation by dilution in the presence of a competing unlabelled 
ligand (or “chase”). Each of the points are explained in more detail below;
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Initial association . Prior to dissociation radioligand (L) is incubated with the receptor (R) for a 
period of time, which on occasion is sufficient for the system to reach a state of equilibrium 
(L +  R ^  L.R) (Figure 5.1a). In the case of high affinity agonist binding to the adenosine 
receptor, L.R is the high affinity agonist-receptor-G protein ternary complex.
D issociation by dilu tion  alone. Dissociation of L from L.R can be performed by dilution of 
the radioligand well below its K p . The radioligand L will then dissociate from the receptor 
until it reaches an equilibrium corresponding to the new lower concentration of radioligand 
(Figure 5.1b). Even at low concentrations the radioligand binds to the receptor to an extent 
and the observed rate of dissociation will be a consequence of both the “on” and “off’ rates 
of the radioligand for the receptor. This re-association should be negligible if the radioligand 
is diluted to < 0.1 k d .
Prevention o f rebinding o f a radioligand by a “chase” ligand. When dissociation is per­
formed by dilution in the presence of a high concentration of a competing unlabelled ligand 
(X), the binding site is rapidly occupied by unlabelled ligand as radioligand dissociates from 
the receptor (Figure 5.1c). Due to the very much higher concentration of unlabelled lig­
and than radioligand the receptor effectively remains occupied by unlabelled ligand and 
re-association of radioligand to the receptor is blocked. The rate of dissociation of radioli­
gand observed in the presence of a high concentration of unlabelled ligand is predominantly 
determined by the radioligand off-rate and is not influenced by the on-rate. The addition of 
chase ligand combined with dilution of the association incubation offers a number of experi­
mental benefits when studying the adenosine A | receptor over the addition of a small volume 
of very concentrated chase ligand with minimal dilution. As non-specific binding can depend 
on the amount of radioactivity present rather than the concentration of radioligand, an assay 
volume of 100 /A requires less radioactivity than the same concentration of radioligand in a 
greater volume of 2 ml. Therefore the incubation of membranes and radioligand in a small 
volume (100 //l) followed by dilution into a large volume (2 ml) may reduce non-specific bind­
ing of radioligand compared to incubation in a greater volume (such as 1 or 2 ml) followed 
by addition of a small volume of very concentrated chase ligand. Also, it may be difficult 
to make sufficiently concentrated solutions of chase ligand if the chase solution itself will be 
significantly diluted by addition to the association incubation.
Effect o f the chase ligand and its nature on the dissociation rates. In simple monomeric 
systems the kinetics of dissociation should be independent of the method of dissociation and 
the pharmacology of chase ligand (Figure 5.Id). The kinetics of dissociation by means of
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dilution only should be compatible with dissociation by dilution containing a high concentra­
tion of unlabelled chase ligand. Although chase ligand prevents re-association of radioligand 
to the receptor, the extent and kinetics of dissociation by the two methods may not be ab­
solutely identical. If the receptors are clustered together the dilution protocol allows the 
possibility that the radioligand, after dissociation from one receptor molecule, can have a 
high probability of rebinding to a nearby unoccupied receptor because of the locally high 
concentration of receptors. This option is not available to the chase protocol because all 
neighbouring receptors are occupied by the chase ligand.
5.3 The kinetics of the association of [^HJDPCPX to the 
adenosine receptor.
q
[ HJDPCPX associated rapidly to membranes prepared from the A^HE cell line, with observed rate 
constants of association (k0^g) of 0.26 ±  0.01 and 0.30 ±  0.01 m in '1 at 0.2 and 1.0 nM [^HJDPCPX 
respectively (both n =  2). Levels of bound [^HJDPCPX reached a maximum after approximately 
20 minutes, before decaying to a plateau. Association of 0.3 nM [^HJDPCPX appeared to exhibit a 
larger difference between maximum and final equilibrium specific binding than 1 nM [^HJDPCPX 
(data not shown). 100 /zM GTP increased specific [^HJDPCPX binding consistent with its ability to 
disrupt receptor-G protein complexes and increase the binding of inverse agonists and the decrease 
in [^HJDPCPX binding at long incubation times appeared to be attenuated in the presence of GTP 
(not shown).
All membranes used for the radioligand binding experiments presented in this study were in­
cubated with 3 U/m l of the adenosine catabolising agent, adenosine deaminase, for 30 min before 
incubation with radioligand. The [^HJDPCPX association kinetics described in the above para­
graph were treated in this manner as well. The pretreatment of A^HE membranes with adenosine
q
deaminase and the membrane permeabilising agent saponin before incubation with [ HJDPCPX 
was investigated further. The association of 0.3 nM [^HJDPCPX to A^HE membranes follow­
ing different 30 min pre-incubation conditions is shown in Figure 5.2 on page 117. Adenosine 
deaminase and saponin pre-treatment both increased [^HJDPCPX binding at all time points. The 
greatest difference between maximum and plateau [^HJDPCPX SB was observed in the absence of 
adenosine deaminase. Complex antagonist-GPCR association curves of this form are unusual, but 
have been described in GPCR systems such as the muscarinic M2  receptor for the split receptor 
(Novi et al., 2003). However, a straightforward mechanism may be responsible for the decay of
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Figure 5.1 D ifferent conditions used to  in vestigate the dissociation of 
ligand from a receptor.
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Figure 5.1: (a ) Prior to dissociation, radioligand (L) is incubated with receptor (R), often until the 
system reaches equilibrium (L +  R =5=^  L.R). (b )  Following dissociation by dilution alone the level 
of bound radioligand is reduced according to the new lower concentration of L. (c) In the presence 
of a high concentration of competing unlabelled “chase” ligand (X ), L will not re-associate to the 
receptor once it has dissociated, (d )  In simple monomeric systems the kinetics of dissociation 
should be independent of the method of dissociation and the pharmacology of chase ligand. See 
page 113 for more detailed description.
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O
bound [ HJDPCPX with time; slow release of endogenous adenosine from the membrane prepa­
ration may progressively compete with the binding of [3H]DPCPX. Pre-incubation of membranes 
with both adenosine deaminase and saponin almost entirely removes the slower inhibitory compo­
nent observed in the binding of [3HJDPCPX. It is possible that the reason saponin is required in 
the membrane pre-incubation is that it enables adenosine deaminase access to all the adenosine 
present in the membrane preparation. In all binding assays presented here (other than Figure 5.2) 
membranes were incubated with adenosine deaminase, but not saponin, for 30 min prior to incu­
bation with radioligand (Chapter 2.2.3 on page 51). 30 ^g/m l saponin was present in all binding 
assays during incubation of radioligand with membranes.
5.4 The kinetics of the dissociation of [^HJDPCPX from the 
adenosine receptor.
[3H JD PCPX  dissociated rapidly from A ^HE, A ^L E  and A ^R -G F P -G a j  membranes and the data 
could be described reasonably well by a simple mono-exponential function (Figure 5.3 on page 118). 
Following dissociation by dilution, [3H ]D P C P X  binding decays to levels expected from the diluted
O
concentration of [ HJDPCPX. Dilution in the presence of a high concentration of competing un­
labelled ligand (10~® M DPCPX or 10'4 M CHA) results in dissociation of [^HJDPCPX to non­
specific levels. The mean rate constants of dissociation (kQfj) for A^HE, A^LE and A^R-GFP-Gcq 
membranes in all conditions were 0.22 ±  0.01 (n =  5), 0.24 ±  0.02 (n =  3) and 0.23 ±  0.02 (n = 14) 
min" 1 respectively ( t |  3.2, 2.9 and 3.0 min respectively). The low number of replicate estimates 
deters conclusive analysis of variance, and the s.e.m.s of each mean overlap, showing a lack of any 
significant difference with the data above. Addition in the 2 ml chase of saponin, which perme- 
abilises vesicular structures in the membrane preparation (Cohen et al., 1996b), did not noticeably 
alter the rate of dissociation of [^HJDPCPX. The rate constant of dissociation was similar when 
10"6 M DPCPX, 10~4 M CHA, 10"4 M GTP or 10 fag/ml saponin was present in the chase solution 
(or indeed when 10~4 M CHA, 10“4 M GTP and 10 /ig/ml saponin were all present). The rate 
of dissociation of [3H]DPCPX from the adenosine A^ receptor appears to be independent of the 
agonist or antagonist pharmacology of the competing chase ligand used to prevent [^HJDPCPX 
rebinding. Non-linear regression suggests the dissociation of [3H]DPCPX might not be absolutely 
monoexponential, possibly possessing more than one component, although this was only an indica­
tion as the deviations from monoexponential curves were small and were not investigated further.
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Figure 5.2 T he association  o f [^H JDPCPX to  A-^HE m em branes.
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Figure 5.2: Representative experiment investigating the association of 0.3 nM pH]DPCPX to 
AjHE membranes, performed in duplicate. The effect of 1.2 Units ml adenosine deaminase and 
0.2 mg/ml saponin in the 30 min membrane pre-incubation prior to association is shown. 30 /ig/'ml 
saponin was present in all association time points, as for all radioligand binding experiments.
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Figure 5.3 T he dissociation  of [^HJDPCPX from the adenosine
receptor.
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Figure 5.3: Representative [^HJDPCPX dissociation curves, showing the dissociation of
pH]DPCPX from A^LE membranes by 20-fold dilution in the presence or absence of CHA or 
DPCPX chase. The concentration of [^H]DPCPX before 20-fold dilution was 10 nM. The rate 
constant of dissociation was similar when 10"® M DPCPX or 10"^ M CHA was present in the 
2 ml chase solution (kQff 0.23 and 0.22 min"1 respectively for the curves above). All [3H]DPCPX 
dissociation experiments were performed at RT (22°C).
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5.5 The kinetics of the association of [3H]CHA to A^HE and 
A^R-GFP-Ga^ membranes.
The association of [ H]CHA to A^HE membranes was best described by a two-phase model of 
exponential association. The two-phase exponential association of [3H]CHA was observed in the 
usual association assay volume of 100 fil and also in volumes of 2 ml. Data from a single experiment 
investigating the dependence of the association of [3H]CHA on the concentration of [3H]CHA 
in a volume of 100 pi is showm in Figure 5.4 on the following page. Higher concentrations of
O
[ H]CHA showed a greater extent of binding and also a faster initial rate of association, as would 
be expected. Figure 5.5 on page 122 plots mean parameters describing the two components of the 
association of [ HjCHA to A jH E membranes. The observed rate of the fast component of [3H]CHA 
association was dependent on the concentration of [3H]CHA (Figure 5.5a). Linear regression of 
all the individual observations (rather than mean values) showed a significantly non-zero slope 
(P = 0.007) with a p-axis intercept of 0.1 min"1 and a slope of 0.02. For a simple binding process 
the equation, kQbs — k+i\L*\ + k - 1 , describes the observed association with the y-axis intercept 
(0.1 m in '1) representing the off rate (fc_i) of [3HjCHA1. This estimate agrees with the mean fast 
rate constant for the dissociation of [3H]CHA from A^HE membranes in the presence of a high 
concentration of CHA (in order to measure dissociation of [3H]CHA without rebinding) which was 
0.12 ±  0.01 (n =  28). [The kinetics of the dissociation of [3H]CHA from the A^R are described 
later, in Chapter 5.6 beginning on page 124.]
The product of the observed rate (k ^ g ) and amplitude of the association of [3H]CHA is the 
initial rate. This parameter is the gradient of the association curves at t —► 0, and is useful as it 
combines two estimates from experimental observations. Figure 5.5c shows the clear dependence 
of the initial rate on the concentration of [3H]CHA for the fast component of the association of 
[3H]CHA. Linear regression observed a significantly non-zero slope (P < 0.0001) as indicated on 
the graph by the broken line. Figures 5.5a and 5.5c show the fast component of the association 
of [3H]CHA is entirely dependent on the concentration of [3H]CHA. This is consistent with this 
component being a simple bimolecular interaction obeying the law of mass action.
The slow component of the association of [3H]CHA to A^HE membranes is illustrated in the 
same manner in Figures 5.5b and 5.5d. The dependence of the slow component of [3HjCHA as­
sociation on the concentration of [3H]CHA is less distinct than for the fast component. Linear 
regression of kQ^ s against [3HJCHA concentration for the slow component did not show a sig-
1k 0bs = k+i.[L*} +  k - 1; k obs is th e  observed ra te , k + 1 and  fc_i are th e  on and  off ra tes respectively and [L*] is 
th e  concen tra tion  of [3 H jC H A .
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Figure 5.4 Two-phase exponential association of [3H]CHA to A 1HE
m embranes.
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Figure 5.4: Representative pHjCHA association curves from a single experiment indicating the 
extent and initial rate of association to HE membranes axe dependent on the concentration of 
pH]CHA. The association of [^HJCHA at the four concentrations shown was best fit in all cases 
to a two phase model of exponential association. The pHJCHA association curves shown were 
performed in a total volume of 100 /xl. The association curves above are the same data as shown in 
Figure 4.2 on page 83, but expressed as association time courses rather than HJCHA saturations.
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nificantly non-zero slope (Figure 5.5b), however linear regression of the initial rate did show a 
significantly non-zero slope (P =  0.04, line not showm on Figure 5.5d). It is possible that the slow 
component of the association of [3H]CHA to A^HE membranes is not entirely dependent on the 
concentration of [3H]CHA, although with the limited data presented here it is difficult to establish 
an absolute relationship either way. The initial fast association of [3H]CHA appears to be the 
result of binding to readily available high affinity agonist binding sites, forming the high affinity 
agonist-receptor-G protein complex. The slow rate of [3H]CHA association may be influenced by 
a factor other than [3H]CHA concentration, which may include the recruitment of extra G protein 
into the receptor environment.
The data described in Figure 5.5 also provides an insight into the relative amplitudes of the 
fast and slow components of [3 HjCHA association. There is not enough information at higher
O
concentrations of [ HjCHA to directly estimate the maximum of each amplitude, but the data 
from Figure 5.4 when expressed as a saturation curve (Figure 4.3 on page 84) extrapolates to a 
maximum [3H]CHA Bmax of 4.1 pmol/mg protein. Fitting the data shown in Figures 5.5e and 
5.5f to a sigmoidal dose-response curve constrained to a top of 2.05 (50% of 4.1) and bottom of 
0 generates a curve which is compatible with the observed results. Little difference was observed 
between best fit sigmoidal dose response curves with fixed or variable slopes. Best fit sigmoidal 
dose response curves for both components showred similar log ECgp's of 8.5 and 8.8 (fast and slow 
respectively). The data  appears to be consistent with a model where there is a 1:1 stoichiometry 
between the amplitudes of the two components of [3HjCHA association. However there is not 
enough data to establish this definitively. 1:1 stoichiometries of kinetic processes and equilibrium 
binding properties becomes of interest when considering receptor dimerisation, and is discussed 
later.
o
Preliminary investigations characterised the association of [°H]CHA (11 ±  3 nM, n = 2) to 
membranes prepared from AjR-GFP-Gcq cell lines 2H7 and 3D4 ([3H]DPCPX Bmax 1-8 and 
6.5 pmol/mg protein respectively, see Table 4.3 on page 95). Table 5.1 on page 123 lists mean 
estimates of k0^s and the initial rate obtained in the same manner as for A^HE described above and 
illustrated in Figure 5.5. For both membranes the association of [3HjCHA was best described by a 
two phase model of exponential association. There is insufficient data to determine with certainty 
whether there is a real difference in the rates of [3H]CHA association between membranes prepared 
from A^R-GFP-Gcq cell lines 2H7 and 3D4, although there is the suggestion of faster association 
with membranes from cell line 3D4 which expresses a higher concentration of the A^R-GFP-Gaj 
construct. All rate constants of association shown in Table 5.1 were faster for membranes 3D4 
than 2H7.
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Figure 5.5 T h e dep en d en ce o f th e  rate o f association  o f [^H]CHA to  
A ^H E  m em branes on th e  concentration  o f [3 H ]C H A .
Fast component of pH]CHA association Slow component of [^H]CHA association
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Figure 5.5: (a  &: b ) The effect of the concentration of [3H]CHA on the observed rates of the two
components of association to A^HE membranes in volumes of 100 /d (•) and 2 ml (o). (c  Sz d) The
kinetics of [3H]CHA association are also represented as initial rates, the product of the observed
rate constant and the amplitude of each component, (e  &: f) The amplitude of each component
of [3H]CHA association plotted against log [3H]CHA concentration. Data are shown for 100 //I
and are the mean (±  s.e.m.) of two independent experiments, one of which is shown in Figure 5.4.
The 2 ml data are from a single experiment._______________________________________________
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Table 5.1 P relim in ary  d ata  on th e  k inetics of th e  association  of  
[^H ]CH A to  A ^R -G FP-G ctj m em branes.
A ^ R -G F P -G aj m em branes 2H7 3D4
^obs, fast (m n^ ? n =  2) 0.22 ±  0.10 0.30 ±  0.03
^obs,slow (m*n ’ n =  2) 0.013 ±  0.004 0.023 ±  0.009
fast initial rate of association (pmol/mg protein/min, n = 2) 0.11 ±  0.04 0.39 ±  0.08
slow initial rate of association (pmol/mg protein/m in, n =  2) 0.005 ±  0.002 0.013 ±  0.005
[3H]DPCPX Bmax from Table 4.3 (pmol/mg protein) 1.77 ±  0.08 6.52 ±  0.55
High affinity [3H]CHA binding capacity (pmol/mg protein) 1.13 3.57
Table 5.1: Association time courses for the association of [3H]CHA to membranes prepared from 
AjR-GFP-Gaj cell lines 2H7 and 3D4 were performed as for A^HE membranes (six total and 
non-specific points each in duplicate; as shown in Figure 5.4). Data was fit to a two-phase model 
of exponential association. D ata shown are mean non-linear regression parameters for the rate 
constant of association of [3H]CHA (k ^ g )  from two independent experiments. The initial rate 
of association, the product of the observed rate of association (k ^g ) and the amplitude of the 
component, is the gradient of the association curves at t —> 0 as plotted for A^HE membranes on 
Figure 5.5 on the previous page. The mean concentration of [3H]CHA was 11 ±  3 nM (n =  2). 
The high affinity [3H]CHA binding capacity is the population of total agonist binding which is 
of high affinity and was obtained by multiplying [3H]DPCPX Bmax and frH from Table 4.3 on 
page 95.
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5.6 The kinetics of agonist dissociation from A^HE mem­
branes.
The dissociation of radiolabelled agonist from A^LE and HE membranes was investigated in the 
same manner as for [3H]DPCPX. In contrast to the dissociation of [3H]DPCPX, the dissociation of 
radiolabelled agonist was complex, heterogeneous and sensitive to the pharmacology of chase ligand. 
As for the association of agonist to the adenosine A^receptor, dissociation typically exhibited 
two components of different rate constants. The slower component observed has traditionally 
been termed “agonist locking,” postulated to be the result of the formation of pseudo-irreversible 
agonist-receptor complexes (Cohen et a l , 1996b; Waldhoer et a/., 1999). Agonist dissociation 
with “agonist locking” is typically described by a mono-exponential dissociation of agonist, to a 
plateau greater than non-specific binding. The results presented here instead favour two phase 
exponential dissociation to non-specific levels over a period of several hours in the presence of a 
high concentration of competing unlabelled ligand. In this section the dissociation of [3H]CHA 
from the adenosine A jreceptor is investigated in detail.
5.6.1 D issocia tion  o f  [^H ]CH A from  A^H E m em branes by 20-fold dilu­
tion .
Following 1 hour association at 22°C in a volume of 100 /d, the dissociation of [3H]CHA from 
A} HE membranes by means of 20-fold dilution (2 ml) in assay buffer was mono-exponential and 
incomplete (Figure 5.6 on page 126). Mean levels of bound [3H]CHA remaining after dissociation 
by 20-fold dilution are shown in Table 5.2 on page 126. The level of [3H]CHA specific binding 
remaining following dilution was far greater than that expected from the remaining concentration 
of [3H]CHA. Figure 5.6 illustrates tha t the dissociation of [3H]CHA by 20-fold dilution does not 
decay to expected levels and was best described by a one-phase model of exponential dissociation 
to a plateau. The extent of dissociation of [3H]CHA after 10 and 60 min was not dependent on 
the concentration of [3H]CHA. After 180 min dissociation the level of bound [3H]CHA showed a 
significant (P =  0.02), but shallow, dependence on the concentration of [3H]CHA (Figure 5.7a on
O
page 127. However, at all three dissociation time points and at all concentrations of [^HJCHA the 
level of bound [3H]CHA remaining was far in excess of the levels expected from the concentration 
of free [3H]CHA following 20-fold dilution. Preliminary data on the dependence of the rate of 
dissociation of [3H]CHA on the concentration of [3H]CHA is shown in Figure 5.7b. The dissociation 
of [3H]CHA from A1HE membranes by 20-fold dilution appears to be a simple mono-exponential
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process (for which the rate constant of dissociation is dependent on the concentration of [3H]CHA) 
which decays to a plateau of pseudo-irreversibly bound [3H]CHA which is not reversed by 20-fold 
dilution alone.
Dissociation of [3H]CHA initiated by 20-fold dilution containing 10"4 M GTP resulted in rapid 
loss of most bound [3H]CHA (Figure 5.6). This indicates that the majority of bound [3H]CHA 
which is not dissociated by 20-fold dilution is associated with high affinity agonist-receptor-G 
protein complexes. Dissociation of [3H]CHA in the presence of 10'4 M GTP was best described 
by a two-phase exponential decay to non-specific levels. Most bound [3H]CHA is rapidly removed 
by GTP although a fraction (approximately 15%) dissociates slowly. The dissociation of [3H]CHA 
in the presence of G TP is described in more detail in Section 5.6.4 on page 143.
5.6.2 T he d issocia tion  o f [^H ]CH A in th e presence o f a high concentra­
tion  o f un lab elled  ligand.
When the dissociation of radioligand is performed by dilution into buffer, the level of binding 
at equilibrium should be dependent on the final concentration of radioligand. The observed rate 
of dissociation should not be dependent on the concentration of radioligand. Dissociation can 
also be measured by dilution in a high concentration of an unlabelled competing ligand, generally 
termed a “chase.” This prevents rebinding of radioligand once it has dissociated, and results 
in an observed rate of dissociation which should be close to the off-rate (kQfj) of that ligand. 
Figure 5.1 on page 115 illustrates the differences between the two approaches. Having investigated 
the dissociation of [3H]CHA from A^HE membranes by 20-fold dilution (described above), the 
dissociation of [3H]CHA in the presence of high concentrations of unlabelled agonist or antagonist 
is described here.
Following 1 hour association at 22°C, the dissociation of [3H]CHA from A^HE membranes was 
sensitive to the presence and agonist or antagonist pharmacology of the chase ligand (Figure 5.8 
on page 129). The dissociation curves performed in the presence of chase ligand were complex 
and were not well described by a simple mono-exponential model of dissociation, as used for the 
dissociation of [3H]CHA by 20-fold dilution alone. Instead, the dissociation of [3H]CHA when 
performed in high concentration of chase ligand was best fit in by far the majority of cases by a 
two-phase model of exponential dissociation to a plateau of non-specific levels. As can be seen in 
Figure 5.8, dissociation in the presence of 10"4 M CHA (CHA chase) resulted in greater dissociation 
of [3H]CHA than either 10-6 M DPCPX (DPCPX chase) or dilution alone. Table 5.3 on page 130 
shows mean levels of bound [3H]CHA remaining (as a percent of t 0) at three time points when
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Figure 5.6 D issoc ia tion  o f [^H]CHA from the A ^R -G  protein  com plex
by 20-fold dilution.
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Figure 5.6: Representative curves of the dissociation of [3H]CHA from A^HE membranes. In 
the experiment shown above, 5.5 nM [3H]CHA was incubated with 20 /ig of AjHE membrane 
protein for one hour at 22°C in a total volume of 100 /d. Dissociation was initiated by a 20-fold 
dilution into 2 ml of buffer at RT. Dissociation of [3H]CHA was performed in the absence (blue 
curve) and presence (black curve) of 10"^ M G TR The expected level of specific binding following 
20-fold dilution of 5.5 nM [3H]CHA is indicated by the blue arrow. Dissociation of [3H]CHA by 
dilution only was best fit by a model of mono-exponential decay to a plateau (dissociation rate 
constant estimates are illustrated in Figure 5.7b on page 127). In the presence of 10”^ M GTP 
the dissociation of [3H]CHA was best described by a two-phase model of exponential decay to 
non-specific levels.
Table 5.2 B ou n d  [^H ]C H A  rem aining after d issociation  by 20-fold
d ilu tion .
Dissociation time (min) 10 60 180
[3H]CHA % specific binding remaining (n =  22) 87.4 ±  1.2 70.9 ±  1.3 65.4 ±  1.6
Table 5.2: Mean levels of bound [3H]CHA remaining after 10, 60 and 180 min dissociation by 20- 
fold dilution. The level of bound [3H]CHA remaining after 10 and 60 min was not dependent on the 
concentration of [3H]CHA (data not shown). A significant (P =  0.02), but shallow, dependence 
of the level of bound [3H]CHA remaining after 180 min on the concentration of [3H]CHA was 
observed and is illustrated in Figure 5.7a on page 127.
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Figure 5 .7  T h e d ep en d en ce o f th e  rate and exten t o f d issociation  of 
[^H]CHA from  A ^H E  m em branes on th e concentration  o f [^H]CHA.
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Figure 5.7: (a) The level of bound [3H]CHA remaining after 3 hours (180 min) of dissociation 
following 20-fold dilution in buffer (as a percentage of bound [3H]CHA at t =  0) is to an extent 
dependent on the concentration of [3H]CHA during association (and hence also during dissocia­
tion). Linear regression showed a slope with a shallow but significantly non-zero slope (P = 0.02), 
indicated by the broken line. Results shown are the mean (±  s.e.m.) of observations performed 
in duplicate, (b) Preliminary data indicates the observed rate of [3H]CHA dissociation (kobs)
O
following 20-fold dilution alone may be dependent (P =  0.02) on the concentration of [J H]CHA 
during the association phase of the experiment. Results shown are individual estimates of the rate 
of dissociation obtained by non-linear regression using a model of one-phase exponential decay. In 
both graphs the rr-axis is the concentration of [3H]CHA during the 60 min association prior to 
initiation of dissociation by 20-fold dilution._______________________________________________ _
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dissociation is performed by dilution alone or dilution in the presence of either CHA or DPCPX 
chase. At all time points CHA chase enhanced the dissociation of [3H]CHA to a greater extent 
than DPCPX chase or dilution alone. The enhancement of the dissociation of [3H]CHA by dilution 
containing DPCPX (relative to dilution alone) was negligible after 10 min but more pronounced 
after 60 and 180 min (Table 5.3). Enhanced dissociation of [3H]CHA by CHA relative to DPCPX 
is a novel finding, consistent with the presence of a cooperative system. Table 5.4 on page 130 
describes mean parameters of the two-phase exponential dissociation of [3H]CHA by dilution in 
the presence of DPCPX or CHA. Unpaired t tests showed no significant difference for both the 
fast and slow rate constants of dissociation between the two chases. However, the amplitude of 
each component was significantly different for each chase (P < 0.0001 and P =  0.0001 for the fast 
and slow component respectively). The two rate constants of dissociation were approximately 100 
fold different. When the data are analysed by a 2-exponential model, enhancement of [3H]CHA 
dissociation by CHA appears to be manifest as a change in the relative amplitudes of the two 
components of dissociation rather than a difference in the rate constants of dissociation. None of 
the four parameters of dissociation (k_  ^ pA §T’ sPanFAST’ ^ - 1  SLOW’ ^  sPanSLOW) o^r both 
CHA and DPCPX chase were dependent on the concentration of [3H]CHA during the 60 min 
association prior to dissociation (Figure 5.9 on page 131). This is in contrast to the apparent 
dependence of the rate of dissociation of [3H]CHA by 20-fold dilution alone on the concentration of 
[3H]CHA. The mean concentration of [3H]CHA during the 100 /d 60 min association was 4.6 ±  0.8 
nM (n =  11) covering a range of 0.4 to 8.4 nM.
The ability of CHA to enhance the dissociation of [3H]CHA relative to dilution alone and 
dilution containing DPCPX is a phenomenon that can be described as “agonist-induced agonist 
dissociation.” Agonist-induced agonist dissociation was also observed using membranes from A^LE, 
A^R-GFP and A^R-G FP-Gaj cell lines. The dependence of features of the kinetics of agonist 
dissociation is described in Chapter 6 on page 165.
O
Identical experiments using the high efficacy adenosine A^ receptor agonist [ H]NECA at A^HE 
membranes were very similar to the experiments described above using [3H]CHA. The dissociation 
of [3H]NECA in the presence of 10-6 M DPCPX or 10"4 M CHA was best described by a two- 
phase exponential decay to non-specific levels and CHA showed a greater ability than DPCPX to 
enhance the dissociation of [3H]NECA (data not shown).
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Figure 5.8 T he d issociation  of [^H]CHA from A^HE membranes by 
dilution in th e presence of a high concentration of CHA or D P C PX .
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•  20-fold dilution with 10-6 M DPCPX ch ase
•  20-fold dilution with 10"* M CHA ch ase
Figure 5.8: Representative [3H]CHA dissociation curves by dilution in the presence or absence 
of CHA or DPCPX. Dissociation by 20-fold dilution alone (•) was best fit by a model of mono­
exponential dissociation decaying to a plateau, as described in Section 5.6.1. Dissociation of 
[3H]CHA in the presence of 10"4 M CHA (•) or 10‘6 M DPCPX (•) were best fit by a model of two- 
phase exponential dissociation decaying to non-specific levels. Data shown is a single experiment 
performed in duplicate, except for the t= 0 time point which was measured in sextuplicate.
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Table 5.3 M ean  leve ls  o f  bound  [^H]CHA rem aining after dissociation  
in th e p resence o f  a h igh  concen tration  o f  com peting unlabelled ligand.
Dissociation time (min) 10 60 180
Dissociation by 20-fold dilution,
% specific binding remaining (±  s.e.m.) 
(from Table 5.2, n =  22)
87.4 ±  1.2 70.9 ±  1.3 65.4 ±  1.6
20-fold dilution in the presence of 
10'6 M DPCPX 
(n =  28)
86.1 ±  1.6 64.0 ±  1.7 46.6 ±  1.6
20-fold dilution in the presence of 
10-4 M CHA 
(n =  29)
67.6 ±  1.4 44.2 ±  1.2 35.3 ±  1.2
Table 5.3: Mean levels of bound [3H]CHA remaining at A^HE membranes after 10, 60 and 180 
min of dissociation by 20-fold dilution, or dilution in the presence of a high concentration of CHA 
or DPCPX. Three time points from the full dissociation curves were chosen for tabulation.
Table 5 .4  M ean  b est fit param eters describing th e two-phase  
exp on en tia l d isso c ia tio n  o f [^H ]CH A from A ^H E m em branes.
Two-phase exponential dissociation Fast Slow
Rate (k_i) and amplitude (span) k_i (min ^) span (%SB) »—1‘ ? B
i 1—* span (%SB)
10'6 M DPCPX chase (n =  9) 0.12 ±  0.05 34.3 ±  1.8 1.4 ±  0.5 x l0“3 65.4 ±  2.0
10“4 M CHA chase (n =  10) 0.17 ±  0.03 48.3 ±  1.8 1.6 ±  0.4 xlO '3 51.0 ±  2.1
Table 5.4: Mean param eters (±  s.e.m.) from two-phase exponential dissociation of [3H]CHA from 
AjHE membranes in the presence of CHA or DPCPX. Unpaired t tests showed no significant 
difference for both the fast and slow rate constants of dissociation between the two chases. The 
amplitudes of both the fast and slow components were significantly different between the two chases 
(P < 0.0001 and P =  0.0001 for fast and slow respectively). The mean concentration of [3H]CHA 
during the 60 min association prior to initiation of dissociation was 4.1 ±  0.8 and 4.5 ±  0.8 nM for
Q
DPCPX and CHA chases respectively. Figure 5.9 on the next page shows the range of UH]CHA 
concentrations used and investigates the dependence of all four parameters for both chases on the 
concentration of [3H]CHA.
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Figure 5.9 T he four kinetic param eters describing the dissociation of 
[3 H ]C H A  in th e  presence of CH A or D P C P X  chase.
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Figure 5.9: The four kinetic parameters (k_1?pAST’ sPanFAST’ k-l,SLOW ’ sPanSLOW) describing 
[^H]CHA dissociation in the presence of CHA or DPCPX chase are independent of the concentra­
tion of [^H]CHA prior to dilution. Linear regression found no significant dependence of any of the 
four parameters for either chase on the concentration of [3H]CHA prior to 20-fold dilution. Mean 
values reported in Table 5.4 on the previous page are indicated as straight lines above.
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5.6.3 T he effect o f  ligand efficacy and th e  p oten cy  o f unlabelled  ligands 
on th e  d issocia tion  o f [^H jCH A.
In the experiments described above, concentrations of CHA and DPCPX well above their 
values for the adenosine A^ receptor were used above to prevent rebinding of [3H]CHA following 
dissociation from the receptor. Both ligands enhanced the dissociation of [3H]CHA to a greater 
extent that 20-fold dilution alone, and 10"^ M CHA showed a greater ability to enhance [3H]CHA 
dissociation than 10 ^ M DPCPX. These high concentrations may cause non-specific effects on 
dissociation therefore the potency of chase ligands to enhance the dissociation of [3H]CHA was 
investigated. In order to do so, the dissociation assay above was modified to reduce the number of 
time points but increase the number of variables.
5.6.3.1 T he sim plified “5-point” d issociation  assay.
A simplified “5-point” dissociation assay was designed which enabled up to six concentrations of 
chase ligand at three dissociation time points to be measured in duplicate along with the t —0 point 
in sextuplicate; all on one 48-tube rack. The 5-point dissociation assay could also be adapted to 
use several different chase ligands, concentrations of [3H]CHA, or different membrane preparations. 
As shown above, dissociation curves using an equation for two-phase exponential decay could be 
fitted to the reduced number of points (see Figure 5.10 on page 134 for an example of curves fitted 
to 5-point dissociation results). In detail, the 5-point dissociation assay was composed as described 
below.
1. t — 0 was performed in sextuplicate (as for the detailed dissociation time course experiments) 
in order to accurately characterise the level of bound [3H]CHA immediately prior to dilution 
(all other points were in duplicate). Non-linear regression was not fixed at 100% for t = 0.
2. The 10 min dissociation time point was chosen in order to estimate the fast component of 
dissociation.
3. The 60 min time point was chosen because the fast component of dissociation appeared to 
be largely complete by then.
4. The 180 min time point; the dissociation of [%]CHA between 60 and 180 min should be 
largely the result of the slow component of [3H]CHA dissociation.
5. Non-specific binding; as for the detailed dissociation time course experiments the two-phase 
exponential decay curves were constrained to a plateau of non-specific binding.
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The 5-point dissociation assay was also used to characterise the kinetics of dissociation of [3H]CHA 
from membranes prepared from the A1R-GFP and A1R-GFP-Gai cell lines. The 5-point disso­
ciation assay enabled rapid characterisation of membranes from all 23 AjR-GFP-Gcq cell lines 
and a selection of A jR -G FP cell lines in order to investigate the dependence of the kinetics of 
[ H]agonist dissociation on the level of receptor expression, for which the results are presented in 
Chapter 6.
Table 5.5 on page 135 details mean estimates of all four parameters of [3H]CHA dissociation in 
the presence of CHA or DPCPX (k.^p^g^p, spanp^g^p, k_j g p o w , and spa^SLOw) using the 5- 
point dissociation assay. The effect of the concentration of [3H]CHA during the 60 min association 
on the kinetics of dissociation was investigated and is shown in Figure 5.11 on page 136. Over a 
100-fold range of [3H]CHA concentration (0.1 to 11 nM) all four parameters of dissociation were 
not observed to be dependent on the concentration of [3H]CHA, except for the fast rate constant 
of dissociation (k_]_ pAgpO hi the presence of DPCPX which did show a significant dependence on 
the concentration of [3H]CHA (P =  0.02). As all the other parameters were not dependent on the 
concentration of [3H]CHA the estimates were pooled-together in order to generate a larger sample 
size (n =  18) for which the means are listed in Table 5.5. Table 5.5 generated using the 5-point 
dissociation assay can be directly compared to the same parameters estimated by the detailed 
dissociation assay (Table 5.4 on page 130). Both tables show that the amplitudes of both the fast 
and slow components are significantly different depending on whether CHA or DPCPX is used 
as the chase ligand. In both tables the ability of CHA to enhance the dissociation of [ H]CHA 
to a greater extent than  DPCPX appears to be manifest as an increase in the amplitude of the 
fast component rather than a change in the rate  constants of dissociation. The mean estimate 
of k_i pAST in t ^e presence of DPCPX chase for the 5-point dissociation assay is shown within 
square brackets in Table 5.5, because of the failure to prove independence from the concentration 
of [3H]CHA. Although not proved statistically, Tables 5.5 and 5.4 essentially appear to be in 
good agreement. It appears th a t the simplified “5-point” dissociation assay is a reliable alternative 
to the full length “11-point” dissociation assay and enabled experiments which would have been 
prohibitive (in time and consumption of materials) using the more detailed assay.
5.6.3.2 The enhancem ent o f  [3 H ]C H A  dissociation  by partial agonists.
So far the ability of unlabelled ligands to enhance the dissociation of [3H]CHA from the adenosine 
A^ receptor has been investigated using only two ligands, an agonist of high efficacy (CHA) and an 
inverse agonist (DPCPX). Here experiments investigating the ability of partial agonists GR190178, 
GR161144 and GR162900 and the antagonist N0840 to enhance the dissociation of [ H]CHA are
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Figure 5.10 E xam ples o f 5-point [^H]CHA dissociation curves.
% [3H]CHA  
specific binding 
(t = 0)
Dissociation time (min)
•  20-fold dilution
• 20-fold dilution with 10-6 M DPCPX ch ase
• 20-fold dilution with 1CT4 M CHA ch ase
Figure 5.10: Representative A jH E [3H]CHA dissociation curves using three dissociation time 
points (10, 60 and 180 min in duplicate) and one time point immediately prior to initiation of 
dissociation (t =  0, in sextuplicate). The 100 //I association volume was incubated for 60 min, as 
usual, prior to initiation of dissociation by addition of 2 ml buffer. Dissociation by 20-fold dilution 
alone (•) was fitted to a model of mono-exponential dissociation to a plateau. Dissociation of 
[3H]CHA in the presence of CHA (•) or DPCPX (•) were analysed using a model of two-phase 
exponential decay constrained to a plateau of non-specific binding. The above curves are similar
in nature to the more detailed dissociation assay shown in Figure 5.8 on page 129.
100
20
0
60 190 1R0
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Table 5.5 M ean param eters describing tw o-phase exponential 
dissociation  o f  [^H ]C H A from  A ^H E m em branes using th e  5-point 
dissocia tion  assay.
Two-phase exponential dissociation Fast Slow
Rate (k .i) and amplitude (span) k_i (m in 'l) span (%SB) k_i (m in'l) span (%SB)
10“6 M DPCPX chase (n =  18) [0.05 ± 0 .01} 37.7 ±  4.3 2.0 ±  0.4 xl0~3 62.5 ±  4.2
10"4 M CHA chase (n =  18) 0.09 ±  0.01 50.0 ±  1.6 2.0 ±  0.1 xlO-3 50.0 ±  1.6
Table 5.5: Mean param eters (±  s.e.m.) from two-phase exponential dissociation of [3H]CHA from 
A^HE membranes using the simplified 5-point dissociation assay illustrated in Figure 5.10 on the 
preceding page. Both the fast and slow amplitudes showed a significant difference between each 
chase (P — 0.01 and P =  0.009 for fast and slow spans respectively). There was no significant 
difference between the mean values for the slow rate constant of dissociation. The fast rate constant 
of dissociation was significantly different between the two chases (P =  0.009) however the fast rate 
constant of [3H]CHA dissociation with DPCPX chase was dependent on the concentration of 
[3H]CHA (P =  0.02) and is shown within square brackets. Figure 5.11 on the next page illustrates 
this dependence along with all the other kinetic parameters for both chases in the same manner as 
Figure 5.9. The mean concentrations of [3H]CHA during the 60 min association prior to dissociation 
were 2.4 ±  0.6 nM and 3.0 ±  0.8 (for CHA and DPCPX chases respectively, both n =  18) and the 
ranges of concentrations are shown in Figure 5.11.
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Figure 5.11 The four kinetic param eters describing [% ]C H A  
dissociation in th e presence of C H A  or D P C P X  chase; estim ated using 
the “5-point” dissociation assay.
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0.000 0 4 8 12
[3 H]CHA (nM) [3 H]CHA (nM)
•  20-fold dilution with K t4 M CHA
•  20-fold dilution with 10-« M DPCPX
Figure 5.11: Using results from the 5-point dissociation assay, the dependence on the concentration 
of [3H]CHA prior to dissociation (rr-axis) of the four kinetic parameters (k ^ p ^ S T ’ sPanFAST’ 
k_i SLOW’ sPanSLOw) describing [3H]CHA dissociation in the presence of CHA (•) or DPCPX 
(•) chase was investigated. Linear regression found no significant dependence of any of the four 
parameters for either chase on the concentration of [3H]CHA prior to dilution, except for the rate 
constant of dissociation for the fast component in the presence of DPCPX chase (P = 0.02). Where 
the parameter was not dependent on the concentration of [3H]CHA the mean value reported in 
Table 5.5 is indicated as a straight line. Linear regression of the fast rate constant of dissociation 
in the presence of DPCPX is indicated by the broken line shown. For comparison, y-axis are drawn 
with the same scale as in Figure 5.9 on page 131.
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described. The equilibrium binding properties of the partial agonists GR190178, GR161144 and 
GR162900 are described in Figure 4.6 on page 91 where the ratio of affinities ( j ^ )  may agree with 
their observed efficacy at the adenosine receptor. The 5-point dissociation assay was used to 
investigate the ability of these ligands to enhance the dissociation of [3H]CHA from A1HE and 
A jR-GFP membranes. Table 5.6 on the next page lists the levels of bound [3H]CHA remain­
ing following 10, 60 and 180 min dissociation in the presence of 10"6 M GR190178, GR161144, 
GR162900 and N0840. All four unlabelled chase ligands shown in Table 5.6 were used at a con­
centration of 10"6 M. In all four membrane preparations shown in Table 5.6, GR190178 appears 
more effective a t enhancing the dissociation of [3H]CHA than GR161144 and GR162900 especially 
at the shorter dissociation time points. N0840 is least effective at enhancing the dissociation of 
[3H]CHA, although it is also the ligand with the lowest affinity for the adenosine A^ receptor. 
N0840 was shown in Chapter 4 to have a log affinity of 6.23 ±  0.07 (n =  3) for the adenosine A} 
receptor (Figure 4.4 on page 86). It is likely that 10‘^ M N0840 is not sufficient to maximally 
enhance the dissociation of [3H]CHA.
Mean values describing the kinetics of [3H]CHA dissociation from the data reported in Table 5.6 
are not reported because of the limited number of experiments performed along with uncertainty of 
the effective concentration for maximum enhancement of dissociation (investigated below). Also, 
the kinetics of dissociation of [3H]CHA from membranes prepared from the A^R-GFP and A^R- 
GFP-Gcq cell lines is described in much more detail in Chapter 6.
5.6.3.3 The poten cy  o f chase ligands to  enhance the dissociation o f [3H]CHA.
The 5-point dissociation assay was also used to estimate the potency of chase ligands to enhance 
[3H]CHA dissociation, using five concentration of chase ligand at three dissociation time points. 
Figure 5.12 on page 140 shows typical dose-response curves of the ability of CHA and DPCPX 
to enhance the dissociation of [3H]CHA relative to 20-fold dilution with no chase ligand. The 
y-axis in each of the graphs in Figure 5.12 on page 140 is the difference between the level of bound 
[3H]CHA remaining following 20-fold dilution alone, and the level of bound [3H]CHA remaining in 
the presence of the chase ligand. The units of the y-axis are the same as for the dissociation curves, 
such as Figure 5.10. W here possible, the data were fit by a sigmoidal dose response curve with 
the bottom constrained to zero. The maxima of curves shown in Figure 5.12 agree quantitatively 
with the mean levels of bound [3H]CHA remaining shown in Table 5.3 on page 130. After 10 min 
DPCPX chase does not enhance the dissociation of [3H]CHA relative to 20-fold dilution alone, 
however enhancement of dissociation is observed after 60 min and to a greater extent after 180 
min. The CHA chase enhances the dissociation of [3H]CHA at all time points measured, and with
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Table 5.6 E nhancem ent o f  th e  d issociation  o f [3 H ]C H A  from  A XH E and 
A ^R -G F P m em branes in th e  presence o f ligands o f in term ediate efficacy.
Dissociation time (min)
10"® M chase ligand 1 0 60 180
A} HE membranes
GR190178 65.1 ±  6 .8 37.6 ±  3.5 28.1 ±  3.4
GR161144 68.9 ±  4.6 40.2 ±  3.9 30.1 ±  3.7
GR162900 69.8 ±  3.8 42.5 ±  2.0 29.8 ±  2.8
N0840 64.5 ±  3.8 47.7 ±  8 .6 37.8 ±  8 .8
A^R-GFP membranes 5H6 ([3 H]DPCPX Bmax 1-28 ±  0.05 pmol/mg protein)
GR190178 59.0 ±  4.0 37.5 ±  0.7 28.0 ±  0 .8
GR161144 62.2 ±  4.6 39.6 ±  2.4 27.5 ±  0.1
GR162900 68.5 ±  2.1 41.4 ±  2.4 30.2 ±  1.2
N0840 74.9 ±  3.5 54.8 ±  1.7 45.2 ±  1.5
A^R-GFP membranes 5H9 ([3 H]DPCPX Bmax 3.94 ±  0.27 pmol/mg protein)
GR190178 63.9 ±  4.3 37.4 ±  1.1 26.8 ±  0.9
GR161144 67.6 ±  1.8 37.7 ±  3.2 27.3 ±  1.8
GR162900 74.3 ±  4.6 42.0 ±  2.0 27.9 ±  0.7
N0840 74.2 ±  3.5 52.5 ±  1.6 42.8 ±  0.8
A^R-GFP membranes 6 D2  ([3 H]DPCPX Bmax 9-35 ± 1 .1 6  pmol/mg protein)
GR190178 61.3 ±  3.2 34.3 ±  0.6 20.2 ±  3.8
GR161144 61.4 ±  1.0 34.3 ±  0.8 25.2 ±  0.3
GR162900 71.1 ±  2.0 39.6 ±  0.8 28.0 ±  0 .6
N0840 71.4 ±  2.3 55.1 ±  0.6 47.0 ±  3.1
Table 5.6: The extent of [3 H]CHA dissociation from A jH E and A^R-GFP membranes at three 
time points was investigated using four unlabelled ligands of intermediate efficacy (all four used 
at 10" 6  M). D ata shown is the level of bound [3 H]CHA remaining expressed as percent of specific 
binding at t —0 (as in Table 5.3 on page 130), and are mean (±  s.e.m.) of three experiments 
(n =  3) each performed in duplicate (as for all previous dissociation assays reported). Equilibrium 
binding properties of the A 1 R-GFP membranes are listed in Table 4.3 on page 95. The equilibrium 
binding properties of ligands GR190178, GR161144 and GR162900 are investigated in Figure 4.6 
on page 91, and N0840 in Figure 4.4 on page 8 6 ._____ ______________________________________
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low nM potency providing evidence of a specific high affinity interaction driving the mechanism 
of agonist-induced agonist dissociation (Figure 5.12). The enhancement of [3 H]CHA dissociation 
by DPCPX after 180 min was also of low nM potency. The limited enhancement of [3 H]CHA 
dissociation by DPCPX after 60 min made fitting of dose response curves unreliable. Routinely no 
enhancement of [3 H]CHA dissociation by DPCPX after 10 min was observed, and so is indicated 
by a straight line in Figure 5.12. The high concentrations of CHA (10' 4  M) and DPCPX (10' 6  M) 
chases used for Table 5.3 and other Figures are clearly far in excess of those required to effect 
a maximum enhancement of dissociation. However there appear to be no additional non-specific 
interactions and no apparent negative consequences to the use of such high concentrations. The 
nM potency of the enhancement of [3 H]CHA dissociation and the differences between DPCPX and 
CHA chases point to the kinetic phenomenon being related to specific binding at the adenosine 
A^ receptor.
As with the kinetics of the dissociation of [3 H]CHA in the presence of an unlabelled chase 
ligand, the potency of chase ligand to enhance [3 H]CHA dissociation (log EC5 0 ) was also not 
dependent on the concentration of [3 H]CHA added during the 60 min association. Figure 5.13 on 
page 141 shows the lack of any effect of [3 H]CHA concentration on the log EC5 Q of CHA chase 
after 180 min dissociation time. As neither the extent (after 10, 60 & 180 min), kinetics (k_  ^PAST’ 
spanpAST’ k-1  SLOW’ ^  sPanSLOw) anc* cbase potency (log EC5 0 ) of [3 H]CHA dissociation in 
the presence of CHA or DPCPX chase were dependent on the concentration of [3 H]CHA, estimates 
from the four concentrations of [3 H]CHA shown in Figure 5.13 were pooled in order to increase 
the sample size (n =  8 ).
The experiments reported in Table 5.6 investigated the ability of the partial agonists GR190178, 
GR161144 and GR162900 and the antagonist N0840 to enhance the dissociation of [3 H]CHA. These 
were all performed at a concentration of chase ligand of 10' 6  M. However the log affinity of N0840 
for A^HE membranes was approximately 10' 6  M (Figure 4.4 on page 8 6 ). It is likely that the 
reduced ability of N0840 to enhance the dissociation of [3 H]CHA compared to the agonist chases 
(Table 5.6) is due to an insufficient concentration of N0840. Figure 5.14 on page 142 shows examples 
of chase ligand dose response curves using GR190178, GR161144, GR162900 and N0840 performed 
in the same manner as for CHA and DPCPX. After 180 min GR190178, GR161144 and GR162900 
appear to have a lower log EC^qs than CHA or DPCPX. The enhancement of [3 H]CHA dissociation 
by N0840 has not reached a maximum by 10"^ M, which suggests that affinity at equilibrium may 
be related to the potency of the enhancement of [3 H]CHA dissociation.
Mean log EC 5 0 S of the enhancement of [3 H]CHA dissociation by all the chase ligands examined 
are reported in Table 5 .7  on page 144. As suggested by the individual dose response curves
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Figure 5.12 C H A  and D P C P X  dose-response curves of the  
enhancem ent o f [3 H ]C H A  dissociation from A XHE membranes.
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Figure 5.12: Representative CHA and DPCPX dose response curves of their ability to enhance 
the dissociation of [3 H]CHA relative to dilution only. Three dissociation time points are shown 
(10, 60 and 180 min). The 10 min DPCPX data was not well fitted by a sigmoidal dose response 
curve, so is indicated as a straight line. Data shown is from an individual experiment performed 
in duplicate. Sigmoidal dose response curves were constrained to a bottom of 0. Mean parameters 
from non-linear regression of dissociation dose response curves are shown in Table 5.7 on page 144.
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Figure 5.13 T h e p oten cy  o f th e enhancem ent of the dissociation of 
pH ]C H A  from  A ^H E m em branes by C H A  or D P C P X  is not dependent 
on th e  concentration o f [% ]C H A .
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•  CHA c h a se  log EC50 after 10 min dissociation
•  CHA c h a se  log EC50 after 60 min dissociation
•  CHA c h a se  log EC50 after 180 min dissociation
•  DPCPX c h a s e  log EC50 after 180 min dissociation
Figure 5.13: In the presence of 10' 4  M CHA or 10" 6  M DPCPX chase the chase potency (log EC5 0 ) 
of the enhancement of [3 H]CHA dissociation was independent of the concentration of [3 H]CHA 
prior to dilution. Shown are individual estimates of potency (log EC5 0 ) for the enhancement of 
[3 H]CHA dissociation. The fitting of sigmoidal dose response curves to data obtained for DPCPX 
chase after 10 and 60 min dissociation was unreliable and is not reported. The mean values of each 
condition are indicated as the straight lines shown. As none of the parameters were dependent on 
the concentration of [3 H]CHA, the estimates were pooled for each chase ligand for a larger sample
size (n =  8  for CHA and DPCPX chases) and are shown in Table 5.7 on page 144.
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Figure 5.14 D ose response curves o f enhanced [3 H]CHA dissociation  
from A^H E m em branes using chase ligands of interm ediate efficacy.
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Figure 5.14: Representative individual dose response curves of the enhancement of the dissociation 
of [3 H]CHA from A^HE membranes after 180 min by agonists GR190178, GR161144, GR162900 
and the antagonist N0840. Data shown are mean values (±  s.e.m.) from a single experiment 
measured in duplicate. The GR190178 points have an error which is too small to be visible on the 
graph above. Sigmoidal dose response curves were constrained to a bottom of 0. Mean parameters 
from non-linear regression of dissociation dose response curves are shown in Table 5.7 on page 144.
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(Figures 5.12 and 5.14), the estimates of log EC^q appear to increase in potency with time and 
CHA and DPCPX chases appear to be more potent than  the partial agonists and N0840. Just as 
CHA and DPCPX show similar high affinity binding to the adenosine A^ receptor at equilibrium 
(Chapter 4.2 on page 80), their ability to enhance the dissociation of [3 H]CHA is also of similar 
low nM potency. However the maximum enhancement estimated by the sigmoidal dose response 
curves (Enhancementmax) after 180 min dissociation time was significantly different (P =  0 .0 0 0 1 ) 
between the CHA and DPCPX chases. Both rate constants for the dissociation of [3 H]CHA were 
not significantly different between CHA and DPCPX chases (Tables 5 .4  and 5.6), showing agonist- 
induced agonist dissociation to be manifest as an increase in the amplitude of the fast component 
of the dissociation of [3 H]CHA. Table 5.7 supports this by showing equal potency of both CHA 
and DPCPX to enhance the dissociation of [3 H]CHA, with agonist-induced agonist dissociation 
the result of a greater extent of dissociation. Casual inspection of the log EC5 0  values reported in 
Table 5.7 indicates an increase in the potency of CHA with increasing dissociation time. This is 
also illustrated in Figure 5.13. This trend appears to decrease with agonists of progressively lower 
efficacy, to the extent where GR162900 shows similar potency at all three time points.
No results are presented for DPCPX chase after 10 and 60 min dissociation time in Table 5.7 
as sigmoidal dose response curves could not be reliably fit to the small, if any, enhancement of 
[3 H]CHA dissociation. The maximum projected level of the enhancement of [3 H]CHA dissociation 
(Enhancementmax) by N0840 is not reported because N0840 was not used at sufficiently high con­
centrations to determine the limit of its ability to enhance dissociation of [3 H]CHA (as illustrated 
in Figure 5.14).
5.6.4 E nhanced [^H ]C H A  d isso c ia tio n  by unlabelled  ligands in th e  pres­
ence o f G T P .
At nM concentrations most bound [3 H]CHA is removed rapidly from the adenosine A i  receptor 
by 10‘ 4  M GTP (Figure 5.6 on page 126). The ability of unlabelled ligands to enhance the 
dissociation of [3 H]CHA from A^HE membranes in the presence of 10' 4  M GTP was investigated. 
Figure 5.15 on page 146 shows typical [3 H]CHA dissociation curves illustrating agonist-induced 
agonist dissociation in the presence of G TP relative to 20-fold dilution with GTP alone. In the 
presence of GTP, DPCPX showed enhancement of [3 H]CHA dissociation intermediate between 
CHA and GTP, and G TP alone. The dissociation of [3 H]CHA in all three conditions containing 
GTP was best described by a two-phase model of exponential decay to non-specific levels. Table 5.8 
on page 147 lists mean levels of bound [3 H]CHA remaining after dissociation for 10, 60 and 180
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Table 5 .7  T h e p o ten cy  o f  th e  ab ility  o f unlabelled  ligands to  enhance 
th e  d issocia tion  o f [^HJCHA from A-^HE m em branes.
Dissociation time (min) Chase ligand log EC 5 0 Enhancementmax (%SB)
CHA chase (n =  8 )
1 0 -8.25 ±  0.20 17.1 ±  2.9
60 -8.81 ±  0.18 24.3 ±  1.4
180 -9.18 ±  0.09 27.8 ±  1.8
DPCPX chase (n =  8 )
180 -9.33 ±  0.20 14.6 ±  1.7
GR190178 chase (n = 2 )
1 0 -7.37 ±  0.35 11.7 ±  0.1
60 -7.87 ±  0.02 26.3 ±  1.0
180 -8.19 ±  0.10 31.7 ±  1.7
GR161144 chase (n =  2)
1 0 -7.65 ±  0.20 12.5 ±  1.1
60 -7.80 ±  0.10 27.1 ±  0.9
180 -8.03 ±  0.10 34.7 ±  0.4
GR162900 chase (n =  2)
1 0 -7.83 ±  0.14 4.8 ±  0.7
60 -7.64 ±  0.01 19.1 ±  0.6
180 -7.66 ±  0.12 30.8 ±  2.2
N0840 chase (n =  2)
60 -6.37 db 0.27 -
180 -5.52 ±  0.46 -
Table 5 .7 : Average (±  s.e.m.) log EC 5 0  and maximum enhancement values from nonlinear regres­
sion of sigmoidal dose response curves of the ability of unlabelled ligands to enhance the dissociation 
of pHJCHA relative to  dilution only. Examples of individual chase ligand dose response curves are 
shown in Figures 5.12 (CHA & DPCPX) and 5.14 (GR190178, GR161144, GR162900 and N0840).
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min in all three dissociation conditions in the presence of GTP (in the same manner as Tables 5.2,
5.3 and 5.6). As observed in the absence of GTP, CHA enhanced the dissociation of [3 H]CHA 
to the greatest extent a t all tune points. Estimation of the rate constant of the fast component
O
of [ HJCHA dissociation was ill-defined as the fast component was largely complete before the 
first dissociation tune point (5 min; Figure 5.15). The smaller sample size (n =  4 ) compared to 
Tables 5.4 (n =  9 and 10) and 5.6 (n =  18) discourages meaningful statistical comparison, but 
again it appears th a t the ability of CHA to enhance the dissociation of [3  HJCHA is largely manifest 
as an increase in the amplitude of the fast component rather than a change in the rate constants 
of dissociation.
10"® M DPCPX was equally effective at enhancing the dissociation of [3 H]CHA from A^HE 
membranes in the presence or absence of 10~4  M GTP (Figure 5.16 on page 148). The relative 
ability of 10”^  M CHA to enhance the dissociation of [3 H]CHA was even more pronounced in the 
presence of GTP. Agonist-induced agonist dissociation is observed in the presence of GTP, and is 
very effective a t enhancing the dissociation of [3 H]CHA from GTP-insensitive high affinity binding 
sites. GTP is present within cells in physiological conditions, so the observation of agonist-induced 
agonist dissociation in both the presence and absence of GTP supports the proposition that it may 
have a physiological function.
5.6.5 T h e effect o f  [^H ]C H A  con cen tration  on th e  d issociation  o f [^HjCHA
The association of [3  HJCHA to the adenosine A^ receptor was best described by a two-phase ex­
ponential model of association. As described above, the fast rate constant of the association of 
[3 H]CHA to  A^HE membranes was dependent on the concentration of [3HJCHA (Figure 5.5 on 
page 122). The fast component of association is consistent with a simple bi-molecular interaction 
of [3HJCHA binding to  readily available high affinity sites on the receptor. Whether the slow com­
ponent of [3  HJCHA association is dependent on the concentration of [3  HJCHA was less clear. It is 
possible the slow component of association is largely driven by processes such as the recruitment 
of G protein into the receptor environment. The evidence from Figure 4.3, on page 84, is that at 
longer incubation times the increase in [3 H]CHA binding seems to be the result of an increase in 
[3 H]CHA Bmax (recruitment of G protein) rather than an isomerisation which would result in an 
increase in affinity. Extrapolation to  the y-socis intercept of the plot shown in Figure 5.5a agrees 
almost precisely with the observed fast rate  constant of [3HJCHA dissociation in the presence of 
CHA (0.12 ±  0.01 m in 'l, n =  28). The y-axis intercept is the predicted off-rate if binding is simple.
O
The presence of unlabelled CHA during dissociation prevents rebinding of dissociated [°HJCHA, 
and provides a means of measuring the off-rate directly. Preliminary data indicated that the ob-
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Figure 5.15 C H A  and D P C P X  enhance the dissociation of [3H]CHA  
from A ^H E m em branes even in the presence o f GTP.
% [3H]CHA  
specific binding
0 60 120 180 
Dissociation time (min)
•  20-fold dilution
•  20-fold dilution with 10-6 M DPCPX
• 20-fold dilution with 10^  M CHA
• 20-fold dilution with 10"4 M GTP
o20-fold dilution with 10-4 M GTP & 10-6 M DPCPX
o 20-fold dilution with 1 0 ^  M GTP & 10"6 M CHA
Figure 5.15: Representative [3 H|CHA dissociation curves by 20-fold dilution in the presence or 
absence of CHA, DPCPX and GTP. Data shown is a single experiment (also shown in Figure 5.8 
on page 129) with measurements in duplicate, except for the t = 0  time point which was measured 
in sextuplicate.
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Table 5.8a E x ten t o f  bound [^H jCH A rem aining after d issociation  from  
A ^ H E  m em branes in th e  presence o f G TP.
Dissociation time (min) 1 0 60 180
10"4  M GTP chase
22.1 ±  1.7
(n =  6)
11.6 ±  1.3
(n =  6)
9.3 ±  1.4
(n =  4)
10' 4  M GTP +  10" 6  M DPCPX
2 0 .0  ±  2 .1
(n =  5)
9.2 ±  1.6
(n = 5)
6.4 ±  1.7
(n =  4)
10"4  M GTP +  10"4  M CHA
9.1 ±  1.3
(n  =  5)
3.5 ±  0.8
(n =  5)
3.1 ±  1.5
(n =  4)
Table 5.8b T w o-phase ex p o n en tia l d issociation  o f [^HJCHA from A^HE  
m em branes in th e  presence o f G TP.
Two-phase exponential dissociation Fast Slow
Rate (k_]J and amplitude (span) k_i (m in 'l) span(%SB) k.^ (min‘l) span(%SB)
10' 4  M GTP chase
(n = 5)
0.58 ±  0.06 77.9 ±  2.3 8.9 ±  1.7 xlO' 3 22.1 ±  2.3
10’ 4  M GTP +  10" 6  M DPCPX
(n = 4)
0.61 ±  0.09 79.8 ±  2.7 12 ±  3.5 xlO- 3 20.2 ±  2.7
10"4  M GTP +  10~6  M CHA
(n = 4)
2.3 ±  1.3 89.8 ±  1.3 20 ±  9.0 xlO' 3 1 0 .2  ±  1.3
Table 5.8: (a) Levels of bound [3 H]CHA remaining in the presence of 10' 4  M GTP are expressed as 
percent of bound [3 H]CHA before dissociation (at t —0), as for Tables 5.2, 5.3 and 5.6 (pages 126, 
130 and 138 respectively).
(b) As for the dissociation of [3 H]CHA in the absence of GTP, dissociation was fit to a model of 
two-phase exponential decay to a plateau of non-specific binding. [3 H]CHA and A^HE membranes 
were incubated for 60 min at RT before initiation of dissociation by 20-fold dilution in the presence 
of 10‘ 4  M GTP.
The mean concentrations of [3 H]CHA during the 60 min association were 3.9 ±  1.5, 3.2 ±  1.3 and
3.5 ±  1.1 nM where indicated in the above tables as n =  4, 5 and 6  respectively.
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Figure 5.16 T he relative enhancem ent of [^H]CHA dissociation by 
C H A  and D P C P X  in th e presence or absence of GTP.
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•  20-fold dilution with 10'6 M DPCPX
o 20-fold dilution with 10^ M GTP & 10-6 M DPCPX
• 20-fold dilution with 10"4 M CHA
o 20-fold dilution with 10-4 M GTP & 10-6 M CHA
Figure 5.16: The data presented in Figure 5.15 on page 146 were transformed by normalising the 
level of bound [3 H]CHA remaining after 20-fold dilution to 100%. The level of bound [3 H]CHA 
remaining in the presence of CHA and DPCPX was then expressed as a percent of “dilution only” 
levels at each time point. Biphasic curves were fit to the data for illustrative purposes only. There 
was little apparent difference between the DPCPX chase response in the presence or absence of 
GTP, so the curve shown was generated using mean data of the two.
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served rate of the dissociation of [3 H]CHA by 20-fold dilution alone may be dependent on the 
concentration of [3 H]CHA (Figure 5.7 on page 127). The 5-point dissociation assay was used to 
investigate the effect of concentration of [3 H]CHA on the kinetics of dissociation in the presence of 
CHA or DPCPX. The only param eter which showed a significant dependence on [3 H]CHA concen­
tration was the fast rate constant of dissociation in the presence of DPCPX (P =  0.02; Figure 5.11 
on page 136). DPCPX chase appears to show little enhancement of [3 H]CHA dissociation during 
the fast component of dissociation relative to 20-fold dilution alone (Table 5.3 on page 130). The
O
slow component of [ H]CHA dissociation may be largely responsible for the observed ability of 
DPCPX to enhance dissociation of [3 H]CHA relative to dilution alone. This is supported by the 
dependence on the concentration of [3 H]CHA of both the observed rate of dissociation by dilution 
alone (Figure 5.7) and the rate constant of the fast component of dissociation in the presence of 
DPCPX (Figure 5.13).
5.6.6 T he effect o f  a ssocia tion  tim e and tem perature on [^H]CHA dis­
sociation .
Detailed time course experiments were designed in order to investigate how the rate and extent 
of the dissociation of [3 H]CHA from A^HE membranes, and the differences in these values when 
DPCPX or CHA are used as chase ligand, vary with the period of [3 H]CHA association and the 
temperature of incubation. As part of this protocol, [3 H]CHA association time courses at the 
different temperatures were measured.
These associations of [3 H]CHA to A jH E  membranes were fit to a model of one phase exponen­
tial association although there was an indication tha t the association might be biphasic (described 
in more detail in Chapter 5.5 on page 119). The observed rate constant of association (kobs) 
for 5.1 nM [3 H]CHA increased with incubation temperature, with kobs of 0.024, 0.038 ±  0.003, 
0.086 ±  0.004 and 0.174 ±  0.001 min- 1  when measured at 15, 2 2 , 30 and 37°C respectively (n = 2 , 
except 15°C where n =  1). Figure 5.17 on the following page shows the association time courses 
at all four tem peratures from one experiment. Receptor binding at 30 and 37°C was unstable 
after 90 and 30 min respectively and these later times were excluded from estimation of the asso­
ciation kobs at these tem peratures. The association curves presented in Figure 5.17 were fit to a 
two-phase model of exponential association for visualisation only. Quantitative interpretation of 
the two-phase association curves was unreliable and the mean rate constants of association (kobs) 
presented above were estimated from one-phase exponential curves fit to the same data.
At each point in the [3 H]CHA association time course, dissociation was initiated as described
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Figure 5.17 T he effect o f tem perature on the association of [3H]CHA
at A ^H E m em branes.
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[3H]CHA 
specific binding 500- 
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• 15°C
• 22°C
• 30°C
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Figure 5.17: pH]CHA association time courses were performed at four different temperatures; 
15°C, 22°C (room tem perature), 30°C and 37°C. The data shown above are from a single experi­
ment measured in duplicate. The initial rate of association increased with temperature up to 30°C. 
At 30°C binding was unstable and decayed after approximately 90 min. At 37°C levels of bound 
[^H]CHA decreased from 30 min onwards. Where binding was largely stable, data were fit to a 
model of two-phase exponential association as for Figure 5.4 on page 120. The decay of pH]CHA 
binding at higher temperatures and longer times is indicated for visual clarity only as the straight 
broken lines shown.
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above by means of a 20 fold dilution in the presence of either 10- 4  M CHA (CHA chase) or 
10 ^ M DPCPX (DPCPX chase), and bound [3 H]CHA measured after 10 and 60 minutes. Three 
dissociation time points (0 , 1 0  and 60 min) were chosen in order to obtain an estimate of the rate 
constant of the fast component of [3 H]CHA dissociation. Specific [3 H]CHA binding was normalised 
to observed levels immediately prior to initiation of dissociation (%SB at t = 0, as frequently used 
above for example in Figures 5.6, 5.8 and 5.10). The data from the dissociation time course 
experiments following different periods of association were combined in order to visualise the effect 
of association time. Figure 5.18 on the next page illustrates how data from dissociation time 
courses was combined to look at the effect of association time on the level of bound [3 H]CHA 
remaining after identical periods of dissociation. In this manner, Figure 5.18 describes the level
O
of bound [^HJCHA remaining after 60 min dissociation, following lengths of association between 5 
and 180 min. Both the DPCPX and CHA chases were more effective at enhancing the dissociation 
of [3 H]CHA following shorter periods of association, i.e. “agonist-locking” increases with the period 
of incubation of membranes and [3 H]CHA prior to dilution and initiation of dissociation.
The dissociation time courses presented in Figure 5.18 were performed at 15°C. The effect of 
association time on the levels of bound [3 H]CHA remaining at all four temperatures (15, 2 2 , 30 k. 
37°C) and two dissociation time points (10 and 60 min) is shown in Figure 5.19 on page 154. The 
difference between dissociation by CHA or DPCPX chase is greatest at lower temperatures and 
shorter association times (Figure 5.19). This difference is still present after 3 hours at 15 and 22°C, 
but is abolished after 60 min at 30°C and after 10-15 min at 37°C. CHA and DPCPX chases were 
both less effective at enhancing [3 H]CHA dissociation following longer periods of association. In all 
conditions, less agonist-locking is observed after shorter periods of association prior to dissociation.
Interestingly the dissociation of [3 H]CHA after 60 min by CHA chase appears to extrapolate 
to a non-zero y-axis intercept at zero association time independent of temperature (Figure 5.19). 
However, the ?/-axis intercept of dissociation in the presence of DPCPX appears to increase pro­
gressively with decrease in tem perature. This raises the question of whether the dissociation of 
[3 H]CHA by agonist or antagonist chase ligand is differentially sensitive to temperature. This 
provides further evidence of mechanistic differences between the enhancement of [3 H]CHA dis­
sociation by CHA and DPCPX. The y-axis intercept at zero association time may represent the
O
initial, or preset, dissociation characteristics of the system that are modified as [ H]CHA binds. It 
is unknown whether the fast and slow components of [3 H]CHA association represent two separate 
receptor complexes, or whether there is a degree of isomerisation or equilibrium between the two.
Figure 5.20 on page 155 illustrates in more detail the extrapolation of one of the curves in 
Figure 5.19 to its x-axis intercept. The x-axis intercept of approximately 30 min would relate to
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Figure 5.18 T he use o f d issociation  tim e course data to investigate the  
effect o f association  tim e on [3 H ]C H A dissociation.
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Figure 5.18: The dissociation of [3 H]CHA from A^HE membranes was measured at two dissociation 
time points (10 and 60 min) following association for 5 to 180 min. Data from dissociation time 
course experiments was combined to investigate the effect of incubation time prior to dilution 
(“association time”) on the level of bound [3 H]CHA remaining after 60 min dissociation by 20-fold 
dilution in the presence of 10" 6  M DPCPX (•) or 10~4  M CHA (•) chase. The dissociation time 
courses above were performed at 15°C and are from a single experiment measured in duplicate. 
The concentration of [3 H]CHA during the 100 /d association incubation with AXHE membranes 
was 5.8 nM.
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the start of the 30 min membrane incubation with adenosine deaminase, prior to incubation with 
radioligand. It is possible th a t once the membranes are warmed to RT a mechanism involved in 
agonist-locked pseudo-irreversible binding is begun. It may be possible to investigate this further 
by altering the conditions of membrane preparation, such as preparing membranes in the presence 
of adenosine deaminase. Then pre-incubation with adenosine deaminase immediately prior to the 
assay would be unnecessary.
The initial rate constant of [3 H]CHA dissociation was estimated from specific binding measured 
after 0 , 1 0  and 60 minutes of dissociation following each association time, essentially obtaining an 
estimate of the fast component of dissociation (see legend to Figure 5 .2 1  on page 156). Unlike the 
rate of [ H]CHA association, there was no evidence of a temperature dependence to the rate of 
dissociation over 60 minutes. In the absence of any obvious temperature dependence, the estimated 
kGff’s for all tem peratures were pooled in order to investigate the effect of association time on kQgp 
(Figure 5.21). CHA chase appeared to stimulate the initial rate of [3 H]CHA dissociation relative 
to DPCPX chase association times up to approximately 60 minutes.
Similar experiments investigating the effect of association time on the dissociation of [3 H]NEC A 
from A^HE membranes in the presence of 10"^ M CHA or 10”® M DPCPX chase observed greater 
“agonist locking” following longer periods of association in the same manner as described above for 
[3 H]CHA (data not shown).
5.7 D iscussion.
The kinetics o f  th e  binding o f  [3H ]D P C P X  at the adenosine receptor.
Chapter 4 described the binding of antagonists DPCPX, theophylline and N0840 at the adenosine 
Ai receptor at equilibrium as simple and monophasic. Work presented in this Chapter showed 
that the kinetics of antagonist binding at the adenosine A^ receptor is simple, rapid and mono­
exponential. The kinetics of the association of [3 H]DPCPX to the adenosine A i  receptor was rapid 
and mono-exponential when endogenous adenosine was removed from the membrane preparation
O
(Figure 5.2 on page 117). Previous studies have described the association of [ HJDPCPX to the
1 ^
adenosine A^ receptor as biphasic, composed of a rapid (0.17 min for 0.2 nM [ H]DPCPX) and 
much slower component (Cohen et al. 1996b). The reported slow component of the association of 
[3 H]DPCPX was removed in the presence of GTP and it was proposed that the decay of long-lasting 
adenosine-receptor-G protein complexes present in the membrane preparations was responsible for 
the slow association of [3 H]DPCPX. The nature of the association of [ H]DPCPX presented in 
this study also provides evidence for the presence of endogenous adenosine within the membrane
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Figure 5.19 T he effect o f association  tim e and tem perature on the 
dissociation  o f  [3 H ]C H A  in th e presence of D P C P X  or CHA.
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Figure 5.19: The association of [3 H]CHA with AXHE membranes was performed in 100 fil volumes 
for 5  to 180 min, after which dissociation was initiated by 2 0 -fold dilution (2  ml) in the presence 
of either 10“4  M CHA (•) or 10- 6  M DPCPX (•) and bound [3 H]CHA measured after 10 and 
60 minutes. Points are expressed as percent of [3 H]CHA specific binding observed at the same 
association time and no dissociation (%SB at dissociation t = 0). Results shown are the mean of 
two separate experiments measured in duplicate, except 15°C which is one experiment with points 
in duplicate. For 22, 30 and 37°C the mean concentration of [ H]CHA in the 100 /d association 
was 5.5 ±  0.4 nM (n =  2). At 15°C the concentration of [3 H]CHA was 5.8 nM._______________
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Figure 5.20 “A gonist locking” may be absent prior to membrane 
pre-incubation.
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Figure 5.20: Non-linear regression of the data presented in Figure 5.19 to a simple exponential 
curve often extrapolated to an x-axis intercept between 0 and -60 min. Shown above is the effect 
of association time on the extent of [3 H]CHA binding following 60 min dissociation in the presence 
of 10"4  M CHA (as shown on Figure 5.19 on the preceding page). Non-linear regression of the 
individual data-sets used to generate the above graph best fit to curves with mean x-axis intercept 
o f -24 ±  9 min and y-maoc of 65 ±  3 % with rate 0.020 ±  0.007 min  ^ (n =  2).
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Figure 5.21 T he effect o f association  tim e on the fast rate constant of
[% ]C H A  dissociation.
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Figure 5.21: Effect of association time on the estimate of initial fast rate constant of [3 H]CHA 
dissociation (k0 fj) by 10' 4  M CHA (red) or 10" 6  M DPCPX (blue) chase. As described above, k0g 
was estimated from specific binding measured after 0 , 1 0  and 60 minutes of dissociation following 
each association time. kQg  was estimated using the equation, y = span.e~kt +  plateau, where 
y is [3 H]CHA SB following dissociation time t of 10 min, span is amplitude of dissociation to 
plateau, plateau is [3 H]CHA SB following 60 min dissociation, and k is estimate of dissociation 
rate constant (kQfj). Lines are shown for illustrative purposes only.
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preparations although not exclusively as pre-bound adenosine-receptor-G protein complexes. It 
appears that incubation of membrane preparations with adenosine deaminase for 30 min at RT 
is not sufficient to remove all endogenous adenosine present. Figure 5.2 provides evidence for the 
presence of adenosine in the membrane preparations which is not pre-coupled to receptor-G protein 
complexes and which progressively inhibits the association of [3 H]DPCPX.
The differences in the association of [3 H]DPCPX at the adenosine Aj receptor described by 
Cohen et al. (1996b) and the data  presented here appear to be the result of differences in the condi­
tions during membrane preparation. Cohen et al. (1996b) prepared membranes in the presence of 
saponin unlike the membranes used in this study. The presence of saponin may trigger the release 
of adenosine stored in vesicular structures and expose adenosine to the adenosine receptor po­
tentially resulting in the formation of “locked” adenosine-A ^  receptor-G protein complexes. The 
slow release of adenosine from these complexes may give rise to the slow increase in [3 H]DPCPX 
binding at longer incubation times observed by Cohen et al. (1996b). For the membranes used 
in the present study, in the absence of adenosine deaminase during the 30 min membrane pre­
incubation (Figure 5.2; closed squares) it is likely that adenosine is being slowly released from the 
membranes and is the reason for the peaking of the [3 H]DPCPX association curve and subsequent 
decay caused by binding of adenosine. It should be noted that formation of a plateau at longer 
times does not necessarily indicate tha t adenosine release has stopped or slowed down because the 
plateau is approximately 50% of maximum levels of bound [3 H]DPCPX observed in the presence 
of both adenosine deaminase and saponin. This 50% level corresponds to the expected fraction 
of high affinity agonist binding sites and much higher levels of endogenous adenosine would be 
required to begin to occupy the low affinity binding sites. In the presence of adenosine deaminase 
(Figure 5.2; circles) the [3 H]DPCPX association curves show a slight decrease in binding at long 
times. An explanation may be th a t in the presence of adenosine deaminase, endogenous adeno­
sine being released will be catabolised effectively but not instantly. A small amount of adenosine 
may therefore be capable of binding to the receptors to slowly form very long-lived adenosine-A} 
receptor—G protein complexes. It would be predicted tha t in the presence of GTP (or similar 
guanine nucleotide) this decrease in [3 H]DPCPX binding with time would not be observed. This 
was not tested experimentally here, although Cohen et al. (1996b) reports clearly monophasic 
[3 H]DPCPX association to  the A i  receptor in the presence of guanine nucleotide.
The dissociation of [3 H]DPCPX from the adenosine Ax receptor was rapid and can be de­
scribed by a simple mono-exponential function decaying to predicted levels of binding (Figure 5.3 
on page 118). The rate  constant of dissociation was not sensitive to the presence of GTP or a 
competing unlabelled ligand such as DPCPX or CHA. Dissociation of [3 H]DPCPX was not sen­
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sitive to the agonist or antagonist pharmacology of the competing ligand. The rate constant of 
[ H]DPCPX dissociation was similar for HE, A^LE and A^R-GFP-G&j membranes. Simple 
mono-exponential dissociation of [3 H] DPCPX from the adenosine A^ receptor is characteristic 
of a simple reversible bimolecular interaction between receptor and ligand. The dissociation of 
[ HJDPCPX from recombinantly expressed adenosine A^ receptor described here is similar to that 
observed at endogenous (Gerwins et al. 1990, Klotz et al. 1990) and recombinant (Cohen et al. 
1996b) expressed A^ receptor .
The biphasic associa tion  o f  [^H]CH A at th e  hum an adenosine receptor.
The association of [3 H]CHA at A^HE membranes was best described by a two-phase model of 
exponential association and the extent and initial rate of association were clearly dependent on 
the concentration of [3 H]CHA (Figure 5.4 on page 120). Both the observed rate (Figure 5.5a) and 
the estimated initial rate (Figure 5.5c) of the fast component of [3 H]CHA association were clearly 
dependent on the concentration of [3 H]CHA. This is consistent with fast rate of association being 
driven by the binding of [^H]CHA at readily available high affinity binding sites. Generally these 
available high affinity binding sites are thought to be pre-coupled receptor-G protein complexes 
to which agonist binds to form the high affinity agonist-receptor-G protein ternary complex. The 
dependence of the slow component of [3 H]CHA association on the concentration of [3 H]CHA was 
much less distinct. W ith the limited data  here it is difficult to establish an absolute relationship, 
although the observed rate constant of association for the slow component was not dependent on 
the concentration of [3 H]CFIA (Figure 5.5b). It appears the slow component of [3 H]CHA asso­
ciation is significantly influenced by a process other than binding at immediately available high 
affinity binding sites. The slow increase in [3 H]CHA binding may be the result of formation of new 
high affinity binding sites by the recruitment of extra G protein into the receptor environment or 
promiscuous coupling to  another G protein. The observed rate constants of [3 H]CHA association 
are consistent with reported bi-exponential association of 2 nM [3 H]CHA to CHO membranes 
recombinantly expressing the human adenosine A^ receptor with observed rate constants of asso­
ciation of 0.08 i  0.01 and 7 ±  6  xlO ^ min  ^ (Cohen et al. 1996b).
Although the results presented here are limited, the relative amplitudes of each component 
of high affinity [3 H]CHA association are consistent with a 1:1 stoichiometry at all concentrations 
of [3 H]CHA (Figure 5.5e & 5.5f). This was also observed in Chapter 4, where the slow increase
O
in [3 H]CHA Bmax with time had an amplitude of approximately 50% of maximum [ H]CHA 
Bmax (Figure 4.3 on page 84). When a GPCR such as the adenosine A^ receptor exhibits a 1.1 
stoichiometry of binding components or receptor states it raises the consideration of the presence of
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receptor dimers, the receptor may exist in a dimeric form pre-coupled to a single G protein forming 
one high affinity agonist binding site for every dimeric complex. The slow component of binding 
may reflect the formation of a high affinity binding site resulting from structural rearrangement of 
the receptor signalling complex and the recruitment of extra G protein. The observation that the 
apparent log affinities of [3 H]CHA for the fast and slow components are similar (approximately
8.5 and 8 .8  respectively) provides a rationalisation of why no heterogeneous high affinity agonist 
binding is detected.
Preliminary data  showed both components of the association of [3 H]CHA to membranes ex­
pressing the A^R-GFP-Gaj fusion construct were comparable at high and low levels of receptor 
expression (Table 5.1 on page 123). The effect of the level of receptor expression on the association 
kinetics of [3 H]CHA was not investigated further.
The d issociation o f  [^H]CH A from  th e hum an adenosine A j  receptor.
In contrast to the rapid and complete dissociation of [3 H]DPCPX from the adenosine Aj receptor, 
the dissociation of [3 H]CHA by 20-fold dilution was incomplete with levels of bound [3 H]CHA de­
caying to a plateau much greater than  tha t expected for the remaining concentration of [3 H]CHA 
(Figure 5.6 on page 126). Such pseudo-irreversible agonist binding has often been termed “agonist 
locking.” The mechanism of agonist locking is unknown. The majority, but not all, of bound 
[3 H]CHA was rapidly dissociated by dilution in the presence of 100 /liM GTP showing agonist, 
receptor and G protein all influence formation of the “locked” complex. The observed rate of 
dissociation of [3 H]CHA (but not the relative amplitude) appeared to be dependent on the con­
centration of [3 H]CHA during the 60 min incubation prior to initiation of dissociation by 20-fold 
dilution (Figure 5.7 on page 127b). This dependence of dissociation on concentration is a strong 
indicator that a simple bi-molecular interaction behaving according to the law of mass action is 
not operating. Approximately one third of [3 H]CHA specific binding was capable of dissociating 
from A^HE membranes following 2 0 -fold dilution alone.
In the presence of a high concentration of unlabelled antagonist (DPCPX) or agonist (CHA), 
the dissociation of [3 H]CHA was enhanced relative to dilution alone and was best described by a 
model of two-phase exponential dissociation decaying to non-specific levels over a period of several
o
hours. In addition, unlabelled CHA was able to enhance the dissociation of [°H]CHA to a greater 
extent than DPCPX (Figure 5.8 and Table 5.3 on pages 129 and 130 respectively). The ability 
of CHA to enhance the extent of [3 H]CHA dissociation relative to DPCPX was manifest as a 
change in the amplitude of the fast component of dissociation, with both chase ligands showing 
indistinguishable effects on the rate constants of dissociation for each component (Table 5.4 on
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page 130).
Studies have reported varying degrees of pseudo-irreversible “agonist locking” at the adenosine 
A i receptor. Following dilution alone, Stiles (1988) showed no dissociation of agonist from the 
solubilised adenosine receptor. Using membranes prepared from CHO cells recombinantly ex­
pressing the human adenosine A j receptor approximately 50% of total bound [^H]CHA remained 
after 10-fold dilution in the presence of a chase of 3 mM theophylline (an adenosine A^ receptor 
antagonist) (Cohen et al. 1996b). In the presence of an excess of unlabelled agonist, dissociation 
of 50-80% of specific bound radiolabelled agonist has been reported for the rat (Schwabe & TYost 
1980), pig (Leid et al. 1988) and human (Waldhoer et al. 1999) adenosine A^ receptor. The 
differences observed between these reports appear to be largely due to differences in methodology 
but may also be influenced in the use of adenosine A^ receptor preparations of different receptor 
densities from different species. Reports of “agonist locking” in the literature are commonly re­
ported as levels of bound ligand remaining or as mono-exponential decay to a plateau. The results 
presented here provide a novel detailed description of the dissociation of [^H]CHA in the presence 
of an unlabelled ligand which was best described as a two-phase exponential decay with a 1 0 0 -fold 
ratio in the rate constants of dissociation for the two components. Furthermore, the agonist CHA 
enhanced the dissociation of [^H]CHA to a greater extent than DPCPX. This ability of an un­
labelled agonist to enhance the dissociation of a radiolabelled agonist is termed “agonist-induced 
agonist dissociation.”
In order to increase the throughput of the [^H]CHA dissociation assay the number of data points 
was reduced to three dissociation time points along with total and non-specific binding (Figure 5.10 
on page 134). The 5-point dissociation assay was reliable and generated results similar to those of 
the full-length dissociation assay (compare Tables 5.4 and 5.5, pages 130 and 135 respectively, for 
mean parameters from the full-length and 5-point dissociation assays respectively). The 5-point 
dissociation assay enabled the investigation of properties such as the potency of the enhancement 
of dissociation by chase ligand, which would have not been feasible with the full-length dissociation 
assay.
T he poten cy  o f  chase ligands to  enhance the dissociation o f [**H]CHA from the hum an  
adenosine receptor.
The abilities of both CHA and DPCPX chase ligands to enhance the dissociation of [^H]CHA were 
highly potent and specific (Table 5.7 on page 144) and independent of the concentration of [^H]CHA 
(Figure 5.13 on page 141). The high potency of CHA (and the other agonists examined) suggest 
tha t the effects are mediated at receptor-G protein complexes and not at uncoupled receptors.
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DPCPX chase showed no enhancement of [3 H]CHA dissociation after 10 min and only a little 
after 60 min. The differences between CHA and DPCPX chases shown in Figure 5.12 support the 
observations of the kinetics of [3 H]CHA dissociation where agonist-induced agonist dissociation is 
largely due to an increase in the amplitude of the fast component of dissociation. This is what 
appears to be reflected in Figure 5.12. In Table 5.7 (page 144) the potency of CHA chase increases 
with dissociation time which may be a reflection of being referenced against dilution alone which 
has generally reached a plateau after approximately 60 min. Of interest is to also estimate the 
potency of CHA chase relative to DPCPX chase rather than dilution alone. This may provide a 
reflection of the potency of the specific mechanism by which agonist-induced agonist dissociation 
is manifest.
It was not clear whether the difference in the ability of CHA and DPCPX to enhance the 
dissociation of [3 H]CHA was the result of their different efficacy or some other difference in the 
molecular properties of the two ligands. Unlabelled chase ligands of intermediate efficacy to CHA 
(a high efficacy agonist) and DPCPX (an inverse agonist) were employed in order to investigate 
the effect of chase ligand efficacy on agonist-induced agonist dissociation. The data presented 
in Table 5.6 on page 138 describes trend for GR190178 to be most effective at enhancing the 
dissociation of [3 H]CHA relative to GR161144 and GR162900. The rank order for enhancing 
dissociation of [3 H]CHA is GR190178 > GR161144 > GR162900 in essentially all of the data 
presented in Table 5.6. In Chapter 4, GR161144 and GR162900 were shown to have considerably 
reduced G TP shift at the adenosine A^ receptor compared to GR190178 and CHA (Figure 4.6 on 
page 91).
In addition to the correlation between agonist efficacy and the extent to which an agonist can 
enhance the dissociation of [3 H]CHA, the potency of the these agonists to enhance dissociation 
is described in Table 5.7 on page 144. The observed increase in log potency from 10 to 180 min 
was 0.93 ±  0.22, 0.82 ±  0.37, 0.38 ±  0.22 and -0.17 ±  0.20, for CHA, GR190178, GR161144 and 
GR162900 respectively. The increase in agonist potency between 10 and 180 min follows the same 
rank order as for the extent of dissociation (Table 5.6) and GTP shift observed at equilibrium 
(Figure 4.6). The same rank order of increase in potency was observed between 10 and 60 min, 
and between 60 and 180 min. These observations provide strong evidence that estimates of agonist 
efficacy observed in equilibrium binding experiments can be related to other responses of the 
receptor to agonist binding, such as agonist-induced agonist dissociation observed here.
Only one limited report has been published describing the binding of GR190178, GR161144 
and GR162900 at the human adenosine receptor. Equilibrium binding (including GTP shift) 
and functional assays ([3 3 S]GTP7 S binding and elevation of intracellular Ca2 + ) all showed a rank
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order of efficacy of GR190178 >  GR161144 > GR162900 (Sheehan et al. 2000). No significant 
difference in the stimulation of a cAMP-linked reported gene was observed for the three agonists, 
illustrating the added complexity in the interpretation of results from downstream amplification of 
the response to agonist binding at the receptor. In other responses the rank order of efficacy was 
GR190178 > GR161144 > GR162900 which was the same as that observed in the equilibrium and 
kinetic experiments presented here. The study reported another agonist, GR79236, which showed 
efficacy greater than GR190178 but less than NECA.
Further evidence of the specific and potent nature of the enhancement of agonist dissociation 
by an unlabelled chase is provided by the estimate of chase ligand log EC5 Q in Table 5.7. High 
efficacy ligands CHA and DPCPX show a high potency (sub-nanomolar) after 180 min, and partial 
agonists GR190178, GR161144 and GR162900 show decreasing potency. While the potency of a 
chase ligand to enhance the dissociation of [^H]CHA from the adenosine A^ receptor is dependent 
on ligand affinity, there appears to be little difference in the extent of that enhancement between 
agonists of very different efficacy. All the chase agonists studied here appear to show a similar 
ability to promote the extent of dissociation of [^H]CHA after 180 min. The antagonists DPCPX 
and N0840 show a considerably reduced ability to enhance [^H]CHA dissociation (although it 
should be noted N0840 chase was used at a concentration (10“® M) which would not appear to be 
sufficient to produce a maximal response).
G T P-insensitive agonist-induced agonist dissociation.
The dissociation of [^H]CHA by 20-fold dilution in the presence of 10'^ M GTP consisted of 
a very rapid initial dissociation followed by a slow decay of bound [^H]CHA over several hours 
(Figure 5.6 on page 126). This is similar to previous characterisation of [^H]CHA dissociation from 
the adenosine Aj receptor in 10“^ M GTP which shows a slow decay of bound [^H]CHA after a 
very rapid initial dissociation (Cohen et al. 1996b). Figure 5.15 on page 146 shows that even in the 
presence of GTP both CHA and DPCPX can further enhance the dissociation of [^H]CHA from 
the adenosine Aj receptor. The observation of agonist-induced agonist dissociation in the presence 
of GTP suggests th a t the phenomenon may be of physiological significance in live cells where GTP 
is present. Indeed, while the extent of the enhancement of [^H]CHA dissociation by DPCPX was 
similar in the presence or absence of GTP, agonist-induced agonist dissociation was even more 
pronounced in the presence of GTP (Figure 5.16 on page 148). After 3 hours dissociation in the 
presence of both GTP and CHA only 3% of specific [3 H]CHA binding remained (Table 5.8a). The 
very rapid initial dissociation of [^HJCHA in the presence of GTP made accurate estimation of the 
rate constant of dissociation for the fast component difficult, however Table 5.8b provides further
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evidence tha t agonist-induced agonist dissociation is largely manifest as a change in the relative 
amplitude of each component.
Possib le m echanism s o f agonist-induced agonist dissociation.
In general the ability of CHA chase to enhance the dissociation of [^H]CHA, relative to DPCPX 
chase, from A^HE membranes was independent of the concentration of [^H]CHA and was manifest 
as an increase in the amplitude, but not the rate, of the fast component of dissociation. Also, the 
dissociation of [^H]CHA by CHA or DPCPX appears to be differentially sensitive to temperature 
(Figure 5.19). There appear to be differences between the mechanisms by which CHA and DPCPX 
enhance the dissociation of [^H]CHA. The independence of the two rate constants of dissociation 
on the concentration of [^HjCHA and the pharmacology of chase ligand (Figure 5.9) implies that 
the process of the dissociation of [^H]CHA in the presence of an unlabelled ligand is not a sim­
ple bimolecular reaction following the law of mass action. There appears to be two dissociation 
processes, or two states of bound [^H]CHA, that operate through a mechanism independent of 
concentration alone. DPCPX chase may enhance the dissociation of [^H]CHA by preventing the 
rebinding of [^H]CHA following dissociation. “Agonist-locking” by dilution alone may be a com­
bination of; (i) the slowing of the already slow dissociation rate constant found in the presence of 
DPCPX or CHA, and (ii) the possibility of additional slow recruitment of additional G proteins 
to form by [^HjCHA rebinding more high affinity complexes that was manifest in the association 
studies.
CHA is able to enhance the dissociation of pHJCHA to an even greater extent than DPCPX 
which suggests a more “active” mechanism than simple inhibition of rebinding. Agonist-induced 
agonist dissociation provides evidence for communication between bound unlabelled chase agonist 
and bound [^H]CHA. This interaction was of high affinity and high potency. It is not known how 
this interaction may be communicated between agonist binding sites, although it could conceivably 
be transmitted directly through receptor-receptor contacts or through other protein components 
of the receptor signalling complex. Direct receptor-receptor interaction may be the consequence 
of receptor oligomerisation. The dependence of this receptor-receptor communication on the level 
of receptor expression favours the dynamic reversible formation of receptor oligomers rather than 
constitutive receptor oligomerisation.
In summary, the work presented in this Chapter describes the kinetics of [^HJDPCPX binding 
at the human adenosine A j receptor as a simple and reversible bimolecular interaction between 
ligand and receptor. The association of [3 H]CHA to the adenosine A]_ receptor was biphasic 
and the rate constant of association of the fast component was dependent on the concentration
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of [ H]CHA. The slower component of [ H]CHA association encompasses a process which is not 
dependent on the concentration of [^HJCHA and may be a process such as the reorganisation of 
the receptor signalling complex and the recruitment of additional G protein to form further high 
affinity agonist binding sites. The ability of unlabelled chase ligands to enhance the dissociation of 
[ H]CHA relative to 20-fold dilution alone was investigated in detail. Agonists of varying efficacy 
were able to considerably enhance the dissociation of [^H]CHA relative to the antagonists DPCPX 
and N0840, and the magnitude of this enhancement was dependent on the efficacy of the agonist. 
Agonist-induced agonist dissociation provides evidence of highly specific and potent communication 
between high affinity agonist binding sites on adenosine A^ receptors. Such receptor-receptor 
communication may be the consequence of receptor oligomerisation. Chapter 6  continues the 
investigation of the dissociation of [^H]CHA from the adenosine Aj receptor by investigating in 
detail the effect of the level of receptor expression on agonist-induced agonist dissociation.
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The dependence of agonist-induced 
agonist dissociation on the level of 
adenosine A j receptor expression.
6.1 Introduction.
Chapter 5 described the ability of unlabelled agonist to enhance the dissociation of [^H]agonist 
from the adenosine receptor to a greater extent than unlabelled antagonist. This ability is 
termed “agonist-induced agonist dissociation” and is manifest as an increase in the amplitude of 
the fast rate constant of dissociation rather than an increase in the rate of either component. In 
this chapter agonist-induced agonist dissociation was investigated in more detail using membranes 
prepared from the series of cell lines expressing either the A^R-GFP or A^R-GFP-Goij fusion 
constructs at a range of levels of expression.
The aim of the work presented is to determine whether agonist-induced agonist dissociation 
is dependent on the level of receptor expression. This is of significance if agonist-induced agonist 
dissociation is mediated by receptor-receptor interaction and may provide an insight into whether 
the adenosine A^ receptor exists as an oligomeric complex and whether the nature of this complex 
is dependent on the level of receptor expression.
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6.2 The effect of the level o f expression of the A^R-GFP-Gctj 
fusion construct on the extent and kinetics of dissociation  
o f [3H]CHA.
The series of cell lines expressing the A^R-GFP-Gaj fusion construct showed equilibrium bind­
ing indistinguishable from that of the adenosine receptor expressed alone (Chapter 4). The 
dependence of features of equilibrium binding on the level of A^R-GFP-Gcq expression agreed 
with observations of the adenosine A^ receptor expressed at two different densities (A^HE and 
A^LE). Membranes prepared from the AjR-GFP-Gcq cell lines were chosen in order to investigate 
the effect of the level of receptor expression on agonist-induced agonist dissociation because they 
provided a large range of expression level and were considered to be a valid model of the adenosine 
Aj receptor expressed alone.
6.2.1 T he effect o f  th e  level o f A ^R -G F P-G aj expression on th e en­
hancem ent o f [^H]CHA dissociation  by D P C P X .
Detailed pH]CHA dissociation time courses were performed using membranes prepared from 22 of 
the AjR-GFP-Ga^ cell lines. The dissociation time courses were performed in the same manner 
as most of those presented in Chapter 5. Prior to incubation with pH]CHA the AjR-GFP-Gcq 
membranes were incubated at RT for 30 min with adenosine deaminase to remove endogenous 
adenosine. Membranes were incubated with pH] CHA for 60 min in a small volume (100 //l) before 
dissociation was initiated by 20-fold dilution containing either 10"® M DPCPX or 10"^ M CHA. 
Dissociation was performed for periods between 5 min to 180 min.
o
Figure 6.1 on the next page shows the level of bound [°H]CHA remaining after 60 min dis­
sociation in the presence of DPCPX for all of the AjR-GFP-Gcq membranes. Linear regression 
of the mean level for each cell line (n =  22) and all the individual observations (n =  88) both 
showed no s ig n ific an t, dependence of the level of bound pH]CHA on the level of expression of the 
AjR-GFP-Gcq construct after 60 min. Where the mean level of bound pH]CHA is shown for each 
cell line the error shown is the s.e.m. of at least two independent experiments. No dependence on 
the level of receptor expression was also observed for the majority of other dissociation time points 
(Figure 6.2 on page 168 and Table 6.1 on page 169). The decrease in bound pH]CHA with time in 
the presence of DPCPX is clearly illustrated on Figure 6.2. Table 6.1 provides strong evidence that 
the ability of DPCPX to enhance the dissociation of pH]CHA from the adenosine receptor is 
not dependent on the level of receptor expression.
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Figure 6.1 T h e effect o f th e  level o f A ^R -G F P-G aj expression  on the  
enhancem ent o f [3H ]C H A  dissociation  by D P C P X  after 60 min.
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Figure 6.1: Comparison of all individual observations (top) and mean values (bottom) for each 
A^R-GFP-Gaj cell line in order to investigate if the enhancement of dissociation by DPCPX is 
dependent on the level of expression alone or whether the different cell lines influence the response. 
In both cases the level of bound [^H]CHA remaining after dissociation for 60 min following 20-fold 
dilution in the presence of 10"® M DPCPX was not dependent of the level of expression of the 
A^R-GFP-Gaj construct. A straight line is shown in order to indicate the mean, which is listed 
in Table 6.3 on page 174.
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Figure 6.2 T he effect o f th e  level o f A ^R -G F P-G aj expression  on the  
enhancem ent o f [3 H ]C H A  dissociation  by D P C P X  at four d issociation  
tim e points.
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Figure 6.2: At the majority of dissociation time points measured, the ability of DPCPX to enhance 
the dissociation of [^H]CHA was not dependent on the level of expression of the A^R-GFP-Gq  ^
construct. Shown above are four dissociation time points where there was no observed dependence 
on the level of expression. The four dissociation times shown are 5, 30, 60 and 180 min (a, b, 
c and d respectively). The mean level of bound [^H]CHA remaining at each dissociation time is 
indicated by the broken line.
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Table 6.1 S ta tistica l analysis o f  th e  dependence o f D P C P X -en h an ced  
p H ]C H A  dissociation  on th e  level o f A jR -G F P -G a j expression.
Dissociation time (min) Significantly non-zero slope? P value Slope y-intercept
Linear regression of all individual observations (n =  88)
5 Not Significant - - -
10 Significant 0.0002 -0.60 83.4
17 Not Significant - - -
30 Not Significant - - -
45 Not Significant - - -
60 Not Significant - - -
95 Not Significant - - -
125 Significant 0.03 0.41 41.8
180 Significant 0.04 0.43 37.0
Linear regression of mean values from each A^R-GFP-Gaj cell line (n =  22)
5 Not Significant - - -
10 Significant 0.02 -0.57 83.1
17 Not Significant - - -
30 Not Significant - - -
45 Not Significant - - -
60 Not Significant - - -
95 Not Significant - - -
125 Not Significant - - -
180 Not Significant - - -
Table 6.1: The dependence of the enhancement of the dissociation of [^H]CHA by 10“® M DPCPX 
on the level of A jR -G FP-G aj expression was determined for each dissociation time point. As 
illustrated in Figure 6.1 on page 167, the relationship was investigated using the mean for each cell 
line and all the individual observations. As for all statistical significance presented in this study, 
the dependence was considered significant if P < 0.05 (see Chapter 2.3.3 on page 59).
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6.2 .2  T h e effect o f th e  level o f A ^R -G F P-G aj expression  on th e en­
hancem ent o f [3 H ]C H A  dissociation  by C H A .
The effect of the level of expression of the A ^R -G F P -G aj construct on the ability of 10~4 M CHA 
to enhance the dissociation of [^H]CHA after 60 min is shown in Figure 6.3 on the following page, 
with DPCPX data from Figure 6.1 shown for comparison. Linear regression showed a significant 
dependence of the level of bound [^H]CHA on the level of expression of the A ^ R -G F P -G aj construct 
(see Table 6.2 on page 173 for P values). At higher levels of receptor expression, CHA showed a 
greater ability to enhance the dissociation of [^H]CHA. At all dissociation time points studied, both 
the mean levels for each cell line and all the individual observations showed a significant dependence 
of agonist-induced agonist dissociation on the level of receptor expression (Table 6.2). Figure 6.4 
on page 172 illustrates this for four dissociation time points in the same manner as Figure 6.2. 
Table 6.2 provides strong evidence that agonist-induced agonist dissociation is dependent on the 
level of receptor expression, which suggests that the receptor environment and the factors that 
influence receptor behaviour depend on the level of receptor expression.
Tables 6.1 and 6.2 show little difference between the use of mean values for each cell line and all 
the individual observations. This provides evidence for a direct dependence on the level of receptor 
expression rather than differences due to the nature of individual cell lines.
If agonist-induced agonist dissociation is entirely dependent on receptor-receptor communica­
tion determined by the level of receptor expression, then the y-axis intercept of linear regression 
may be expected to correspond to dissociation with no agonist-induced agonist dissociation (i.e. 
dissociation by an antagonist chase). Table 6.3 on page 174 compares the mean levels of bound 
[^H]CHA remaining after dissociation in the presence of DPCPX with the extrapolated y-axis 
intercept of the dependence of receptor expression on the level of agonist-induced agonist disso­
ciation. It is difficult to subject the two parameters to statistical scrutiny especially as it is not 
known if the dependence of residual bound [^H]CHA is linear (or not) with receptor expression 
level. However there does appear to be general similarity between dissociation by DPCPX chase 
and estimated dissociation by CHA in conditions with no receptor-receptor communication (at zero 
levels of receptor expression). Table 6.3 on page 174 provides strong evidence that agonist-induced 
agonist dissociation is entirely dependent on the level of receptor expression. At higher levels of
Q
receptor expression agonist is more effective at enhancing the dissociation of [^H]agonist.
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Figure 6.3 A fter 60 min agonist-induced agonist dissociation is 
dependent on the level o f receptor expression.
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Figure 6.3: As for Figure 6.1 on page 167 the dependence of enhancement of [3H]CHA dissociation 
after 60 min on the level of A^R-GFP-Go^ expression was investigated using individual observations 
and mean values for each cell line. Both approaches showed a significant dependence of agonist- 
induced agonist dissociation on the level of receptor expression (see Table 6.2 on page 173 for P 
values). Linear regression of the CHA chase data is indicated by the red line, and the mean level 
of bound [3H]CHA remaining in the presence of DPCPX is indicated by the blue line.
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Figure 6.4 The enhancem ent of [3H]CHA dissociation by CHA was 
dependent on the level of A ^R -G FP-G qj expression at all dissociation  
tim e points studied.
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Figure 6.4: At all dissociation time points the enhancement of [^H]CHA dissociation by CHA (•) 
was dependent on the level of A^R-GFP-Gaj expression. DPCPX data (•) from Figure 6.1 is shown 
for comparison. Linear regression of the CHA chase data is shown by the red line, as for Figure 6.3. 
The four dissociation times shown are 5, 30, 60 and 180 min (a, b, c and d respectively).
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Table 6.2 S tatistica l analysis o f th e  dependence o f C H A -enhanced
o
[°H ]C H A  dissociation  on th e  level o f A ^R -G F P-G oj expression.
Dissociation time (min) Significantly non-zero slope? P value Slope y-intercept
Linear regression of all individual observations (n =  112)
5 Significant < 0.0001 -1.28 87.6
10 Significant < 0.0001 -1.58 80.7
17 Significant < 0.0001 -1.34 71.6
30 Significant < 0.0001 -1.40 64.8
45 Significant < 0.0001 -1.33 58.0
60 Significant < 0.0001 -1.10 51.6
95 Significant < 0.0001 -0.92 45.8
125 Significant < 0.0001 -0.70 39.9
180 Significant 0.004 -0.41 35.4
Linear regression of mean values from each AjR-GFP-G aj cell line (n =  22)
5 Significant 0.0003 -1.27 87.4
10 Significant < 0.0001 -1.60 80.9
17 Significant < 0.0001 -1.39 72.1
30 Significant < 0.0001 -1.47 65.3
45 Significant < 0.0001 -1.38 58.4
60 Significant 0.0009 -1.14 52.0
95 Significant 0.001 -0.98 46.3
125 Significant 0.008 -0.73 40.1
180 Significant 0.049 -0.43 35.6
Table 6.2: At all dissociation time points agonist-induced agonist dissociation was dependent on 
the level of receptor expression. As illustrated in Figure 6.1 on page 167, the relationship was 
investigated using the mean for each cell line and all the individual observations. As for all 
statistical significance presented in this study, the dependence was significant if P < 0.05 (see 
Chapter 2.3.3 on page 59).
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Table 6.3 A gonist-induced  agonist d issociation  is absent at very low  
levels o f  A^R-GFP-Gctj expression.
Dissociation time 
(min)
Mean [3H]CHA 
%SB remaining in 
10'6 M DPCPX 
(n =  22)
10'4 M CHA chase 
y-axis intercept 
(from Table 6.2)
Difference 
(DPCPX mean - 
CHA y-intercept)
5 86.0 ±  0.8 87.4 -1.4
10 80.0 ±  0.8 80.9 -0.9
17 73.9 ±  0.8 72.1 1.8
30 66.8 ±  0.6 65.3 1.5
45 60.8 ±  0.6 58.4 2.4
60 55.7 ±  0.6 52.0 3.7
95 48.4 ±  0.7 46.3 2.1
125 44.1 ±  0.8 40.1 4.0
180 39.4 ±  0.9 35.6 3.8
Table 6.3: The mean level of bound [3H]CHA remaining after 20-fold dilution in the presence 
of 10'6 M DPCPX compared to the extrapolated level in the presence of 10"4 M CHA at zero 
A^R-GFP-Gaj expression.
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6.2 .3  T he effect o f th e  level o f  A ^R -G F P-G aj expression on th e kinetics  
o f d issociation  o f [^H]CHA in th e  presence o f chase ligand.
It has been shown previously that agonist-induced agonist dissociation at A^HE membranes is 
manifest largely as an increase in the amplitude of the fast component of dissociation rather than 
a change in the rate constants of dissociation (Table 5.4 on page 130). The ability of CHA to 
enhance the dissociation of [3H]CHA from the adenosine A^ receptor has now been examined in 
detail and the kinetic data can be analysed to test whether the same parameter associated with
O
[ H]CHA dissociation is dependent on the level of receptor expression. Table 6.4 on the following 
page clearly shows th a t the increase in CHA-induced [3H]CHA dissociation at greater levels of 
receptor expression is the consequence of an increase in the amplitude of the fast component of 
[3H]CHA dissociation. Both the fast and slow rate constants of [3H]CHA dissociation in the 
presence of CHA were not dependent on the level of receptor expression. These observations 
provide further evidence of two populations of [3H]CHA both bound with high affinity at nM 
concentrations, which show 100-fold different rate constants of [3H]CHA dissociation. The relative 
abundance of each population is dependent on the level of receptor expression.
The kinetics of [3H]CHA dissociation by DPCPX chase were entirely independent of the level 
of AiR-GFP-Gcq expression (Table 6.4). This would be predicted from the insensitivity of the 
extent of [3H]CHA dissociation by DPCPX chase on the level of A^R-GFP-Gcq expression.
6.3 The effect o f the level of A^R-GFP expression on the  
enhancem ent of [ H]CHA dissociation by D P C P X  and 
CHA.
The effect of the level of receptor expression on the dissociation kinetics of [3H]CHA from mem­
branes expressing the A^R-GFP fusion construct at different levels was also investigated. Six 
A^R-GFP membrane preparations were chosen which expressed the fusion construct over a range 
of densities. The cell lines were 5E4, 6H3, 6F12, 5C6, 6E5 and 5E10 (see Table 4.3 on page 95 
for equilibrium binding properties). The effect of the level of receptor expression on the extent 
of [3H]CHA dissociation in the presence of 10“6 M DPCPX or 10"4 M CHA was investigated in 
the same manner as for A^R-GFP-Gaj described above. Figure 6.5 on page 178 shows the effect 
of A^R-GFP expression on agonist-induced agonist dissociation at four of the dissociation time 
points investigated. This can be directly compared to Figure 6.4 showing the greater number 
of A jR -G FP-G aj membranes used. In general the six A jR-G FP membranes showed [3H]CHA
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Table 6 .4a  S tatistica l analysis o f th e  dependence o f th e  k inetics of 
[^H]CHA d issociation  on th e  level o f A pR -G F P -G aj expression.
Parameter of dissociation Significantly non-zero slope? P value Slope y-intercept
1(T4 M CHA chase (n =  22)
k-l,FAST Not Significant - - -
spanp^ST Significant 0.0007 1.4 34.0
k-l,SLOW Not Significant - - -
spangLOW Significant 0.0007 -1.4 65.8
10"6 M DPCPX chase (n =  22)
k-l,FAST Not Significant - - -
spanpAgp Not Significant - - -
k-l,SLOW Not Significant - - -
spangLOW Not Significant - - -
Table 6.4b  M ean param eters describing tw o-phase exponential 
d issociation  o f [^H]CHA from A pR -G FP -G aj m em branes.
Two-phase exponential dissociation Fast Slow
Rate (k_i) and amplitude (span) k_i (min“^) span (%SB) k . | (m in'l) span (%SB)
10"4 M CHA chase (n =  22) 0.10 ±  0.01 - 3.5 ±  0.1 xlO"3 -
10“6 M DPCPX chase (n =  22) 0.10 ±  0.01 31.2 ±  0.8 3.4 ±  0.1 xlO-3 68.5 ±  0.8
Table 6.4: The effect of the level of A^R-GFP-Goj expression on the four parameters describing 
two-phase exponential dissociation of [3H]CHA was investigated by linear regression of the rela­
tionship. The P  value, slope and y-axis intercept (i.e. the behaviour extrapolated to the absence 
of agonist-induced agonist dissociation) are reported where the best fit linear regression line had 
a significantly non-zero slope. The mean of each parameter is reported when no significant slope 
was found.
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dissociation properties very similar to A^R-GFP-Gcq. However the absolute independence of the 
dissociation of [^H]CHA in the presence of DPCPX was less clear for A^R-GFP membranes than 
it was for A^R-GFP-Gcq. This appeared to be largely due to the reduced number of A^R-GFP 
membrane preparations used (6 A1R-GFP compared to 22 AjR-GFP-Gcq) and the reduced range 
of receptor expression levels.
Agonist-induced agonist dissociation at A^R-GFP membranes was similar to that characterised 
in detail at A^R-GFP-Gcq membranes. CHA chase was more effective than DPCPX chase at 
membranes expressing the A^R-GFP construct at higher densities. Unfortunately the data was 
not amenable to the same thorough statistical examination of any dependence on the level of 
receptor expression as was performed for the A^R-GFP-Gaj membranes presented in Tables 6.1 
and 6.2. The mean levels of [^H]CHA remaining at A^R-GFP membranes after 10, 60 and 180 min 
dissociation in the presence of DPCPX is similar to those observed at A^R-GFP-Goj membranes 
(Tables 6.3 and 6.5 on pages 174 and 179).
6.4 Com parison of the enhancem ent of [^Hjagonist dissocia­
tion from the A^R alone and the A^R-G FP and A^R- 
GFP-Gctj constructs.
Following detailed characterisation using A^HE membranes (Chapter 5) membranes from the series 
of A^R-GFP and A^R-GFP-Goj cell lines were chosen in preference to A^LE membranes to 
investigate the effect of receptor expression level on the kinetics of [^H]CHA dissociation for a 
number of reasons. Equilibrium binding at both fusion constructs was essentially indistinguishable 
from A^HE membranes and generally independent of the level of receptor expression (Chapter 4). 
The large number of A^R-GFP and A^R-GFP-Goj cell lines provided a greater resolution, or detail, 
with which to investigate any dependence on the level of receptor expression. Also, experiments 
investigating the dissociation of [^H]CHA from A^LE membranes were very noisy, variable and 
consequently difficult to analyse quantitatively. A^LE membranes were in general difficult to 
obtain clean data with both equilibrium and kinetic binding experiments. Agonist-induced agonist 
dissociation was observed at A^LE membranes in some experiments although the poor quality 
of the data prevented thorough examination. Figure 6.7 on page 182 shows the dissociation of 
[^H]CHA at A^LE membranes with large overlapping error bars at most dissociation time points. 
However there does appear to be a tendency for CHA chase to slightly enhance the dissociation 
of [^H]CHA relative to DPCPX chase. W ith the detailed characterisation of the A^R-GFP-Goj
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Figure 6.5 The dependence of agonist-induced agonist dissociation on 
the level of A ^R -G FP expression.
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Figure 6.5: The dependence of the enhancement of [^H]CHA dissociation on the level of receptor 
expression was investigated with a reduced number of A^R-GFP cell lines compared to AjR-GFP- 
Gcq. Shown above axe the levels of bound pH]CHA remaining after dissociation by 20-fold dilution 
in the presence of 10”® M DPCPX (•) or 10"^ M CHA (•). The six A^R-GFP cell lines were 5E4, 
6H3, 6F12, 5C6, 6E5 and 5E10 (see Table 4.3 on page 95 for equilibrium binding properties). Where 
the level of bound [3H]CHA remaining was not dependent on the level of A^R-GFP expression a 
horizontal line is shown. Where a significant dependence was observed the best fit line from linear 
regression is shown. The four dissociation times shown are 5, 30, 60 and 180 min (a, b, c and d 
respectively).
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Table 6.5 [^HjCHA binding rem aining after d issociation from  
A ^ R -G F P  m em branes in th e presence o f D P C P X .
Dissociation time (min) 10 60 180
A^R-GFP membranes
q
% [ H]CHA specific binding remaining 
after dissociation by 20-fold dilution with 
10"6 M DPCPX chase (n =  12)
77.0 ±  0.6 50.8 ±  1.0 40.7 ±  1.3
AjR-G FP-G aj membranes
% [^H]CHA specific binding remaining 
after dissociation by 20-fold dilution with 
10'6 M DPCPX chase (n =  22)
80.0 ±  0.8 55.7 ±  0.6 39.4 ±  0.9
A^HE membranes
% [^H]CHA specific binding remaining 
after dissociation by 20-fold dilution with 
10"6 M DPCPX chase (n =  28)
86.1 ±  1.6 64.0 ±  1.7 46.6 ±  1.6
Table 6.5: Mean levels of bound [^H]CHA remaining at A^HE, A^R-GFP and A^R-GFP-Ga^ 
membranes after dissociation by 20-fold dilution in the presence of 10"® M DPCPX. Data shown 
is the mean of all individual observations (performed in duplicate) at each time point. Figure 6.5 
on the preceding page shows the same A^R-GFP data (at 60 and 180 min) expressed as a mean 
for each cell line used. A^HE and A^R-GFP-Gaj data are reproduced from Tables 5.3 and 6.3 
(pages 130 and 174) respectively.
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membranes, and to a lesser extent the A^R-GFP membranes, the kinetics of the dissociation of
o
[°H]CHA from A^LE membranes was not investigated further. Previous attempts to characterise 
the dissociation of [3H]CHA from A^LE membranes could not be fit to an equation describing 
monophasic exponential decay and showed no enhancement of [3H]CHA dissociation by CHA 
chase relative to DPCPX chase (Browning 2003).
Figure 6.6 on the following page provides a visual comparison of individual [3H]CHA dissoci­
ation experiments at A} HE, A jR-G FP and AjR-GFP-G aj membranes. The extent of [3H]CHA 
dissociation in the presence of DPCPX chase has been shown above to be essentially indepen­
dent of the level of receptor expression and therefore mean levels can be compared between A^HE, 
A^R-GFP and AjR-GFP-Gcq membranes. Table 6.5 on the previous page lists the levels of bound 
[3H]CHA remaining after 10, 60 and 180 min for A^HE, A^R-GFP and A^R-GFP-Gaj membranes. 
While the levels are not identical, there does not appear to be a sufficient difference between mem­
brane types that could markedly impact on proposed mechanisms of DPCPX-enhanced [3H]CHA 
dissociation. In general, the nature of the dissociation of [3H]CHA from A^HE, A jR-GFP and 
A^R-GFP-Goij membranes was similar.
6.5 D iscussion.
Chapter 4 showed the equilibrium binding properties of membranes prepared from the series of 
A^R-GFP and AjR-GFP-Gcq cell lines were very similar to A^HE membranes which express the 
human adenosine A^ receptor alone. The adenosine A^ receptor fusion constructs appear to be 
representative of the A^ receptor alone and are therefore of considerable interest as models of the 
effect of receptor expression level on receptor behaviour. Chapter 5 described “agonist-induced 
agonist dissociation” at A^HE, A^R-GFP and A^R-GFP-Ga^ membranes. The dissociation of 
[3H]CHA in the presence of excess unlabelled competing ligand was described by a two-phase 
exponential decay to non-specific levels. The agonist CHA was able to enhance the dissociation of 
[3H]CHA to a greater extent than the antagonist DPCPX, and this was manifest as an increase 
in the amplitude of the fast component of [3H]CHA and not a change in the rate constants of 
dissociation. Using membranes prepared from the series of A^R-GFP and AjR-GFP-Gcq cell 
lines the work presented in this chapter investigated in detail the effect of receptor expression level 
on agonist-induced agonist dissociation. Chapter 8 debates in greater detail possible mechanisms 
for the results presented in this Chapter and throughout this study. A more simple summary of 
the results presented in this Chapter is given below.
Detailed characterisation of the kinetics and extent of dissociation showed the mechanism by
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Figure 6.6 V isual comparison of the enhancem ent of [% ]C H A  
dissociation from A^HE, A ^ -G F P -G a j  and A ^ - G F P  membranes.
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Figure 6.6: The dissociation of [^H]CHA from A^HE, Ai R-GFP-Gqj and A^R-GFP membranes. 
As usual, all three membranes were incubated for 60 min at RT in a volume of 100 //I before 
initiation of dissociation by addition of 2 ml buffer containing either 10"6 M DPCPX (•) or 10'4 M 
CHA (•). The concentrations of [^H]CHA during the 60 min incubation before dissociation were 
5.5, 5.0 and 5.7 nM (a, b and c respectively). The A^R-GFP-Gaj membranes were prepared from 
cell line 3F2 and AjR-GFP from cell line 6E5 (see Table 4.3 on page 95 for details on each).
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Figure 6.7 The dissociation of [^H]CHA from A^LE m embranes in the  
presence of D P C P X  or CH A chase.
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Figure 6.7: [^H]CHA dissociation experiments at A^LE membranes were performed in the same 
manner as described above. Membranes were incubated in a small volume (100 /A) for 60 min with 
[^H]CHA before dilution with 2 ml buffer containing either 10"® M DPCPX (•) or 10"^ M CHA 
(•). The data shown are the mean of two experiments (except 20 and 180 min where n =  1), each 
experiment measured in quadruplicate at all time points. The mean concentration of [^H]CHA 
before dilution was 5.4 ±  0.1 nM (n =  2). The curves shown are non-linear regression using a 
two-phase model of exponential decay constrained to a plateau of non-specific binding.
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which DPCPX enhances the dissociation of [^H]CHA from the adenosine receptor is almost 
entirely independent of the level of receptor expression (Figure 6.2 and Table 6.1). The lack of 
any notable dependence on receptor density may favour a more “passive” mechanism by which 
DPCPX enhances the dissociation of [^H]CHA. DPCPX binds at the adenosine A^ receptor after 
[^H]CHA has dissociated and so prevents the re-association of pH]CHA. The ability of DPCPX 
to enhance the dissociation of [^H]CHA relative to the plateau of dilution only suggests “agonist 
locking” encompasses a degree of dissociation and re-association of [^H]CHA.
The ability of CHA to enhance the dissociation of [^H]CHA to an even greater extent than 
DPCPX (agonist-induced agonist dissociation) was more pronounced at greater levels of recep­
tor expression (Figure 6.4). This dependence on receptor expression level was clearly significant 
at all dissociation time points investigated (Table 6.2). Agonist-induced agonist dissociation was 
confirmed as a mechanism manifest as an increase in the amplitude of the fast component of dis­
sociation and not a change in either of the rate constants of dissociation (Table 6.4b on page 176). 
This is the property of the adenosine A^ receptor’s response to the binding of CHA which is de­
pendent on the level of receptor expression. Although linear regression is used here to determine 
the relationship, the nature of this dependence is not known. Indeed one might expect the rela- 
tionship to be dependent on [R] if receptor dimers are being formed. This is discussed further in 
Chapter 8.
In summary, the work presented in this Chapter shows the extent of agonist-induced agonist 
dissociation at the human adenosine Aj receptor is dependent on the level of receptor expres­
sion. This implies tha t the response of the A^ receptor to the binding of agonist is different at 
different levels of receptor density. At greater levels of receptor expression there appears to be 
communication between high affinity agonist binding sites. Conceivably this may be conveyed 
between receptors by direct receptor-receptor interaction, possibly by receptor dimers, or by other 
components of the receptor signalling complex. These ideas are discussed further in Chapter 8.
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The localisation of the human 
adenosine receptor and its GFP 
fusion constructs in cell membrane 
fractions separated by their buoyant 
density.
7.1 Introduction.
The results presented in Chapters 5 and 6 provide evidence for receptor-receptor communication 
between high affinity agonist binding sites at the human adenosine receptor. Agonist stimula­
tion of the adenosine A^ receptor has been shown to stimulate the accumulation of the receptor 
into cell membrane “raft” domains characterised by their elevated level of the protein caveolin 
(Escriche et al. 2003 and Gines et al. 2001). Selective localisation of proteins in and out of cell 
membrane domains has the potential to alter the repertoire of proteins available for interaction 
and a change in the local receptor density may influence aspects of receptor behaviour. The aim 
of the work presented in this Chapter was to establish whether the human adenosine A^ receptor 
membrane preparations used throughout this study were selectively localised in or out of “raft” 
domains.
Cell membrane “raft” domains are typically isolated by means of a density gradient formed by
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high speed centrifugation of a solution of sucrose or a similar compound such as iodixanol. In 
this study iodixanol was chosen as the density gradient medium due to the number of published 
reports of its use including density gradient fractionation of CHO cell membranes (Abrami et 
al. 2001, Abrami et al. 2003, Frenzel Sz Falls 2001). The viscosity of solutions of iodixanol 
is lower than tha t of sucrose and the required density range of iodixanol gradients is also lower 
than for sucrose. Consequently iodixanol gradients are typically smaller in volume, show lower 
viscosity and thus require centrifugation for shorter periods of time. Smaller gradient volumes are 
important as they increase the likelihood of obtaining a clear Western blot directly from the gradient 
fraction without manipulations to increase the protein concentration. The systematic name for 
iodixanol is 5,5 -[(2-hydroxy-l,3-propanediyl)-bis(acetylimino)]bis-[iV,7V bis(2,3-dihydroxypropyl)- 
2,4,6-triiodo-benzenedicarboxamide] and it is essentially a dimer of iohexol. Iohexol is commonly 
employed as a radiopaque contrast agent for X-ray imaging of vascular systems within the body. 
The molecular structure of iodixanol and iohexol is shown in Figure 7.1 on the following page. The 
high density of iodixanol is the result of the substituted triiodobenzene rings which are linked to 
a number of hydrophilic groups.
Here, iodixanol density gradients were used to isolate membrane fractions of different density 
from membranes used for the radioligand binding studies presented in Chapters 4, 5 and 6. The 
molecular composition of these fractions were then characterised by Western blots using antibodies 
against A^R, GFP, Gcq, G a ^ ,  Fyn and caveolin. Table 2.1 on page 57 lists details of the antibodies 
used throughout this study.
7.2 D ensity  gradient fractionation of membranes expressing 
the hum an adenosine receptor.
Following density gradient fractionation, as described in Chapter 2.2.7 on page 54, gradients were 
harvested from top (fraction 1) to bottom  (fraction 7), and any remaining pellet resuspended in 
TNET buffer. The self-generated iodixanol gradient does not form a linear gradient, rather a 
profile with a shallow middle as shown in Figure 7.2 on page 187. The gradients were created 
by centrifugation of layers of 35% (1.2 ml), 30% (3 ml) and 5% (900 yul) iodixanol. The density 
profile of the harvested fractions (Figure 7.2a) generally agrees with the manufacturer’s information 
showing a gradient generated from the centrifugation of 30% iodixanol (Figure 7.2b) although the 
observed densities were somewhat greater.
A} HE and A^LE membranes were fractionated by iodixanol density gradient fractionation 
and characterised by Western blots. Figure 7.3 on page 190 shows Western blots of A^HE and
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Figure 7.1 T he m olecular structures o f iodixanol and iohexol.
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Figure 7.1: (u p p e r)  The molecular structure of iodixanol (molecular weight 1550) used in this 
study for density gradient fractionation, (low er) The molecular structure of iohexol (molecular 
weight 820) typically used as a medium to provide contrast for X-ray examination of vascular 
systems or body cavities.
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Figure 7.2 M ean density of density gradient fractions. 
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Figure 7.2: (a) Mean density (g/ml) of density gradient fractions (1 - 7) from A^HE, A^LE, 
A^R-GFP and A^R-GFP-Gaj membrane fractionations. Data shown represents the mean density 
of the four different fractionations (n =  4 ±  s.e.m.). The measurements of each fraction from 
each gradient were performed in duplicate. Samples from each fraction were diluted 1:1 twice 
in series in 0.85% NaCl before measurement of absorbance at 340 nm referenced against 0.85% 
NaCl alone. P =  pellet resuspended in TNET buffer. The broken line indicates linear regression 
showing a significant (P =  0.007, slope =  0.01) increase in density from fraction 2 through to 7. 
Fraction 1 and the resuspended pellet were not included in the linear regression, (b) Information 
from the OptiPrep documentation showing self-generated iodixanol gradient formation following 
centrifugation at 353,000 g for 1 hr at 4°C. The gradient formed from 30% iodixanol is the top 
curve, as indicated.
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A jLE density gradient fractions using antibodies for A;[R, Gap G a ^  and caveolin. Caveolin 
is commonly employed as a marker of cell membrane domains of lower density, such as rafts. 
Although caveolin is found throughout the cell membrane, it is generally believed to be more 
concentrated in rafts (Waheed Sz Jones 2002). In Figure 7.3 the A^HE gradient clearly shows an 
accumulation of caveolin, and by implication lipid rafts, in fractions 2 and 3. This is strong evidence 
for the successful isolation of caveolin-enriched lipid rafts. The A jLE gradient in Figure 7.3 
shows a less distinct distribution of caveolin throughout the gradients although fractions 3 and 4 
show the greatest level of caveolin. In both the AjHE and A^LE gradients, longer exposure of 
autoradiography film identified the presence of caveolin in all fractions excluding the resuspended 
pellet.
Fyn (a member of the Src family of non-receptor tyrosine kinases) is also frequently employed 
as a marker for cell membrane raft domains, in the same manner as caveolin (see Figure 7.5 on 
page 191). Neither the A^HE or A jLE density gradients showed evidence of Fyn accumulation in 
any of the fractions. Figure 7.4 on page 191 shows a Western blot using an antibody for Fyn against 
unfractionated and fractionated A^HE membranes. The expected Fyn band (approximately 59 
kDa) is possibly faintly visible in unfractionated membranes, indicated by the red arrow, but it is 
not possible to identify accumulation of this band in any density gradient fractions. The molecular 
composition of the additional bands identified by the Fyn antibody were not investigated. Repeated 
attempts using altered blot conditions were unable to detect evidence of Fyn distribution across 
A^HE and A^LE density gradients.
Gcq exhibits a characteristic distribution across membrane density gradients. Figure 7.5 on 
page 191 shows a typical localisation of Gcq following fractionation of COS-7 cell membranes on 
an iodixanol density gradient (Waheed & Jones 2002). Gcq is observed in both “light” and “heavy” 
membrane fractions, with lower signals in the intermediate fractions. This can be seen in both the 
A i HE and A jLE gradients in Figure 7.3.
Gaqg has been shown to not associate with lighter raft membrane fractions, for example as 
shown in Figure 7.5. In agreement with these observations, the A^HE gradient fractions in Fig­
ure 7.3 show a strong localisation of G a ^  in “heavy” fractions 6 and 7. Studies have shown G a ^  
to be localised differently from Goq3 , with G a \2 being found in light raft membrane fractions 
(Figure 7.5). Western blots for G a ^  °f the A^HE gradient were inconclusive, failing to show the 
presence of Gcq2 in any of the A^HE fractions (results not shown).
The distribution of caveolin, G aj and Gaq3  all seem to indicate that iodixanol density gradi­
ent fractionation of A jH E and A jLE membranes has successfully separated more dense “heavy” 
membrane fractions (containing Gax3) from the less dense “raft” fractions (containing caveolin).
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However, with uncertainty remaining over the specificity of the A^R antibodies used in this study 
(shown by the presence of an A^R-sized band in M^R membranes in Figure 3.5 on page 71), it is 
not possible from Figure 7.3 alone to conclude whether the A^R receptor is localised selectively 
into “light” or “heavy” domains of the cell membrane. In both the A^HE and A ^ E  gradients, the 
A^R antibody identifies strong bands in fractions 6 and 7 (Figure 7.3). The A^HE gradient shows 
a greater level of A^R in the lighter fractions and especially fractions 2 and 3. W ithout proof 
of the specificity of the A^R antibodies, it is difficult to conclude whether Figure 7.3 describes a 
difference in A^R membrane localisation dependent on the level of receptor expression.
7.3 D ensity  gradient fractionation of membranes expressing 
A ^R -G FP and A^R-GFP-Ga^ fusion constructs.
The A^R-GFP and A jR-G FP-G aj fusion constructs are clearly identifiable from A^R by their 
increased molecular size. W ith seemingly indistinguishable radioligand binding properties from 
the A^R alone, it is interesting to speculate whether the localisation of the A jR-GFP and A^R- 
GFP-Gcq fusion constructs may be similar to that of A^R. Alternatively, if the localisation of 
A^R and the fusion constructs is different, then it suggests that localisation has an insignificant 
influence on receptor behaviour in the conditions used in this study.
Density gradient fractionation of membranes expressing A^R-GFP and AjR-GFP-Gcq fusion 
constructs was performed in order to investigate whether the constructs were selectively localised 
into components of the cell membrane. The attempts described above investigating the distribution 
of A^R in membrane fractions were inconclusive due to uncertainty over the specificity of the 
antibodies against A^R. Iodixanol density gradient fractionations of membranes expressing A^R- 
GFP and AjR-GFP-Gcq constructs were performed and their molecular composition characterised 
by means of Western blots, shown in Figure 7.6 on page 193. Each of the blots shown in Figure 7.6 
(apart from caveolin) is a separate gel and blot, rather than the same PVDF membrane stripped 
and re-probed with a different antibody. In both the A^R-GFP and A^R-GFP-Ga^ gradients 
caveolin shows a greater accumulation in the lighter fractions, suggesting successful fractionation. 
The membranes used for the fractionations shown in Figure 7.6 were 2G3 (A^R-GFP-Ga^) and 5F4 
(A^R-GFP) which have a [3H]DPCPX Bmax of 3.77±0.41 and 3.97T0.30 pmol/mg respectively 
prior to fractionation. More equilibrium binding properties are described in Table 4.3 on page 95.
The antibodies for A^R and GFP show clearly that both fusion constructs are found predomi­
nantly in the “heavy” fractions 6 and 7, in Figure 7.6. The molecular weight of the A^R-GFP and 
AiR-GFP-Gcq bands observed agrees with those observed in Figure 3.5. The antibody for GFP
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Figure 7.3 D ensity gradient fractionation of A^HE and A^LE 
membranes.
A,R (ab3460)
A ^ E  gradient fractions 
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Caveolin (ab2910) —
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Figure 7.3: A^HE and A^LE membrane density gradient fractions probed for A^R, Gc^, Gcqg 
and the raft marker protein caveolin. Fraction 1 is the lightest, harvested first from the top of 
the centrifuge tube, and fraction 7 the most dense. Following removal of all the fractions, any 
remaining pellet (P) was resuspended in TNET buffer. The mean density of all iodixanol density 
gradients is shown in Figure 7.2 on page 187.
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Figure 7.4 W estern blot of A^HE density gradient fractions for Fyn.
✓
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Figure 7.4: The A^HE density gradient shown in Figure 7.3 on the preceding page was probed 
with an antibody for Fyn, often employed as an indicator of lighter membrane fractions along with 
caveolin. Fyn is expected to appear as a band of approximately 59 kDa, and is possibly present in 
the A^HE membranes prior to fractionation (indicated by red arrow). However there is not strong 
evidence of differential localisation of the 59 kDa Fyn band in any of the gradient fractions (1 to 7) 
or pellet (P). The identity of the other bands identified by the Fyn antibody was not investigated.
Figure 7.5 Exam ple of G protein and raft marker protein distribution  
following density gradient membrane fractionation.
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Figure 7.5: Figure showing distribution of G a ^ ,  caveolin, Gaj and Fyn from COS-7 cells
following flotation and fractionation on an iodixanol density gradient (taken from Waheed & Jones, 
2002).
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detects a very faint presence of the fusion constructs in the other fractions, but these are negligible 
relative to the strong bands observed in fractions 6 and 7. These observations strongly indicate 
that in the absence of agonist treatment both the A jR-GFP and A | R-GFP-Geq fusion constructs 
are not concentrated into less dense domains of the cell membrane such as lipid rafts.
In Figure 7.6 endogenous human Gcq shows the characteristic gradient distribution also ob­
served in Figures 7.3 and 7.5. Human Gcq is expected to show a molecular weight of approximately 
40 kDa, as observed in Figure 7.6. Using the antibody for G ai? the A^R-GFP-Gaj construct ap­
pears to be identified in the same location in fractions 6 and 7 as by the antibodies for A jR  and 
GFP. However, the A jR -G FP gradient also faintly shows these same ‘ Aq R-GFP-Gcq” bands in 
fractions 6 and 7, which is not expected. Western blot of the unfractionated A jR-G FP and A^R- 
GFP-Gcq membranes using this G aj antibody is shown in Figure 7.7 on page 196. Figure 7.7 
clearly shows the presence of a high molecular weight Gcq band in the A^R-GFP membranes, as 
observed in the A jR -G FP gradient in Figure 7.6. W hat this band represents was not investigated, 
although it was not observed using antibodies for A^R or GFP and therefore appears unlikely to 
be the A jR -G FP-G aj construct. This high molecular weight Gcq band, using antibody ab3522, 
was also observed in unfractionated A^HE and A^LE membranes (results not shown), so does not 
appear to be contamination of A jR-G FP membranes or cells with A^R-GFP-Gaj membranes or 
cells especially as the A^R and GFP antibodies do not identify the band.
These complications with the Gcq antibody ab3522 are not particularly significant, bearing in 
mind tha t both the A^R and GFP antibodies clearly show the fusion constructs are not present 
to any significant degree in “light” raft membrane fractions. Also, Chapters 4 and 6 failed to 
determine any effect of the tethered Go; subunit on either binding at equilibrium or the kinetics of 
binding.
7.4 D iscussion.
The work presented in this Chapter provides novel evidence describing differential localisation 
of human adenosine A^ receptor-GFP fusion proteins in domains of the cell membrane. The 
tin m an adenosine A j  receptor when covalently fused to GFP was not observed to any significant 
degree in cell membrane domains of low buoyant density including lipid rafts. Unfortunately direct 
characterisation of membranes expressing the adenosine Aj receptor alone were inconclusive due 
to failure to prove the specificity of the A^R antibodies for the A^R alone. However, the antibodies 
were specific for the A^R fusion constructs A^R-GFP and A^R-GFP-Gq  ^ due to their increased 
molecular size and was further supported by an antibody for GFP.
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Figure 7.6 D ensity gradient fractionation of membranes expressing  
A^R -G FP and A^R -G FP-G aj fusion constructs.
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Figure 7.6: Density gradient fractionation of A^R-GFP and A^R-GFP-Goj membranes, charac­
terised by Western blots using antibodies for AjR, GFP, Gc^ and caveolin. As before, gradient 
fractions were harvested from lightest (fraction 1) to most dense (fraction 7), and any remaining 
pellet (P) resuspended in TNET buffer. See Figure 7.7 on page 196 for Western blot using Goj 
(ab3522) of the unfractionated A^R-GFP and AiR-GFP-Gaj membranes presented in this figure.
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Chapters 4 and 6  observed the binding of ligands at equilibrium and the kinetics of binding 
to the A^R-GFP and AjR-GFP-Gcq constructs to be essentially indistinguishable from the A jR  
alone when expressed at two different densities. It is interesting to speculate whether the A^R alone 
is also excluded from cell membrane domains of low buoyant density and whether this localisation 
is altered in the presence of an agonist or antagonist.
The treatm ent of purified membrane preparations with Triton X-100 followed by centrifuga­
tion in an iodixanol density gradient separated fractions of cell membrane based on their level of 
solubility with Triton and buoyant density. Caveolin was characteristically more concentrated in 
the less dense fractions (Figures 7.3 and 7.6), while G a i3 was accumulated in the most dense frac­
tions (Figure 7.3). All gradients showed a typical distribution of Gap Measurement of the optical 
density of the membrane fractions (Figure 7.2) along with the characteristic distributions of cave­
olin, G aj and G a i3 provide convincing evidence for the separation of less dense detergent-resistant 
membranes (DRMs) from other detergent-soluble more dense membrane fractions. When cova­
lently fused to GFP, the A^R was almost entirely concentrated within the most dense membrane 
fractions (Figure 7.6). No appreciable accumulation of either the A jR-GFP or A jR-GFP-Gaj 
fusion constructs were observed in the less dense “lipid raft” fractions. This was observed using 
antibodies for both A^R and GFP.
Uncertainty over the specificity of both A^R antibodies for the A^R alone prevent conclusions 
being made on the distribution of A^R in A^LE and A^HE membrane fractionations. Both A^LE 
and A^HE gradients show accumulation of A^R in the same dense fractions as observed for A^R- 
GFP and A^R-GFP-Gaj gradients (Figure 7.3). The A jHE membrane fractionation also shows 
accumulation of A^R in caveolin-enriched less dense fractions, which is in contrast to the gradients 
of A^LE, A^R-GFP and A^R-GFP-Ga^ membranes. However, without a confirmed negative 
control for the A jR  antibodies it is not possible to conclude whether density gradient fractionation 
of A^LE and A^HE membranes shows different patterns of A^R distribution.
Other studies have provided evidence of agonist stimulated accumulation of the adenosine 
Ai receptor in caveolin enriched “raft” cell membrane domains although it is open to speculation 
whether this redistribution of receptor has functional significance or whether it is part of the mech­
anism of receptor internalisation (Escriche et al. 2003 and Gines et al. 2001). Unfortunately in the 
present study there was not sufficient time in which to investigate the effect of agonist or antagonist 
treatm ent on density gradient fractionation of A jR-G FP and AiR-GFP-G aj membranes. However 
the A^R-GFP and A iR -G FP-G aj gradients presented here in the absence of agonist treatment 
are entirely consistent with similar studies using non-fusion adenosine Aj receptor. This provides 
further evidence tha t the A jR-G FP and AiR-G FP-G aj fusion constructs exhibit behaviour indis-
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tinguishable from the adenosine receptor alone and further validates their use as models of the 
effect of receptor expression level.
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Figure 7.7 W estern blot o f A ^R -G FP and A ^R -G FP-G aj membranes
for Gaj.
Figure 7.7: Western blot for Go^ (ab3522) of unfractionated A^R-GFP (2G3) and A^R-GFP-Gaj 
(5F4) membranes prior to density gradient fractionation shown in Figure 7.6 on page 193.
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Overall conclusions and future 
directions.
8.1 Summary.
In this section the findings of the previous experimental chapters are drawn together and some 
tentative molecular explanations provided. In addition, a number of suggestions are provided of 
future directions for this work. It is notable that some of the measured parameters are complex 
with 1:1 stoichiometries. This may reflect the presence of receptor dimers.
8.2 The effect o f receptor density on equilibrium binding at 
the hum an adenosine receptor.
Membranes prepared from the A^LE, AjHE, A^R-GFP and AjR-GFP-Go;j cell lines all showed 
essentially the same affinity constants for the G protein-coupled and uncoupled adenosine A^ 
receptor. This consistency, especially of high affinity agonist binding at the G protein-coupled 
receptor, shows th a t the GFP of the fusion constructs does not substantially interfere with the 
binding of G protein to the receptor and formation of the high affinity agonist-receptor-G protein 
ternary complex. Also, there is little (if any) evidence that the covalently-attached G o| subunit 
binds with notable affinity to its attached receptor. The adenosine Aj receptor of the A^R-GFP- 
Gctj fusion construct appears to bind exogenous G protein in a manner indistinguishable from 
the adenosine A j receptor expressed alone (A^LE and A^HE) and the A^R-GFP construct. The 
kinetics of [^H]CHA dissociation axe essentially indistinguishable at A^LE, A^HE, A jR-GFP and
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A^R-GFP-Gaj membranes, further supporting identical binding and activation mechanisms at all 
the membrane types studied (the kinetics of binding are considered in more detail in Section 8.3 
below).
Correspondingly the results for these different adenosine Aj receptor membrane preparation 
types and fusion constructs are considered together, and it is assumed that there are common 
molecular explanations for the observed results.
It should be noted tha t all the processes involved in the interpretation of these complex re­
sults are observed in membrane preparations, and therefore occur in the absence of chemical or 
metabolic energy input. The only processes involved are binding events. While considering possible 
mechanisms it is important to realise that there may be background molecular events occurring 
in the membranes that are not being detected directly. These changes can be the evolution or 
abolition with time of molecular binding processes.
T he effect o f receptor density on frjj.
In all cases the fraction of agonist binding which was of high affinity (frjj) was less than one. From 
the ternary complex model, this implies the receptor is limited in the amount of G protein available 
with which to form high affinity agonist-receptor-G protein complexes. As the total amount of 
Goj is generally believed to be in excess of the total amount of receptor, frjj of less than one 
implies there is segregation between G proteins and receptors. That is, the receptors and/or G 
proteins are substantially clustered away from each other and some receptors may not be in the 
vicinity of G protein at all. An alternative analysis may be that some receptor-G protein complexes 
may not have a 1:1 stoichiometry, frjj extrapolates to between 0.7 and 0.8 at low concentrations 
of receptor (Figure 4.12 on page 102). This may show that 20-30% of receptors do not interact 
with G protein and 70-80% interact to form a complex with 1 :1  (or 2 :2 ) receptor-to-G protein 
stoichiometry at very low levels of receptor expression. As the level of receptor expression increases, 
frjj is reduced, which may be the consequence of a change in the system to a 2 :1  stoichiometry 
with equal proportions of high and low affinity agonist binding sites. Although a straight line is 
shown in Figure 4.12 to illustrate the the dependence of receptor density on frjj, the nature of 
this dependence is not known and may not be linear. Figure 8 .1  on page 204 plots the dependence 
of frjj on log [^HjDPCPX Bmax in order to try  and obtain a more even distribution of Bmax 
data points. The non-linear regression curve shown was constrained to frjj values of 0.70 and 0.35, 
showing the results obtained are consistent with the levelling-off of frjj a t high levels of receptor 
expression at values approximately 50% of those at very low levels of receptor expression. It is 
plausible this reduction in fr j j  at high levels of receptor expression to half of that observed at very
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low levels of receptor expression is the manifestation of adenosine Aj receptor dimerisation where 
only one G protein is bound to each receptor dimer. Further evidence of receptor dimerisation 
from the kinetics of agonist binding, is discussed below.
8.3 The kinetics of agonist binding at the human adenosine 
A i receptor.
The association of [3 H]CHA at the adenosine Aj receptor was biphasic and the rate constant of 
association of the fast component was dependent on the concentration of [3 H]CHA (Figures 5.5a 
& 5.5c on page 122). This is consistent with a simple bimolecular association at readily available 
high affinity agonist binding sites. Figure 4.3 (page 84) suggests there is a slow recruitment of 
additional G protein to form further high affinity agonist binding sites, with a rate constant of 
approximately 0.016 min-^. By extrapolation there is a doubling of the number of high affinity 
agonist binding sites from t = 0 to t =  oo in Figure 4.3. It appears a fraction of the total adenosine 
Ai receptor population exists pre-coupled with G protein, and a further fraction is able to slowly 
form additional high affinity ternary complexes. The mechanism of this slow increase in high 
affinity agonist binding is unknown, and may be the result of the diffusion of additional G protein 
into the receptor environment or a change in the stoichiometry of agonist, receptor and G protein 
in high affinity complexes.
A gonist locking.
Following association for 60 min, the dissociation of [3 H]CHA at the adenosine A^ receptor by 20- 
fold dilution was incomplete (Figure 5.6 on page 126). This pseudo-irreversible binding is termed 
“agonist locking.” Approximately 35% of specific [3 H]CHA binding was reversible (Table 5.2 on 
page 126), and both the reversible and irreversible components were rapidly released by GTP. 
Sensitivity to  GTP indicates both the “locked” and “unlocked” components represent agonist- 
receptor-G protein complexes. The relative amplitudes of the two components were not dependent 
on the concentration of [3 H]CHA used to label the receptor, suggesting this behaviour is an intrinsic 
property of the system and not due to labelling of more than one molecular species with slightly 
different affinities for [3 H]CHA. The observation that the off-rate of the reversible component of 
[3 H]CHA binding was dependent on the concentration of [3 H]CHA used to label the receptor (and 
therefore the concentration of [3 H]CHA following 20-fold dilution) may be explained by the onset
O
of agonist-induced agonist dissociation at the higher concentrations of [^HJCHA.
The phenomenon of agonist locking might be explained by the re-binding of [3 H]CHA following
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dissociation and/or the tune-dependent recruitment of additional G protein into the receptor en­
vironment. The assumption of [^H] agonist re-binding implies the receptors are clustered together 
with a dissociated pH]agonist molecule binding to an unoccupied receptor before it can diffuse 
out of the membrane environment. However agonist locking is observed at membranes expressing 
both high and low levels of the adenosine receptor, and is not observed in the dissociation of
O
[ H]DPCPX. It is possible the receptors only cluster in the presence of agonist, or that the mode 
of access and exit of DPCPX from the receptor is different from that of agonists, disfavouring 
re-binding of pH]DPCPX.
The effect o f D P C P X  on the dissociation o f pHJCH A.
DPCPX appears to prevent or abolish agonist locking. The ability of DPCPX to enhance the 
dissociation of pH]CHA from the adenosine Aj receptor is independent of the level of receptor ex­
pression (for example see Figure 6 .2  on page 168), is essentially absent during the rapid dissociation 
phase of [^H]CHA dissociation (Figure 5.8 on page 129) and only becomes significant relative to 
dilution alone at longer times of 60 min or more (Table 5.3). This behaviour suggests the action of 
DPCPX is manifest by the prevention of [^H]CHA re-binding and/or the recruitment of additional 
G protein, and not by the more active mechanism of agonist-induced agonist dissociation. The 
effect of DPCPX is of nanomolar potency, as might be expected from such an interpretation.
A gonist-induced  agonist dissociation.
Unlabelled agonists rapidly enhanced the dissociation of [^H]agonists, relative to that shown by 
DPCPX, from the adenosine Aj receptor (for example see Figure 5.8 on page 129). This “agonist- 
induced agonist dissociation” is manifest as an increase in the amplitude of the fast component 
of [^HJagonist dissociation, and possibly also the rate constant of dissociation (Tables 5.4 & 5.11, 
Figures 5.9, 5.11 & 5.21). The [^H]CHA dissociation curves are essentially independent of the con­
centration of [^H]CHA used to label the receptors (i.e. the initial receptor occupancy) (Figures 5.9, 
5.11 & 5.13). As this agonist-induced agonist dissociation is dependent on the level of receptor 
expression (Figures 6.4 & 6.5) and is essentially absent at very low levels of expression (Table 6.3 
Sz Figure 6.7), it appears as if there is communication between high affinity agonist binding sites 
in receptor-G protein complexes when the receptors are present at high concentrations.
It should be noted that no evidence is presented here of receptor-receptor interactions in the 
absence of coupled G protein, such as when the receptors were labelled with the inverse agonist 
[^H]DPCPX. Also, all the unlabelled chase agonists examined are very potent at enhancing the 
dissociation of [3 H]agonist, relative to DPCPX chase or dilution alone, and these potencies are
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comparable to those for the high affinity receptor (G protein-coupled) rather than the uncoupled 
receptor (see Figure 4.6 & Table 5.7). This again strongly suggests that this receptor-receptor 
communication occurs by means of high affinity agonist binding at receptor-G protein complexes 
and that receptors uncoupled to G protein do not influence agonist-induced agonist dissociation.
One possible mechanism driving agonist-induced agonist dissociation may be the the reversible 
formation of dimers or receptor-G protein complexes through which agonist-induced agonist dis­
sociation is mediated through intra-oligomer interactions. These dimers may have a 2:1 stoichiom­
etry or 1 :1  stoichiometry of receptor to G protein. Agonists may modulate agonist dissociation by 
means of communication between the two high affinity agonist binding sites of dimeric receptor 
complexes. This communication may occur directly between receptors, or it may be mediated by 
another component of the receptor signalling complex, such as G protein.
The magnitude of agonist-induced agonist dissociation is related to the efficacy of the unlabelled 
chase agonist. Agonists of reduced efficacy showed a reduced ability to promote the dissociation of 
[ H]agonist (Tables 5.6 & 5.7). This provides evidence that the transmission of binding information 
between the two receptors (R) is mediated by the magnitude of the efficacy induced conformational 
changes at the receptor that drives receptor activation. That is, the A-R*-R§-B G protein complex 
has communication between the binding sites for two agonist molecules, A and B, which may have 
the same or different efficacies and induce different conformational changes. The binding of B 
induces an efficacy related conformational change on the receptor molecule to which it binds and 
this change is transm itted to the receptor molecule that has A bound and thereby affects the 
dissociation of A. Equally in this description, the binding of A should affect the dissociation of B.
Agonist-induced agonist dissociation is found in the presence and absence of GTP (Figures 5.15, 
5.16 &; Table 5.8) indicating that the receptor-receptor interactions may be retained at least for a 
short time after the consequences of receptor activation. This finding holds the promise that some 
of these interactions may be present in whole cells.
The preliminary experiments reported in Section 5.6.6 combine the complexities associated 
with the [^H]agonist association time courses with the complexities of [^H]agonist dissociation 
outlined above and the effects of temperature. The initial aim was to provide the maximum 
“window” by which agonist-induced agonist dissociation can be detected. The largest window was 
detected at short incubation times and at 10-60 minutes dissociation (Figure 5.19 on page 154). 
The effect became attenuated with longer pre-incubation times, especially at higher temperatures 
but the deleterious tem perature effect on binding (Figure 5.17 on page 150) may compromise this 
conclusion. It was also noticeable that the amplitude of the slowly dissociating component increased 
with pre-incubation time (Figure 5.19 on page 154), reflecting slow changes in the kinetics of the
201
Chapter 8
system that are occurring during the experiment. These kinetic changes were also detected in the 
estimates of the rate constant of the fast dissociating component with length of pre-incubation 
(Figure 5.21 on page 156).
In summary, considerable qualitative and quantitative information on this complex system has 
been obtained. The results provide evidence of complex mechanisms by which the level of receptor 
activation is controlled. Further kinetic and biophysical experiments are required to elaborate the 
molecular details of the phenomena that have been uncovered.
8.4 Future Directions.
There are several interesting avenues along which the work presented here could be taken. Hopefully 
it would be relatively straightforward to continue the membrane domain fractionation experiments 
in order to investigate the effect of agonist or inverse agonist treatment on the distribution of 
receptor. Other studies have shown accumulation of the receptor in lighter membrane fractions 
following agonist treatm ent, although the functional significance of this is not known (Escriche 
et al. 2003 and Gines et al. 2001). It would be of interest to perform further density gradient 
fractionations of membranes expressing the fusion constructs at several different densities, to in­
vestigate the effect of expression level on the density gradient profile of the receptor. Without 
an antibody shown to be specific for the A^ receptor alone, it is not possible to use the A^LE 
and A jH E membranes to investigate the effect of receptor expression level on the density gradient 
fractionation profile of the Aj receptor. It may also be interesting to fractionate the membranes of 
live cells expressing the A^ receptor, possibly also following agonist or inverse agonist treatment, 
to compare the distribution of the A^ receptor in live cells and the membrane preparations used 
throughout this study.
Further experiments could employ techniques studying the A^ receptor in living cells. Confocal 
microscopy of cells expressing the A j-G FP fusion construct could be used to investigate general 
changes in receptor localisation throughout the whole cell, and may provide an interesting insight 
into changes in the cellular distribution of the A^ receptor with agonist stimulation. At the other 
end of the scale, technologies such as fluorescence correlation spectroscopy (FCS) have begun 
providing insights into the behaviour of the A^ receptor at the level of individual receptors and 
molecules. FCS has been used to investigate the effect of binding of the fluorescently labelled A^ 
receptor antagonist XAC-BY630 on the distribution and diffusional properties of the A^ receptor 
expressed in living CHO cells (Briddon et al. 2004). It would be extremely interesting to use 
these techniques, along with confocal microscopy, to investigate other labelled ligands such as
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other antagonists and possibly even agonists on the diffusion, clustering, internalisation and even 
signalling of the Aj receptor.
Peptides based on the proposed transmembrane helices of the adenosine A]_ receptor were 
synthesised, however there was insufficient time remaining to perform experiments utilising them. 
Studies have proposed that transmembrane helix peptides can disrupt GPCR oligomerisation, 
such as for the dopamine D2  receptor (Ng et al. 1996). It would be interesting to investigate the 
effect of these peptides on agonist-induced agonist dissociation which may be mediated through 
direct receptor-receptor communication. Specific inhibition of agonist-induced agonist dissociation 
by a peptide of one of the transmembrane helices would provide compelling evidence supporting 
communication mediated by direct receptor-receptor interaction.
The adenosine A^ receptor has been proposed to form oligomeric complexes with other GPCRs 
including the dopamine D j receptor (Gines et al. 2000), metabotropic glutamate receptor (Ciru- 
ela et al. 2001), and the P2Y^ receptor (Yoshioka et al. 2001). The co-expression at high 
levels of one of these receptors with the adenosine A^ receptor would enable the investigation of 
receptor-receptor communication within hetero-oligomeric complexes. It would be interesting to 
test whether an unlabelled agonist at the co-expressed receptor could induce the dissociation of 
[^Hjagonist in the same manner as A^ receptor agonists can. Such an observation would provide 
credible evidence of functional implications to A^ receptor hetero-oligomerisation.
Previous work here used the A jLE and A^HE cell lines to investigate the effect of receptor 
density on the functional properties of the adenosine A^ receptor using a [^S ]G T P 7 S binding 
assay. Novel biphasic dose response curves were observed for high efficacy agonists at A^HE 
membranes but not A^LE membranes (Browning 2003, Browning et al. 2000c). Membranes 
prepared from the A jR -G FP and AjR-GFP-Goj cell lines may enable detailed characterisation of 
the dependence of this biphasic dose response curve on the level of receptor expression. Functional 
studies may be more sensitive in detecting the coupling of the A^ receptor to the covalently attached 
G protein of the A^R-GFP-Ga^ construct in the presence of pertussis toxin. The experiments 
presented in Chapter 4 showed no detectable high affinity agonist binding at the A^R-GFP-Go^ 
construct following incubation with pertussis toxin. Bevan et al. (1999) showed NECA stimulation 
of [3 5 S]GTP7 S accumulation at the A^R-GFP-Goij construct following incubation with pertussis 
toxin, however this was much reduced in amplitude and potency relative to [3 5 S]GTP7 S binding 
in the absence of pertussis toxin.
Of course a high-resolution X-ray structure of the human adenosine A^ receptor would be 
useful!
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Figure 8.1 Specu lation  on the nature o f th e change in CH A frjj w ith
[3H ]D P C P X  B m ax.
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Figure 8.1: The data presented in Figure 4.12 on page 102 was transformed to illustrate the 
dependence of frjj on log receptor density ([^HJDPCPX Bmax)- The curve illustrated above was 
constrained to a maximum frjj of 0.70 and minimum of 0.35. Data from cell line 4F2 was removed.
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